{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.13167"}, {"@name": "filename", "#text": "19032_TESE%20cola%c3%a7%c3%a3o%20de%20grau.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "0 \n \n\n \n\n \n\n \n\nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS BIOL\u00d3GICAS \n\nLABORAT\u00d3RIO DE IMUNOLOGIA KEIZO-ASAMI \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS BIOL\u00d3GICAS \n\n \n\n \n\n \n\n \n\n \n\nCRIPTOCOCOSE E DETERMINA\u00c7\u00c3O DO EFEITO ANTIF\u00daNGICO IN VITRO E IN \n\nVIVO POR SISTEMA DE LIBERA\u00c7\u00c3O CONTROLADA COM CICLOPIROX OLAMINA \n\n \n\n \n\n \n\n \n\n \n\nPATRICIA DE OLIVEIRA KOCERGINSKY \n\n \n\n \n\n \n\n \n\n \n\n \n\nFevereiro/2013 \n\nRecife-PE \n\n \n\n\n\n1 \n \n\n \n\n \n\n \n\n \n\nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS BIOL\u00d3GICAS \n\nLABORAT\u00d3RIO DE IMUNOLOGIA KEIZO-ASAMI \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS BIOL\u00d3GICAS \n\n \n\n \n\nCRIPTOCOCOSE E DETERMINA\u00c7\u00c3O DO EFEITO ANTIF\u00daNGICO IN VITRO E IN \n\nVIVO POR SISTEMA DE LIBERA\u00c7\u00c3O CONTROLADA COM CICLOPIROX OLAMINA \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n          Doutoranda: PATRICIA DE OLIVEIRA KOCERGINSKY \n\nOrientadora: Profa. Dra. NEREIDE STELA SANTOS MAGALH\u00c3ES \n\n          Co-orientadora: Profa. Dra. REJANE PEREIRA NEVES \n\n \n\n \n\n \n\n \n\nFevereiro/ 2013 \n\nRecife \u2013 PE \n\n \n\nTese submetida ao Programa de P\u00f3s-Gradua\u00e7\u00e3o em \n\nCi\u00eancias Biol\u00f3gicas do Laborat\u00f3rio de Imunologia \n\nKeizo-Asami do Centro de Ci\u00eancias Biol\u00f3gicas da \n\nUniversidade Federal de Pernambuco para obten\u00e7\u00e3o do \n\nt\u00edtulo de doutor.  \n\n \n \n\n\n\n3 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                          \n\n \n\n                                                         Cataloga\u00e7\u00e3o na fonte \n\nElaine Barroso \n\nCRB 1728 \n\nKocerginsky, Patr\u00edcia de Oliveira \n\n      Criptococose e determina\u00e7\u00e3o do efeito antif\u00fangico in vitro e in vivo por \n\nsistema de libera\u00e7\u00e3o controlada com ciclopirox olamina/ Patr\u00edcia de Oliveira \n\nKocerginsky\u2013 Recife: O Autor, 2013.        \n\n      139 folhas : il., fig., tab. \n\n Orientadora: Nereide Stela Santos Magalh\u00e3es \n\n Coorientadora: Rejane Pereira Neves \n\n Tese (doutorado) \u2013 Universidade Federal de Pernambuco. Centro \n\nde Bioci\u00eancias. Ci\u00eancias Biol\u00f3gicas, 2013. \n\nInclui refer\u00eancias e anexos \n\n \n\n1. Micose 2. Cryptococcus 3. Fungos patog\u00eanicos I. Magalh\u00e3es, \nNereide Stela Santos (orientadora) II. Neves, Rejane Pereira \n(coorientadora) III. T\u00edtulo   \n\n \n\n                     616.969             CDD (22.ed.)                UFPE/CCB-2016-119 \n\n \n\n \n\n \n\n\n\n2 \n \n\nCriptococose e Determina\u00e7\u00e3o do efeito antif\u00fangico in vitro e in vivo por \n\nSistema de Libera\u00e7\u00e3o controlada com Ciclopirox Olamina \n\n \n\nAprovada em: 22 de fevereiro de 2013 \n\n \n\nBANCA EXAMINADORA \n\nOrientadora: Prof\u00aa Dr\u00aa Nereide Stela Santos Magalh\u00e3es  \n\nDepartamento de F\u00e1rm\u00e1cia da Universidade Federal de Pernambuco \n\n \n\nAssinatura: __________________________________________________ \n\n \n\nEXAMINADOR EXTERNO: Prof\u00aa Dr\u00aa Danielle Patr\u00edcia Cerqueira Mac\u00eado \n\nDepartamento de Micologia, Universidade Federal Rural de Pernambuco \n\n \n\nAssinatura: __________________________________________________ \n\n \n\nEXAMINADOR EXTERNO: Prof. Dr. Reginaldo Gon\u00e7alves de Lima-Neto  \n\nDepartamento de Micologia da Universidade Federal de Pernambuco \n\n \n\nAssinatura: __________________________________________________ \n\n \n\nEXAMINADOR EXTERNO: Prof\u00aa Dr\u00aa Mariane Cajuba de Britto Lira \n\nCentro acad\u00eamico de Vit\u00f3ria, Universidade Federal de Pernambuco \n\n \n\nAssinatura: __________________________________________________ \n\n \n\n \n\nEXAMINADOR INTERNO: Prof\u00aa Dr\u00aa Adriana Fontes \n\nDepartamento Biof\u00edsica da Universidade Federal de Pernambuco \n\n \n\nAssinatura: __________________________________________________ \n\n \n\n \n\n \n\nii \n\n\n\n4 \n \n\nDEDICO \n\n \n\nAo meu amado, precioso e \u00fanico Senhor da minha vida, Jesus Cristo, por todo Seu suprimento, \n\namor, ensinamentos, dire\u00e7\u00e3o e principalmente por permanecer fiel as suas promessas, at\u00e9 mesmo \n\nquando eu sou infiel. \n\nAos meus pais: Oliveira e Valda, meus grandes amores. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n               OFERE\u00c7O \n\nAo meu esposo amado Sergio Kocerginsky por tudo que ele me fez \n\nenxergar, reconhecer e aprender com sua dedica\u00e7\u00e3o, sinceridade e \n\namor. \n\niii \n\n\n\n5 \n \n\nAGRADECIMENTOS \n\n \n\n Ao meu Senhor e Salvador Jesus Cristo, autor da minha vida, que me transportou das \n\ntrevas para o reino do seu filho amado; escolheu-me, amou-me com amor eterno e \u00e9 o grande \n\nrespons\u00e1vel por todas as minhas conquistas. A Ele, eu declaro todo o meu amor e toda a \n\nminha gratid\u00e3o para sempre! \n\n  Ao Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq), ao \n\nGrupo de pesquisa SLC e a Coordena\u00e7\u00e3o do Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias \n\nBiol\u00f3gicas da UFPE nas pessoas da Coordenadora Maria Tereza dos Santos Correia, da \n\nsecret\u00e1ria Adenilda. \n\n Aos funcion\u00e1rios do Laborat\u00f3rio de Imunopatologia Keizo-Asami (LIKA) \n\n        Ao prof. Armando Marsden, chefe do laborat\u00f3rio de Micologia M\u00e9dica, pelo seu bom-\n\nhumor, profissionalismo e \u00e9tica, que fazem dele um biom\u00e9dico reconhecido, admirado e \n\nacima de tudo, respeitado.  \n\n\u00c0s doutoras Taciana Antunes e Solange Mesquita por terem gentilmente cedido as \n\namostras de LCR para o desenvolvimento da minha pesquisa e em especial, \u00e0s funcion\u00e1rias \n\ndo laborat\u00f3rio Cibele, Solange, Thayanna e Alcione pelo apoio e simpatia.  Muito obrigada \n\nmeninas!!! Foi um prazer ter conhecido voc\u00eas! \n\nA minha orientadora Nereide Stela Santos Magalh\u00e3es por seu profissionalismo, \n\ncompet\u00eancia e dedica\u00e7\u00e3o \u00e0 vida acad\u00eamica. Obrigada por ter me recebido t\u00e3o bem no grupo \n\nde pesquisa SLC! \n\nA minha co-orientadora Rejane Pereira Neves pela orienta\u00e7\u00e3o maravilhosa e por \n\nsempre desejar o melhor para mim! Obrigada por tudo! \n\n\u00c0s professoras Mariane Lira e Danielle Mac\u00eado por contribu\u00edrem com suas \n\nexperi\u00eancias e saberes para o aperfei\u00e7oamento de minha tese. Dani, obrigada tamb\u00e9m por \n\ntodo apoio, ajuda e incentivo! \n\nAo professor Reginaldo Gon\u00e7alves de Lima-Neto pela amizade e apoio em minha \n\ncaminhada acad\u00eamica desde a minha gradua\u00e7\u00e3o. Parab\u00e9ns por ser um exemplo de \n\ndetermina\u00e7\u00e3o e profissionalismo. Voc\u00ea \u00e9 o irm\u00e3o superinteligente que eu n\u00e3o tive e que \n\nsempre quis ter! :) \n\nAos meus amigos da Micologia, em especial a Carol, Suanni, Fab\u00edola e Mariele por \n\ntodos os momentos bem vividos juntos.  \n\niv \n\n\n\n6 \n \n\n\u00c0s minhas amigas Vanessa Karina e Isabella Mac\u00e1rio para quem tudo que se diga \n\nde bom ainda \u00e9 pouco. N\u00e3o tenho palavras para agradecer toda a ajuda e apoio nos \n\nmomentos mais cr\u00edticos de minha jornada acad\u00eamica! Agrade\u00e7o a Deus por ter amigas \n\nmaravilhosa como voc\u00eas! Que a nossa amizade seja eterna! \n\nAos meus colegas e amigos do SLC, em especial \u00e0s pessoas Pabyton, Rafaela e \n\nMilena. Obrigada pelo apoio, amizade, ensinamentos e horas de descontra\u00e7\u00e3o tamb\u00e9m! \n\nAos alunos de Inicia\u00e7\u00e3o Cient\u00edfica Pedro Soares e Hannah Lyra por terem sido \n\nmuitas vezes meus bra\u00e7os e meus p\u00e9s nos \u201cintermin\u00e1veis\u201d experimentos in vitro e in vivo. \n\nAos meus pais (Oliveira e Valda), meus amores, que sempre me deram o apoio \n\nnecess\u00e1rio para que eu conseguisse vencer todas as dificuldades. \n\nA todas as pessoas, mais pr\u00f3ximas ou distantes, que torceram junto a mim pela \n\nconclus\u00e3o de mais uma etapa da minha vida. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nv \n\n\n\n7 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\"Combati o bom combate, completei a \n\ncarreira, guardei a f\u00e9\" (II Tm 4:7). \n\nvi \n\n\n\n8 \n \n\nRESUMO \n\n \n\nA criptococose \u00e9 uma infec\u00e7\u00e3o f\u00fangica predominantemente oportunista cujos principais \n\nagentes etiol\u00f3gicos s\u00e3o Cryptococcus neoformans e C. gattii. O tratamento de escolha para a \n\nmicose \u00e9 a anfotericina B associada ou n\u00e3o a 5-fluorocitosina seguido de terapia de \n\nmanuten\u00e7\u00e3o com fluconazol. Contudo, falhas no tratamento associadas \u00e0 toxicidade e ao \n\naparecimento de resist\u00eancia aos f\u00e1rmacos t\u00eam sido relatadas, o que torna essencial a \n\ndescoberta de novas alternativas terap\u00eauticas, como a ciclopirox olamina (CPO). Neste \n\ncontexto, o objetivo deste estudo foi caracterizar e avaliar a a\u00e7\u00e3o in vitro e in vivo da CPO \n\nlivre e encapsulada em lipossomas frente a amostras de Cryptococcus neoformans para futura \n\naplica\u00e7\u00e3o no tratamento da criptococose sist\u00eamica. Foram obtidas 30 amostras de \n\nCryptococcus neoformans provenientes de pacientes imunocomprometidos. A prepara\u00e7\u00e3o dos \n\nlipossomas convencionais e furtivos de CPO foi realizada pelo m\u00e9todo da hidrata\u00e7\u00e3o do filme \n\nlip\u00eddico e a caracteriza\u00e7\u00e3o foi realizada avaliando os seguintes par\u00e2metros: tamanho de \n\npart\u00edcula, \u00cdndice de Polidispers\u00e3o (PDI) e taxa de encapsula\u00e7\u00e3o (EE%). Para otimiza\u00e7\u00e3o dos \n\nconstituintes lip\u00eddicos, foi realizado um planejamento fatorial fracionado a 24-1 a partir da \n\nmelhor formula\u00e7\u00e3o obtida nos estudos de pr\u00e9-formula\u00e7\u00e3o. A cin\u00e9tica de libera\u00e7\u00e3o in vitro foi \n\nconduzida para avaliar e comparar estatisticamente o perfil de libera\u00e7\u00e3o dos sistemas \n\nconvencional e furtivo. Adicionalmente, testes de susceptibilidade antif\u00fangica foram \n\nrealizados de acordo com Clinical and Laboratotry Standards Institute (CLSI). Para \n\ncaracteriza\u00e7\u00e3o molecular dos isolados, PCR fingerprinting foi conduzida utilizando os primers \n\nM13 e URA5. O estudo in vivo foi conduzido com camundongos imunossuprimidos, \n\ninfectados com Cryptococcus neoformans (106 cels/mL) e tratados com CPO lipossomal \n\n(Lipo-CPO) (0.5 mg/Kg). As concentra\u00e7\u00f5es de CPO utilizadas na forma livre e encapsuladas \n\nem lipossomas convencionais e furtivos variaram de 0,30 a 625 \u00b5g/mL. Os resultados do \n\nplanejamento fatorial mostraram que o ponto central apresentou caracter\u00edsticas proeminentes \n\ncom redu\u00e7\u00e3o do tamanho de part\u00edcula em 17,1%; melhora do PDI em 15,34% e da quantidade \n\nde f\u00e1rmaco encapsulado (25%). A cin\u00e9tica do lipossoma furtivo apresentou uma velocidade \n\nde libera\u00e7\u00e3o mais controlada quando comparada ao lipossoma convencional. Com rela\u00e7\u00e3o ao \n\nteste de susceptibilidade, todos os in\u00f3culos foram suscept\u00edveis a CPO livre, com atividade \n\nfungist\u00e1tica entre 0,30 e 0,61 ?g/mL e fungicida entre 1,22 e 4,88 ?g/mL. N\u00e3o houve \n\ndiferen\u00e7a relacionada \u00e0 atividade antif\u00fangica entre as formula\u00e7\u00f5es lipossomais convencionais \n\ne furtivas. A atividade fungist\u00e1tica dos lipossomas foi observada em concentra\u00e7\u00f5es variando \n\nde 1,22 e 2,44 ?g/mL. A faixa das concentra\u00e7\u00f5es fungicidas foi de 1,22 a 9,76 ?g/mL. O \n\npadr\u00e3o de bandas do URA5 revelou que todos os isolados apresentam gen\u00f3tipo VNI, \n\ncaracter\u00edstico de C. neoformans. Lipo-CPO apresentou efic\u00e1cia antif\u00fangica comparada \u00e0 \n\nanfotericina B ap\u00f3s 14 dias de infec\u00e7\u00e3o, reduzindo a carga f\u00fangica em aproximadamente 8% \n\nno ba\u00e7o, 41% no f\u00edgado, 63% no pulm\u00e3o e 89% no c\u00e9rebro. O exame histol\u00f3gico evidenciou \n\ninfiltrado celular no f\u00edgado dos grupos tratados com Lipo-CPO e anfotericina B, por\u00e9m com \n\nmenor intensidade quando comparado ao grupo controle. O estudo sugere que a CPO \n\nencapsulada em lipossomas apresenta significativa a\u00e7\u00e3o antimic\u00f3tica frente \u00e0s amostras \n\nsist\u00eamicas de C. neoformans, refor\u00e7ando seu potencial na terap\u00eautica da criptococose.  \n\nPalavras-chave: Criptococose, ciclopirox olamina lipossomal, cin\u00e9tica de libera\u00e7\u00e3o in vitro, \n\natividade antif\u00fangica in vitro, criptococose experimental.  \n\n \n\n \n\n \n\nvii \n\n\n\n9 \n \n\nABSTRACT \n\n \n\nCryptococcosis is an opportunistic fungal infection whose the main ethiological agents \n\nare Cryptococcus neoformans and C. gattii. The treatment of choice for this mycosis is \n\namphotericin B combined or not with 5-fluorocytosine, followed by maintenance therapy with \n\nfluconazole. However treatment failures associated with toxicity and drug resistance has been \n\nreported, which makes it essential to the discovery of new therapies, such as ciclopirox \n\nolamine (CPO). The purpose of this study was to characterize and evaluate the in vitro and in \n\nvivo antifungal activity of ciclopirox olamine in its free form and encapsulated in liposomes \n\nagainst thirty Cryptococcus neoformans isolates obtained from immunocompromised patients \n\nfor future application in systemic cryptococcosis treatment. Preparation of conventional and \n\nstealth liposomes was performed to define particle size, polydispersity index (PDI), CPO \n\namount of encapsulated and efficiency of encapsulation (EE%). For optimization of liposomal \n\nlipid constituents, a 24-1 fractional factorial design was carried out from the prominent \n\nformulation obtained in pre-characterization studies. In vitro release kinetics was conducted to \n\nevaluate and compare statistically the release profile of conventional and stealth liposomes. \n\nAntifungal susceptibility testing was conducted in accordance with the reference method. \n\nRegarding molecular characterization, PCR fingerprinting was carried out by using MT3 and \n\nURA5 primers. Concentrations of CPO used in free form and encapsulated into stealth and \n\nconventional liposomes ranged from 625 to 0.3 ?g.mL-1. Despite of the central point of the \n\nfactorial design have increased the total lipids amount in 35.52%, it showed prominent \n\ncharacteristics when compared with the L4 formulation with improvement of the mean size in \n\n17.1%, PDI in 15.34%  and CPO amount in 25%. The minimum concentrations of \n\nstearylamine to obtain the stable formulation for one month was 5.88 mM. . Kinetics of \n\nstealth liposomes showed a release profile more controlled as compared to conventional \n\nliposomes. All inoculations were susceptible to CPO in its free form, presenting fungistatic \n\nactivity between 0.3 and 0.61 ?g.mL-1 and fungicidal activity between 1.22 and 4.88 ?g.mL-1. \n\nThere was no difference with respect to antimycotic activity between conventional and stealth \n\nliposomal formulations. Fungistatic activity of liposomes was observed at concentrations \n\nranging from 1.22 and 2.44 ?g.mL-1. Fungicidal concentration range was 1.22-9.76 ?g.mL-1. \n\nThe URA5 profile analized demonstrated all isolates are VNI genotype (C. neoformans). The \n\ntreatment with Lipo-CPO showed a reduction of 8% of the C. neoformans population in \n\nspleen, 40.8% in liver, 63% in lungs and 89% in brain after 14 days of infection. Histological \n\nexamination revealed cell infiltrate either Lipo-CPO or Amphotericin B treated groups, but \n\nless intense when compared to control group. The results suggest that Ciclopirox olamine \n\nloaded-liposomes have significant antimycotic activity against Cryptoccocus spp, reinforcing \n\nits potential for in vivo studies and its application in cryptococcosis treatment.  \n \n\nKeywords: Cryptococosis, Ciclopirox olamine lipossomal, Release kinetic in vitro, \n\nAntifungal activity in vitro, experimental cryptococcosis. \n\n \n\n \n\nviii \n\n\n\n10 \n \n\n \n\nLISTA DE FIGURAS \n\n                                             \n\nREVIS\u00c3O DE LITERATURA                                                                                  \n\n \n\nFigura 1 - Contribui\u00e7\u00e3o global de autores Brasileiros no campo da criptococose em \n\ncompara\u00e7\u00e3o aos autores americanos. (A) Varia\u00e7\u00e3o anual (1991\u20132010) da percentagem de \n\nartigos contendo autores brasileiros ou americanos (B) An\u00e1lise do perfil de produtividade \n\ncient\u00edfica comparando estudos onde os autores brasileiros estiveram em qualquer posi\u00e7\u00e3o  \n\nda lista de autores com artigos onde os cientistas brasileiros estiveram na posi\u00e7\u00e3o senior (C) \n\nAn\u00e1lise detalhada de perfis mostrando distribui\u00e7\u00e3o de artigos por autores envolvendo os \n\nprincipais pa\u00edses, incluindo o Brasil. \n\n16 \n\nFigura 2 - Ciclo de infec\u00e7\u00e3o de Cryptococcus spp. (Adaptado de Lin e Heitman, 2006). 17 \n\nFigura 3 - M\u00e9todos diagn\u00f3sticos utilizados na identifica\u00e7\u00e3o de Cryptococcus spp. I) C. \n\nneoformans no l\u00edquor contra-corado com Tinta da China 40X; II) Aspecto muc\u00f3ide de C. \n\nneoformans em \u00e1gar-Sabouraud 2% de glicose; III) Col\u00f4nia de C. neoformans em meio \n\n\u00c1gar Semente de Niger com forma\u00e7\u00e3o de melanina; IV) Ur\u00e9ia de Christensen. A - Teste \n\nnegativo, A \u2013 Teste positivo; V) Auxonograma- Halos evidenciando crescimento f\u00fangico; \n\nVI) Meio CGB: a) C. neoformans b)  C. gattii; VII) Teste de Aglutina\u00e7\u00e3o em l\u00e1tex para \n\ndetec\u00e7\u00e3o de ant\u00edgeno; VIII) Gel de agarose 3% representativo de amplifica\u00e7\u00e3o utilizando \n\nprimer URA5 cortado com enzimas de restri\u00e7\u00e3o Sau96Ie HhaI para identifica\u00e7\u00e3o de C. \n\nneoformans. \n\n31 \n\n \n\nFigura 4 - F\u00f3rmula estrutural da 2-aminoetanol sal do 6-ciclohexil-1-hidroxi4-metil-2-\n\npiridona. \n\n42 \n\nFigura 5 - Estrutura do lipossoma e da bicamada lip\u00eddica (Adaptado de Chorilli et al., \n\n2004). \n\n47 \n\nFigura 6 - Caracter\u00edsticas estruturais de lipossomas convencionais, furtivos, s\u00edtio-\n\nespec\u00edficos e cati\u00f4nicos (Adaptado de LASIC, 1996). \n\n \n\n48 \n\n \n\nARTIGO 1  \n\n \n\nFIG 1 Chemical structure of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one and 2-\n\naminoethanol (ciclopirox olamine). \n\n83 \n\nFIG 2 Scatter plot of the formulations produced using a 24-1 fractional experimental design 98 \n\nix \n\n\n\n11 \n \n\nand effects of response variables: Encapsulation efficiency (%), PDI and Mean size (nm). \n\nThe liposomal formulations were identified with codes from 1 up to 11. Formulations \n\nindicated gray circles were unstable and black circles were stable, respectively. The best \n\nformulations were indicated with a square. \n\n \n\nFIG 3 Release kinetics of CPO from conventional (L11, ?) and stealth liposomes (L11\u2019, ?) \n\nin pH 7.4 phosphate buffer solution at 37 \u00b0C. Data are expressed as mean \u00b1 S.D. (n=3). \n\n100 \n\n  \n\nARTIGO 2  \n\n  \n\nFig.1. The URA5 RFLP profiles after double digestion of amplification products with the \n\nenzymes Sau96I (10 U/?L) and HhaI (20 U/ ?L) of thirty Cryptococcus isolates obtained \n\nfrom cerebrospinal fluid of patients \n\n118 \n\nFig. 2. Bands patterns of microsatellite obtained after PCR amplification of thirty \n\nCryptococcus isolates, obtained from cerebrospinal fluid of patients admitted in public \n\nhospitals of Recife, Pernambuco, Brazil \n\n119 \n\n  \n\nARTIGO 3  \n\nFIG 1 Leukocyte cell counts in dexamethasone-immunosuppressed mice infected with \n\nCryptococcus neoformans URM5811 and treated with Ciclopirox olamine-Loaded \n\nLiposome. EL= Empty Liposome; AmB= Amphotericin B; Lipo-CPO= Ciclopirox \n\nolamine-loaded liposome. *P &lt;0.05, 7 days compared to 14 days of treatment per cell \n\ngroup (ANOVA and Tukey test). \n\n \n\nFIG 2  Seven days after infection, mice were treated daily with Lipo-CPO (0.5 mg/kg Lipo-\n\nCPO) or amphotericin B (0.5 mg/kg) for 7 (A) or 14 days (B). *P &lt;0.05 compared to the \n\nempty liposome group (Tukey test and ANOVA). \n\n \n\n \n\nFIG 3 Histopatological examination of cryptococcosis infection model: 2A and 2B show \n\nnormal glomerulus and tubular cells and hepatocytes without vascular alterations, \n\nrespectively, indicating ausence of CPO citotoxity at 12.5 mg/Kg; 2C-2E demonstrate cell \n\ninfiltrate in the liver of empty liposome, Lipo-CPO and AmB groups after 7 days of \n\ninfection. The histological damage in brain after 7 days is shown in 2F-2H. Liquefative and \n\ncoagulative necrosis are indicated by white and black stars respectively. Yellow arrow \n\nindicates inflammatory infiltrates naer the lesion (400x). \n\n \n\n135 \n\n \n\n \n\n \n\n \n\n136 \n\n \n\n137 \n\n  \n\n \n\n \n\nx \n\n\n\n12 \n \n\nLISTA DE TABELAS \n\n \n\nREVIS\u00c3O DE LITERATURA \n\n \n\nTabela 1- Caracter\u00edsticas fenot\u00edpicas, epidemiol\u00f3gicas e gen\u00e9ticas de C. neoformans e C. \n\ngattii  \n\n \n\nARTIGO 1 \n\n \n\nTable 1. \nPre-formulation studies for encapsulation of Ciclopirox olamine into liposomes  \n\n \n\nTable 2. \n\nTwo-level 24?1 fractional experimental design to study the influence of lipids concentrations \n\nand CPO amount on the characteristics of the CPO-loaded liposomes. \n\nTable 3.  \n\nSusceptibility testing of ciclopirox olamine free and encapsulated in conventional and \n\nstealth liposomes against Cryptococcus strains obtained from Cerebrospinal Fluid. \n\n \n\n52 \n\n \n\n \n\n \n\n97 \n\n \n\n99 \n\n \n\n101 \n\n \n\n \n\nARTIGO 2  \n\n  \n\nTable 1. \n\nPhenotypic and Molecular determination of the Cryptococcus strains \n\n117 \n\n  \n\n  \n\n  \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nxi \n\n\n\n13 \n \n\nSUM\u00c1RIO \n\n \n\nRESUMO............................................................................................................................... vii \n\nABSTRACT........................................................................................................................... viii \n\nLISTA DE FIGURAS........................................................................................................... ix \n\nLISTA DE TABELAS........................................................................................................... xi \n\n1 INTRODU\u00c7\u00c3O......................................................................................................... 13 \n\n2 REVIS\u00c3O DE LITERATURA................................................................................ 15 \n\n2.1 - Criptococose: vias de infec\u00e7\u00e3o e manifesta\u00e7\u00e3o cl\u00ednica.................................. 15 \n\n             2.2 - Criptococose experimental.............................................................................. 19 \n\n             2.3 - Cryptococcus neoformans............................................................................... 21 \n\n2.3.1 - Hist\u00f3rico e aspectos epidemiol\u00f3gicos..................................................... 21 \n\n             2.4 - M\u00e9todos utilizados para identifica\u00e7\u00e3o de Cryptococcus spp........................ 28 \n\n             2.5 - Terapia na Criptococose e Teste de susceptibilidade a antif\u00fangicos..........  36 \n\n             2.6 - Ciclopirox olamina.......................................................................................... 41 \n\n             2.7 - Nanotecnologia Farmac\u00eautica........................................................................ 45 \n\n                   2.7.1 Sistemas de libera\u00e7\u00e3o de f\u00e1rmacos......................................................... 45 \n\n3 REFER\u00caNCIAS................................................................................................................. 53 \n\n4 CAP\u00cdTULO 1  \n\nPhenotypic and genotypic determination of Cryptococcus neoformans clinical isolates. \n\nA ser submetido \u00e0 Mycopathologia \n\n \n\n  81 \n\n5 CAP\u00cdTULO 2 \n\n \n\nAntifungal activity of ciclopirox olamine loaded-liposomes against Cryptococcus \n\nneoformans. A ser submetido \u00e0 Antimicrobial Agents and Chemotherapy \n\n \n\n \n\n \n\n103 \n\n6 CAP\u00cdTULO 3 \n\n \n\nAntifungal activity of ciclopirox olamine-loaded stealth liposomes in mice infected \n\nwith the human fungal pathogen Cryptococcus neoformans. A ser submetido \u00e0 \n\nAntimicrobial Agents and Chemotherapy \n\n \n\n \n\n121 \n\n7 CONCLUS\u00d5ES.................................................................................................................. 126 \n\n8. ANEXOS............................................................................................................................ 127 \n\n  \n\nxii \n\n\n\n14 \n \n\n  \n\n 1 INTRODU\u00c7\u00c3O \n\n \n\n \n\nA criptococose, infec\u00e7\u00e3o f\u00fangica oportunista, cujo principal agente etiol\u00f3gico \u00e9 a \n\nlevedura encapsulada Cryptococcus neoformans, vem assumindo um papel relevante na \n\natualidade por ser uma das micoses mais comuns em pacientes imunocomprometidos com \n\nmal progn\u00f3stico. A inala\u00e7\u00e3o das estruturas vi\u00e1veis desta levedura constitui a principal via de \n\ncontamina\u00e7\u00e3o, podendo a micose ser cut\u00e2nea, pulmonar ou acometer outros \u00f3rg\u00e3os, \n\nprincipalmente meninges (LIN; HEITMAN, 2006; PARK et al., 2009; ALBUQUERQUE; \n\nRODRIGUES, 2012).  \n\nCryptococcus neoformans era reconhecido por apresentar tr\u00eas variedades: C. \n\nneoformans var. neoformans, C. neoformans var. gattii e C. neoformans var. grubii. Em 2002, \n\navan\u00e7os nas pesquisas envolvendo a ecologia, a epidemiologia, a fisiologia e a gen\u00e9tica de C. \n\nneoformans permitiram que Kwon-Chung e colaboradores elevassem C. neoformans var gattii \n\na uma nova esp\u00e9cie: Cryptococcus gattii. Com base nestas informa\u00e7\u00f5es, as antigas variedades \n\ns\u00e3o reconhecidas atualmente por v\u00e1rios autores como esp\u00e9cies e variedades do complexo C. \n\nneoformans, as quais correspondem Cryptococcus neoformans var. neoformans, C. \n\nneoformans var. grubii e C. gattiii. As especies apresentam diferen\u00e7as quanto \u00e0 \n\nepidemiologia, fisiologia, caracter\u00edsticas moleculares e padr\u00e3o de resist\u00eancia aos antif\u00fangicos \n\n(KWON-CHUNG et al., 2002; RIBEIRO; NGAMSKULRUNGROJ, 2008; BYRNES et al., \n\n2010; GUPTA; FRIES, 2010; SAN-BLAS; BURGER, 2011).  \n\nO aparecimento de isolados de Cryptococcus resistentes aos f\u00e1rmacos mais utilizados \n\nno tratamento da criptococose, como a anfotericina B, tem se tornado um problema frequente. \n\nAs op\u00e7\u00f5es terap\u00eauticas s\u00e3o limitadas, particularmente devido \u00e0 toxicidade, resist\u00eancia f\u00fangica \n\ne intoler\u00e2ncia aos medicamentos (NUCCI; MARR, 2005). \n\nDiante deste contexto, diversos agentes antif\u00fangicos t\u00eam sido desenvolvidos e \n\navaliados para o acompanhamento e tratamento de infec\u00e7\u00f5es f\u00fangicas. Entre os agentes, \n\nencontra-se um derivado da classe das hidroxipiridonas, a ciclopirox olamina, cuja atividade \n\nantif\u00fangica foi descrita em 1973. Este f\u00e1rmaco apresenta amplo espectro de a\u00e7\u00e3o \n\nantimicrobiana, antiinflamat\u00f3ria, antitumoral e excelente penetra\u00e7\u00e3o tissular, sendo eficaz \n\ncontra fungos de interesse m\u00e9dico como as leveduras (NIEWERTH et al., 2003). Contudo, \n\npesquisas in vivo relacionadas ao uso da ciclopirox olamina no tratamento da criptococose \n\n\n\n15 \n \n\nsist\u00eamica ainda n\u00e3o foram realizadas at\u00e9 o momento, sobretudo quando se refere ao \n\nencapsulamento de f\u00e1rmacos atrav\u00e9s de sistemas nanoestruturados como os lipossomas \n\n(SHAIKH; PAWAR, 2010). \n\n  Os lipossomas s\u00e3o ferramentas importantes na elucida\u00e7\u00e3o do mecanismo de a\u00e7\u00e3o de \n\nv\u00e1rios f\u00e1rmacos sobre as mais complexas membranas biol\u00f3gicas, assim como veicular \n\nmedicamentos em locais determinados minimizando os efeitos adversos encontrados na \n\nterapia convencional (SANTOS-MAGALH\u00c3ES et al., 2000; RODRIGUES et al., 2001; \n\nZHANG; GRANICK, 2006; CAVALCANTI et al., 2011). \n\n As vantagens do uso de lipossomas como sistema de libera\u00e7\u00e3o de f\u00e1rmacos incluem o \n\ntamanho e caracter\u00edstica da superf\u00edcie da part\u00edcula que pode ser facilmente manipulada para \n\nalcan\u00e7ar o s\u00edtio alvo; controle e estabilidade do f\u00e1rmaco no transporte aumentando a efic\u00e1cia \n\nterap\u00eautica e reduzindo os efeitos colaterais; incorpora\u00e7\u00e3o do f\u00e1rmaco no sistema sem outra \n\nrea\u00e7\u00e3o qu\u00edmica preservando a atividade do f\u00e1rmaco; utiliza\u00e7\u00e3o do sistema atrav\u00e9s de v\u00e1rias \n\nformas de administra\u00e7\u00e3o como nasal, oral, intra-ocular, parenteral entre outras (MAJET; \n\nKUMAR, 2000; BIRNBAUM; BRANNON-PEPPAS, 2003; MOHANRAJ; CHEN, 2006; \n\nPEER et al., 2007; DAVIS; CHEN; SHIN, 2008; ZHANG et al., 2008; OLSON et al., 2010).  \n\nCom o intuito de desenvolver novas alternativas terap\u00eauticas para o tratamento da \n\ncriptococose, o presente estudo teve como objetivo caracterizar e avaliar a a\u00e7\u00e3o in vitro da \n\nciclopirox olamina livre e encapsulada em lipossomas frente amostras de Cryptococcus \n\nneoformans para futura aplica\u00e7\u00e3o no tratamento da criptococose sist\u00eamica. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n \n\n \n\n \n\n\n\n16 \n \n\n2. REVIS\u00c3O DA LITERATURA \n\n \n\n2.1 Criptococose: vias de infec\u00e7\u00e3o e manifesta\u00e7\u00e3o cl\u00ednica \n\nA criptococose, conhecida anteriormente por Torulose, Blastomicose Europ\u00e9ia ou \n\nDoen\u00e7a de Busse- Buschke, \u00e9 uma micose de evolu\u00e7\u00e3o aguda, subaguda ou cr\u00f4nica, \n\npotencialmente fatal, que vem assumindo um papel relevante na atualidade por ser uma das \n\nmicoses mais comuns em pacientes imunocomprometidos (PARK et al. 2009; FRIES; COX, \n\n2011). Al\u00e9m do homem, a doen\u00e7a pode acometer animais dom\u00e9sticos, principalmente c\u00e3o e \n\ngato; al\u00e9m de animais silvestres (LIN; HEITMAN, 2006).  \n\nEm humanos, a criptococose \u00e9 comumente diagnosticada em pacientes com \n\nimunodepress\u00e3o celular, como os soropositivos para o V\u00edrus da Imunodefici\u00eancia Humana \n\n(HIV). Nos \u00faltimos anos, o aumento do n\u00famero de casos da S\u00edndrome da Imunodefici\u00eancia \n\nAdquirida foi acompanhado pelo aumento da incid\u00eancia de criptococose (PAPPALARDO; \n\nMELHEM, 2003; PARK et al. 2009; FRIES; COX, 2011). Dessa forma, esta micose \n\natualmente \u00e9 considerada a doen\u00e7a oportunista com alto \u00edndice de morbidade e mortalidade \n\n(PARK et al., 2009; ALBUQUERQUE; RODRIGUES, 2012).  \n\nSegundo levantamento realizado por Park e colaboradores em 2009, estima-se que \n\naproximadamente 1,000,000 de casos de meningite criptococ\u00f3cica ocorram a cada ano em \n\npacientes com AIDS, resultando 600,000 mortes no per\u00edodo de tr\u00eas meses de infec\u00e7\u00e3o (PARK \n\net al., 2009). No Brasil, a doen\u00e7a foi recentemente caracterizada como a micose que causa \n\nmaior n\u00famero de mortes neste grupo de pacientes (PRADO et al., 2009). Com base nestes \n\ndados, Albuquerque e Rodrigues (2012) em sua revis\u00e3o sobre o perfil da criptococose e \n\nesp\u00e9cies patog\u00eanicas de Cryptococcus nos \u00faltimos 20 anos, verificaram que o Brasil e em \n\nsegundo lugar, os Estados Unidos, s\u00e3o os respons\u00e1veis pela produ\u00e7\u00e3o t\u00e9cnico-cient\u00edfica na \n\n\u00e1rea. Especificamento no Brasil, os principais estados respons\u00e1veis por tal produ\u00e7\u00e3o s\u00e3o \n\nMinas Gerais (15%), S\u00e3o Paulo (25%), Rio de Janeiro (31%) e Rio Grande do Sul (16%) \n\n(Figura 1). \n\n\n\n17 \n \n\n          \n\n \n\nFigura 1. Contribui\u00e7\u00e3o global de autores Brasileiros no campo da criptococose em compara\u00e7\u00e3o \n\ncom autores americanos. (A) Varia\u00e7\u00e3o anual (1991\u20132010) da percentagem de artigos contendo autores \n\nbrasileiros ou americanos (B) An\u00e1lise do perfil de produtividade cient\u00edfica  comparando estudos onde os autores \n\nbrasileiros estiveram em qualquer posi\u00e7\u00e3o  da lista de autores, com artigos onde os cientistas brasileiros \n\nestiveram na posi\u00e7\u00e3o senior (C) An\u00e1lise detalhada de perfis mostrando distribui\u00e7\u00e3o de artigos por autores \n\nenvolvendo os principais pa\u00edses, incluindo o Brasil.  (ALBUQUERQUE; RODRIGUES, 2012). \n\n \n\nCom rela\u00e7\u00e3o ao fungo, v\u00e1rios autores consideram C. neoformans como pertencente a \n\num complexo formado por esp\u00e9cies e variedades, as quais correspondem Cryptococcus \n\nneoformans var. neoformans, C. neoformans var. grubii e C. gattiii (BYRNES et al., 2010; \n\n\n\n18 \n \n\nGUPTA; FRIES, 2010; PEDROSO et al., 2010; DELIO et al., 2010; SAN-BLAS et al., 2011; \n\nALBUQUERQUE; RODRIGUES, 2012). \n\nAl\u00e9m destas, Khawcharoenporn e colaboradores (2007) afirmam que C. albidus e C. \n\nlaurentii, consideradas sapr\u00f3bias, foram relatadas como agentes de infec\u00e7\u00e3o. Os mesmos \n\nautores citam outras esp\u00e9cies isoladas de material cl\u00ednico, consideradas, contudo, de menor \n\nimprt\u00e2ncia como C. uniguttulatus, C. curvatus, C. adeliensis, C. humiculus, C. luteolus e C. \n\nmacerans. \n\nDe acordo com Honsho et al. (2003) e Kommers et al. (2005), a primo infec\u00e7\u00e3o por C. \n\nneoformans var. neoformans e C. gattii \u00e9 pulmonar, seguida de dissemina\u00e7\u00e3o. A alta \n\npreval\u00eancia da levedura em isolados ambientais, aliada a rara transmiss\u00e3o homem-homem ou \n\nanimal-animal, indica que a infec\u00e7\u00e3o \u00e9 adquirida atrav\u00e9s de fontes ambientais do fungo, \n\nespecialmente a partir de inala\u00e7\u00e3o de blastosporos oriundos de excretas de aves (Figura 2). \n\nPor\u00e9m, a criptococose pulmonar n\u00e3o possui caracter\u00edsticas espec\u00edficas, logo, o diagn\u00f3stico \n\ndiferencial torna-se dif\u00edcil. Esta aus\u00eancia de sintomas proporciona o aumento de casos \n\nsubdiagnosticados de criptococose, principalmente em pacientes imunocompetentes (ZHU et \n\nal., 2002).  \n\n \n\n                      Figura 2. Ciclo de infec\u00e7\u00e3o de Cryptococcus spp.  \n\n \n\n    Fonte: Adaptado de LIN; HEITMAN, 2006. \n\n \n\n\n\n19 \n \n\nDe acordo com Hull; Heitman (2002) e Abegg et al. (2006), algumas evid\u00eancias \n\ncorroboram com o fato da infec\u00e7\u00e3o prim\u00e1ria ser nos pulm\u00f5es como a identifica\u00e7\u00e3o de excretas \n\nde aves como reservat\u00f3rio ambiental e a descoberta, de part\u00edculas infecciosas com tamanho \n\ncompat\u00edvel com a deposi\u00e7\u00e3o alveolar (0,5 a 2 \u00b5m). Associado a isto, est\u00e3o o reconhecimento \n\nde pneumonia criptococ\u00f3cica e a descri\u00e7\u00e3o de n\u00f3dulos subpleurais. \n\n Segundo N\u00fa\u00f1ez et al. (2000), a infec\u00e7\u00e3o pulmonar prim\u00e1ria no imunocompetente \u00e9, na \n\nmaioria das vezes, assintom\u00e1tica e regressiva, com resposta imunol\u00f3gica e evolu\u00e7\u00e3o para cura. \n\nEntretanto, de acordo com Vilchez et al. (2002) e Casali et al. (2003), a partir de uma les\u00e3o \n\npulmonar no imunodeprimido, pode haver progress\u00e3o, com dissemina\u00e7\u00e3o por via linfo-\n\nhematog\u00eanica, para outros sistemas, em especial para o sistema nervoso central (SNC). Neste \n\n\u00f3rg\u00e3o, meningoencefalite f\u00fangica \u00e9 a forma cl\u00ednica mais freq\u00fcente com 75% dos casos. \n\nNo sistema nervoso central, al\u00e9m da meningoencefalite criptococ\u00f3cica, podem ocorrer \n\nquadros de meningite e encefalite. A sintomatologia inclui cefal\u00e9ia e mudan\u00e7a \n\ncomportamental, podendo evoluir para sinais de irrita\u00e7\u00e3o men\u00edngea e v\u00f4mitos. Em casos mais \n\ngraves, verifica-se confus\u00e3o mental, apatia e edema papilar. Observada sob a forma de \n\nmeningoencefalite, pode ter curso fulminante e de outra forma, pode representar uma \n\nreativa\u00e7\u00e3o de foco latente ou eclodir em virtude de reinfec\u00e7\u00e3o por nova exposi\u00e7\u00e3o ao agente \n\n(CASALI et al., 2001; PAPPALARDO;  MELHEM, 2003; CORTI et al., 2008).  \n\nBivanco; Machado; Martins (2006); Dilhuydy et al. (2007) e Dillon et al. (2011) \n\nafirmam que al\u00e9m de acometer os sistemas respirat\u00f3rio e nervoso, a criptococose pode \n\nmanifestar-se atrav\u00e9s de les\u00f5es cut\u00e2neas visualizadas principalmente na face e membros \n\nsuperiores, sendo representada por m\u00e1cula avermelhada, p\u00e1pulas, p\u00fastulas, n\u00f3dulos ou \n\n\u00falceras. Em indiv\u00edduos que fazem uso de corticosteroides, \u00e9 observado vasculite com eritema \n\ne endurecimento. Por\u00e9m, este tipo de manifesta\u00e7\u00e3o cl\u00ednica da criptococose \u00e9 menos comum, \n\nmais prevalente no norte da Europa, e atinge cerca de 10% a 15% dos pacientes. \n\nSegundo Idnurm et al. (2005), a preval\u00eancia de infec\u00e7\u00e3o por C. neoformans est\u00e1 \n\ndiretamente relacionada com o grau de exposi\u00e7\u00e3o \u00e0 levedura e com a condi\u00e7\u00e3o imune do \n\nhospedeiro. De acordo com Reolon et al. (2004); N\u00fa\u00f1ez et al. (2000); Moreira et al. (2006) e \n\nLin; Heitman (2006) e Corti et al. (2008), os primeiros relatos da infec\u00e7\u00e3o revelam \n\nimunodepress\u00e3o celular em fun\u00e7\u00e3o do uso de cortic\u00f3ides, diabetes mellitus, linfoma e l\u00fapus \n\neritematoso sist\u00eamico. Al\u00e9m disso, soma-se a esses grupos de risco, indiv\u00edduos sob \n\nantibioticoterapia, leuc\u00eamicos, transplantados e portadores de tumores, alterando dessa forma \n\no perfil epidemiol\u00f3gico para a patologia. \n\n \n\n\n\n20 \n \n\n2.2 Criptococose experimental \n\n Os modelos de infec\u00e7\u00e3o experimental s\u00e3o importantes para o estudo da patog\u00eanese e \n\npara o acompanhamento do tratamento. Estes ocupam posi\u00e7\u00e3o essencial no estudo de doen\u00e7as \n\ninfecciosas como resultado de problemas \u00e9ticos da exposi\u00e7\u00e3o de seres humanos a agentes \n\npotencialmente letais (WILES et al., 2006). \n\n A indu\u00e7\u00e3o de infec\u00e7\u00f5es em modelos animais bem definidos fornece informa\u00e7\u00f5es a \n\ncerca do processo da doen\u00e7a, aproximando-se do contexto natural, apesar das diferen\u00e7as \n\nexistentes entre as infec\u00e7\u00f5es naturais e as induzidas. O modelo \u00e9 somente uma representa\u00e7\u00e3o \n\ndo processo natural da doen\u00e7a, e dever\u00e1 ser apropriado para o processo que se deseja estudar, \n\nenvolvendo v\u00e1rios fatores, como por exemplo, a integra\u00e7\u00e3o do conhecimento com os \n\nm\u00faltiplos ambientes em que a doen\u00e7a se estabelece (WILES, et al., 2006). \n\n No estudo da criptococose, os modelos mais utilizados s\u00e3o ratos, coelhos e \n\ncamundongos para avaliar principalmente a patogenicidade, os fatores de virul\u00eancia do micro-\n\norganismo, a imunidade do hospedeiro e a efic\u00e1cia de f\u00e1rmacos antif\u00fangicos. A escolha da \n\nesp\u00e9cie animal e a via de inocula\u00e7\u00e3o do micro-organismo depende do objetivo e do grau de \n\nreprodutibilidade desejado (PERFECT, 2005). \n\n Segundo Casadevall; Perfect (1998) podem ser utilizadas para indu\u00e7\u00e3o da criptococose \n\nas vias: intraperitoneal, intracerebral, intravenosa, intranasal e intratraqueal. Contudo, a via \n\nintraperitoneal \u00e9 a mais escolhida pela facilidade de inocula\u00e7\u00e3o. A intravenosa tamb\u00e9m \u00e9 uma \n\nt\u00e9cnica importante quando aplicada, pois trata-se an\u00e1lise quantitativa e padronizada, al\u00e9m de \n\nfornecer respostas a respeito da dissemina\u00e7\u00e3o do micro-organismo para os diferentes \u00f3rg\u00e3os. \n\n Segundo Wickes; Kwon-Chung (2002) e Perfect (2005), os camundongos s\u00e3o os \n\nanimais de laborat\u00f3rio mais suscept\u00edveis \u00e0 infec\u00e7\u00e3o por Cryptococcus, bem como s\u00e3o modelos \n\nmais indicados pelo baixo custo, pela facilidade no manuseio, e devido \u00e0 disponibilidade de \n\ndiversas linhagens geneticamente conhecidas. De acordo com os autores, as infec\u00e7\u00f5es nestes \n\nanimais podem ser subcl\u00ednicas ou letais a depender do tamanho do in\u00f3culo, via de inocula\u00e7\u00e3o \n\ne virul\u00eancia do isolado. Quanto aos animais, o sucesso da infec\u00e7\u00e3o depender\u00e1 da linhagem e \n\ndo estado imunol\u00f3gico.  \n\n  Conforme Segal; Baum (1994), quando se trata de infec\u00e7\u00e3o experimental, alguns \n\nestudos podem ser conduzidos avaliando a dissemina\u00e7\u00e3o e o tropismo do micro-organismo \n\npara diferentes tecidos, assim como a sobrevida do hospedeiro e a resposta terap\u00eautica. \n\n A quantifica\u00e7\u00e3o da carga antif\u00fangica em diferentes \u00f3rg\u00e3os permite avaliar a \n\ndissemina\u00e7\u00e3o do micro-organismo e sua depura\u00e7\u00e3o pelo hospedeiro. A avalia\u00e7\u00e3o da \n\nsobreviv\u00eancia do hospedeiro \u00e9 feita determinando-se a taxa de sobreviv\u00eancia ou de morte dos \n\n\n\n21 \n \n\nanimais, de acordo com o per\u00edodo de tempo ap\u00f3s a infec\u00e7\u00e3o experimental. A an\u00e1lise dever ser \n\npadronizada com rela\u00e7\u00e3o ao peso, idade e padr\u00e3o de resposta imunol\u00f3gica, comparando-se os \n\ntempos de evolu\u00e7\u00e3o da infec\u00e7\u00e3o at\u00e9 a morte do animal (CHRETIEN et al., 2002; WICKES; \n\nKWON-CHUNG, 2002). \n\n Capilla e colaboradores (2006) utilizaram em suas pesquisas um modelo experimental \n\nde criptococose para analisar o efeito da imunodefici\u00eancia e imunossupress\u00e3o induzida por \n\nglicocorticoides p\u00f3s-infec\u00e7\u00e3o induzida por via intravenosa com Cryptococcus neoformans \n\nvar. neoformans e C. gattii em camundongos da linhagem BALB/c. Os camundongos \n\nimunocompetentes foram infectados por via endovenosa com um in\u00f3culo de 106 c\u00e9lulas/mL \n\nde Cryptococcus gattii e os camundongos imunossuprimidos foram  infectados com in\u00f3culo \n\nde  105 c\u00e9lulas/mL de Cryptococcus neoformans var. neoformans. Os autores verificaram que \n\nos camundongos infectados com C. gattii desenvolveram mais frequentemente les\u00f5es externas \n\ne prolapso retal. A an\u00e1lise quantitativa das unidades formadoras de col\u00f4nia demonstrou maior \n\ncoloniza\u00e7\u00e3o da levedura no c\u00e9rebro, f\u00edgado e pulm\u00f5es em camundongos infetados por C. \n\nneoformans var. neoformans. \n\n Medeiros et al. (2010), verificaram a atividade antif\u00fangica do fitoter\u00e1pico beta-\n\nlapachona em um modelo de criptococose disseminada por Cryptococcus neoformans var \n\nneoformans utilizando camundongos su\u00ed\u00e7os imunossuprimidos com dexametasona (0,5 mg/ \n\ncamundongo). No estudo, a anfotericina B foi utilizada na concentra\u00e7\u00e3o de 0,5 mg/Kg para \n\nfins de compara\u00e7\u00e3o, uma vez que \u00e9 o f\u00e1rmaco de escolha para o tratamento da criptococose. A \n\nan\u00e1lise quantitativa das unidades formadoras de col\u00f4nias foi realizada a partir de fragmentos \n\ndo ba\u00e7o, f\u00edgado, rins, pulm\u00e3o e c\u00e9rebro. Como resultado, os autores observaram que o \n\ntratamento com ?-lapachona (10 mg/Kg) reduziu significativamente a quantidade de levedura \n\nno ba\u00e7o, pulm\u00e3o e f\u00edgado sete dias ap\u00f3s a infec\u00e7\u00e3o. Al\u00e9m disso, o fungo foi eliminado do \n\nba\u00e7o e f\u00edgado e teve sua carga reduzida em aproximadamente 104 vezes nos pulm\u00f5es e \n\nc\u00e9rebro ap\u00f3s 14 dias de infec\u00e7\u00e3o quando comparado com o grupo controle. A histopatologia \n\nrevelou necrose liquefativa e infiltrado celular no c\u00e9rebro em ambos os grupos tratados com \n\n?-lapachona e anfotericina B. \n\n De acordo com Graybill (2000) e Medeiros et al. (2010), a utiliza\u00e7\u00e3o de um modelo \n\nanimal para estudo da efic\u00e1cia de f\u00e1rmacos \u00e9 fundamental para o entendimento dos \n\nmecanismos de virul\u00eancia de micro-organismos como leveduras do g\u00eanero Cryptococcus e \n\npara propor novas alternativas, sendo esse um caminho essencial no trajeto de estudos in vitro \n\nat\u00e9 seu uso em pacientes.  \n\n \n\n\n\n22 \n \n\n2.3 Cryptococcus neoformans  \n\n2.3.1 Hist\u00f3rico, caracter\u00edsticas moforfofisiol\u00f3gicas e aspectos epidemiol\u00f3gicos \n\n O g\u00eanero Cryptococcus re\u00fane aproximadamente 38 esp\u00e9cies de leveduras, fungos \n\nunicelulares, que se reproduzem predominantemente por brota\u00e7\u00e3o e caracterizam-se, em geral, \n\npor apresentar c\u00e1psula mucopolissacar\u00eddica, col\u00f4nia muc\u00f3ide, capacidade assimilativa a v\u00e1rias \n\nfontes de carbono, capacidade de produzir melanina; aus\u00eancia de capacidade fermentativa e \n\nsensibilidade a cicloheximida (BARNETT et al., 2000; DE HOOG et al., 2000; IKEDA et al., \n\n2002).            \n\nEstudos envolvendo a levedura iniciaram-se em 1894 com o pesquisador Francesco \n\nSanfelice, analisando  \u201cblastomicetos\u201d do suco de algumas frutas, isolou a partir do suco de \n\np\u00eassego um micro-organismo com estrutura semelhante a uma levedura encapsulada, o qual \n\ndenominou de Saccharomyces neoformans. O referido isolado foi inoculado \n\nexperimentalmente em animais, sendo capaz de produzir les\u00f5es. Este trabalho, publicado pela \n\nRevista do Instituto de Higiene da Universidade de Cagliari (It\u00e1lia), foi o marco inicial para \n\noutros estudos (BIVANCO; MACHADO; MARTINS, 2006). \n\nNa mesma \u00e9poca, Otto Busse, um patologista, e Abraham Buschke, um cl\u00ednico, \n\nrelataram separadamente o isolamento de um fungo com as mesmas caracter\u00edsticas, \n\nproveniente de uma les\u00e3o na t\u00edbia, semelhante a um sarcoma, de uma mulher com 31 anos. \n\nBusse descreveu o organismo como fungo, resistente ao tratamento com hidr\u00f3xido de s\u00f3dio e \n\no denominou Saccharomyces sp. (LACAZ et al., 2002a; SIDRIM; ROCHA, 2004; \n\nBIVANCO; MACHADO; MARTINS, 2006).  \n\nNa It\u00e1lia, outro organismo similar \u00e0 levedura obtida por Bushcke foi isolado por \n\nSanfelice (1895), desta vez a partir de um linfonodo de um boi, o qual nomeou S. lithogenes. \n\nCurtis (1896) descreveu um caso similar ao relatado por Busse e Buschke, isolando o agente a \n\npartir de uma les\u00e3o tumoral no quadril, o qual foi denominado S. tumefasciens. Constantin, \n\nem 1901, considerou essa esp\u00e9cie como S. hominis, agente da chamada blastomicose europ\u00e9ia \n\n(RIPPON, 1982; LACAZ et al., 2002a; SIDRIM; ROCHA, 2004). \n\nEm 1902, Frothingam reconheceu a mesma esp\u00e9cie em uma les\u00e3o pulmonar em um \n\ncavalo, em Massachussetts. Estes \u00faltimos achados estabeleceram o fato de que a doen\u00e7a \n\nacomete tanto animais quanto humanos (RIPPON, 1982; MITCHELL; PERFECT, 1995). \n\nAp\u00f3s examinar as v\u00e1rias culturas isoladas, o micologista franc\u00eas Vuillemin (1901) n\u00e3o \n\nvisualizou ascosporos, caracter\u00edsticos do g\u00eanero Saccharomyces e as transferiu para o g\u00eanero \n\nCryptococcus, previamente estabelecido por Kutzing (1833), ao demonstrar que o termo \n\n\n\n23 \n \n\nanterior era inadequado, sendo considerados, ent\u00e3o, como C. hominis os isolados de Busse e \n\nBuschke e C. neoformans, o de Sanfelice (RIPPON, 1982; SIDRIM; ROCHA, 2004). \n\nVon Hansemann (1905) \u00e9 citado como o primeiro a observar a levedura causando \n\nmeningite, e esta forma cl\u00ednica da micose n\u00e3o era diagnosticada ante mortem at\u00e9 Verse relatar \n\num caso em 1914 (RIPPON, 1982; MITCHELL; PERFECT, 1995). \n\nEm 1916, nos Estados Unidos, Stoddard e Cutler observaram alguns casos de \n\nblastomicose com les\u00f5es cut\u00e2neas e sist\u00eamicas, de onde isolaram uma levedura por estes \n\ndenominada Torula histolytica e a doen\u00e7a torulose. Os autores evidenciaram retra\u00e7\u00e3o da \n\nc\u00e1psula da levedura em meio \u00e0s les\u00f5es tissulares e interpretaram erroneamente como uma lise \n\ncelular causada pelo fungo no tecido hospedeiro (RIPPON, 1982; LACAZ et al., 2002; \n\nSIDRIM; ROCHA, 2004). \n\nRhoda Benham (1935) revisou os isolados identificados como Saccharomyces, \n\nCryptococcus e Torula, analisando morfologia, patogenicidade e reatividade frente a fatores \n\ns\u00e9ricos, concluindo que todos pertenciam a um s\u00f3 g\u00eanero. Em 1950, essa mesma autora \n\nprop\u00f4s a designa\u00e7\u00e3o C. neoformans (Sanfelice) Vuillemin 1901, que se tornou definitiva, \n\nsendo esta esp\u00e9cie, o principal agente etiol\u00f3gico da criptococose (RIPPON, 1982; SIDRIM; \n\nROCHA, 2004). \n\nOutros autores, embora indicando C. neoformans como agente etiol\u00f3gico \n\npredominante na criptococose, tamb\u00e9m relatam a ocorr\u00eancia de outras esp\u00e9cies como  C. \n\nlaurentii e C. albidus, por\u00e9m em menor freq\u00fc\u00eancia (MCCURDY; MORROW, 2001; \n\nAVERBUCH et al., 2002; LEE et al., 2004).  \n\nEm 1951, Emmons relatou pela primeira vez a fonte de infec\u00e7\u00e3o, afirmando a presen\u00e7a \n\nda levedura no solo. Ap\u00f3s quatro anos, o mesmo autor detectou cepas virulentas de C. \n\nneoformans em excretas e ninhos de pombos e observou quadros de pneumonia grave da \n\ncriptococose em trabalhadores que demoliam pr\u00e9dios antigos (EHRENSING; SAAG, 2001).   \n\nEm 1978, Kwon-Chung prop\u00f4s o g\u00eanero Filobasidiella para a fase sexual com duas \n\nvariedades F. neoformans var. neoformans (sorotipos A, D e A/D), sendo descrita como \n\nteleomorfo de C. neoformans var. neoformans   e  F. neoformans var. bacillispora (sorotipos \n\nB e C), correspondendo ao teleomorfo de C. neoformans var. gattii (ZAITZ et al., 1998). As \n\nduas variedades eram as \u00fanicas reconhecidas para C. neoformans at\u00e9 que FRANZOT et al. \n\n(1999) identificaram uma terceira variedade denominada C. neoformans var. grubii.  \n\nEm 2002, avan\u00e7os nas pesquisas envolvendo a ecologia, epidemiologia, fisiologia e \n\ngen\u00e9tica de C. neoformans permitiram que Kwon-Chung e colaboradores elevassem C. \n\nneoformans var gattii a uma nova esp\u00e9cie: Cryptococcus gattii. Com base nestas informa\u00e7\u00f5es, \n\n\n\n24 \n \n\nas antigas variedades s\u00e3o reconhecidas atualmente por v\u00e1rios autores como esp\u00e9cie e \n\nvariedades do complexo C. neoformans, as quais correspondem Cryptococcus neoformans \n\nvar. neoformans, C. gattiii e C. neoformans var. grubii. (BYRNES et al., 2010; \n\nALBUQUERQUE; RODRIGUES, 2012).  \n\nDe acordo com Meyer et al. (2003); Enanche-Angoulvant et al. (2007); Bovers; \n\nHagen; Boekhout (2008); Consenso em criptococose (2008) Huston; Mody (2009); Delio et \n\nal. (2010) e Albuquerque; Rodrigues (2012), C. neoformans e C. gattii, assim como outros \n\nmicro-organismos, possuem caracter\u00edsticas fenot\u00edpicas, epidemiol\u00f3gicas e gen\u00e9ticas que \n\npermitem classific\u00e1-los em n\u00edvel de variedades, sorotipos e tipos moleculares (tabela 1).  \n\n Cryptococcus neoformans var. neoformans e C. gattii desenvolvem-se in vitro entre 48 \n\ne 72h, produzindo col\u00f4nias muc\u00f3ides, lisas, de colora\u00e7\u00e3o branca a creme, sendo o grau de \n\nmucosidade da col\u00f4nia dependente da forma\u00e7\u00e3o da c\u00e1psula mucopolissacar\u00eddica \n\n(ZARAGOSA et al., 2006). \n\n A presen\u00e7a da c\u00e1psula mucopolissacar\u00eddea \u00e9 uma caracter\u00edstica distinta entre as \n\nesp\u00e9cies, sendo considerada importante fator de virul\u00eancia, antifagoc\u00edtico e imunodepressor. \n\nAproximadamente 90% da c\u00e1psula \u00e9 constitu\u00edda pelos polissacar\u00eddeos glucuronoxilomanana, \n\ngalactoxilomanana e manoprote\u00edna (CASALI et al., 2001; NISHIKAWA et al., 2003).  \n\nSegundo Zaragosa et al. (2006), a diferen\u00e7a na estrutura das glucuronoxilomananas da \n\nparede celular permitiu a identifica\u00e7\u00e3o dos cinco sorotipos conhecidos atualmente, todos \n\npatog\u00eanicos para o homem: Cryptococcus neoformans var. neoformans (sorotipos D e AD), \n\nCryptococcus gattii (sorotipos B e C) e mais recentemente, Cryptococcus neoformans var. \n\ngrubii (sorotipo A). O tamanho da c\u00e1psula \u00e9 determinado pelo gen\u00f3tipo e condi\u00e7\u00f5es de \n\ncrescimento, apresentando a levedura pequenas c\u00e1psulas quando no ambiente e c\u00e1psulas \n\nespessas durante a infec\u00e7\u00e3o. \n\nNo aspecto micromorfol\u00f3gico, observa-se c\u00e9lulas de leveduras globosas ou alongadas, \n\ncom ou sem brotamento. Pseudohifas est\u00e3o ausentes ou s\u00e3o rudimentares (REOLON et al., \n\n2004; BIVANCO; MACHADO; MARTINS, 2006). Este pat\u00f3geno oportunista \u00e9 detectado em \n\nindiv\u00edduos imunocompetentes e imunologicamente comprometidos, bem como em detritos de \n\norigem vegetal, frutas, pele de animais, e principalmente em excretas de pombos e outras \n\naves, onde pode permanecer vi\u00e1vel por mais de dois anos (LARSSON et al., 2003; PEREIRA; \n\nCOUTINHO, 2003; TABOADA, 2004). \n\nA criptococose por C. neoformans, representa a quarta causa mais freq\u00fcente de \n\ninfec\u00e7\u00e3o oportunista em pacientes com AIDS. Dentre as infec\u00e7\u00f5es f\u00fangicas, esta micose \u00e9 a \n\nprincipal respons\u00e1vel pela morbidade e mortalidade desses pacientes. Na maioria dos pa\u00edses, a \n\n\n\n25 \n \n\npreval\u00eancia da infec\u00e7\u00e3o em pacientes com AIDS tem se mantido na faixa de 5 a 10%, \n\nenquanto que este \u00edndice chega a 15-50% em pa\u00edses africanos (DUIN et al., 2002; JAIN et al., \n\n2005; ALBUQUERQUE;RODRIGUES, 2012).  \n\nNo Brasil, pesquisas mostram que 4,5% das infec\u00e7\u00f5es oportunistas associadas a \n\npacientes portadores de HIV s\u00e3o causadas predominantemente por C. neoformans var. \n\nneoformans. Al\u00e9m disso, a mortalidade em pacientes com criptococose, com ou sem doen\u00e7a \n\npredisponente, fica em torno de 40 a 66% (CORR\u00caA et al., 1999; DARZ\u00c9 et al., 2000;  \n\nPAPPALARDO; MELHEM, 2003; JANBON, 2004).  Apesar da import\u00e2ncia de uma melhor \n\ncompreens\u00e3o da amplitude da epidemia do HIV/SIDA nas diferentes regi\u00f3es do pa\u00eds, n\u00e3o h\u00e1 \n\ndados precisos da epidemiologia da criptococose na regi\u00e3o Nordeste do Brasil. A \n\ncaracteriza\u00e7\u00e3o cl\u00ednica e epidemiol\u00f3gica da doen\u00e7a se reflete no desenvolvimento de \n\nestrat\u00e9gias de preven\u00e7\u00e3o e defini\u00e7\u00e3o das bases para a assist\u00eancia m\u00e9dica aos doentes \n\ninfectados (ALBUQUERQUE; RODRIGUES, 2012). \n\nFernandes et al. (2000), realizaram estudo sobre a preval\u00eancia da meningoencefalite \n\ncriptococ\u00f3cica em 50 pacientes com AIDS provenientes do Hospital de Doen\u00e7as Tropicais de \n\nGoi\u00e2nia e relataram que todos apresentaram as manifesta\u00e7\u00f5es cl\u00ednicas caracter\u00edsticas de \n\ncriptococose meningoencef\u00e1lica como cefal\u00e9ia, v\u00f4mito e ocasionalmente febre. As amostras \n\nforam submetidas ao exame direto com tinta da China e as variedades detectadas atrav\u00e9s do \n\nmeio CGB, com percentagem de 94% de C. neoformans var. neoformans. De acordo com os \n\nautores, a identifica\u00e7\u00e3o de C. gattii em tr\u00eas casos (6%), foi considerado de grande \n\nimport\u00e2ncia, visto que mesmo em regi\u00f5es end\u00eamicas de criptococose, onde C. gattii \u00e9 mais \n\nfreq\u00fcente, este agente tem sido raramente correlacionado com criptococose do SNC em \n\nportadores do v\u00edrus da imunodefici\u00eancia adquirida.  \n\nDa mesma forma, Silva et al. (2008), utilizando meio L- Canavanina Azul de \n\nBromotimol (CGB)  para a detec\u00e7\u00e3o de  C.  neoformans var. neoformans e C. gattii isoladas \n\nde 35 pacientes com criptococose atendidos no Hospital Escola da Universidade Federal do \n\nTri\u00e2ngulo (HE-UFTM), verificaram que C. neoformans var. neoformans  foi prevalente, \n\nencontrada em 88,6% dos casos. A maioria dos pacientes acometidos de criptococose foi do \n\nsexo masculino, correspondendo a 85,7% dos casos (n=30), sendo 42,8% na faixa et\u00e1ria entre \n\n30 e 40 anos. Com rela\u00e7\u00e3o \u00e0 sorologia para HIV, 85,7% dos pacientes tinham sorologia \n\npositiva.  \n\nMoreira et al. (2006), afirmam que a maioria dos estudos envolvendo esp\u00e9cies de \n\nCryptococcus e criptococose, ressaltam mais os aspectos cl\u00ednicos e terap\u00eauticos, contudo, a \n\nepidemiologia e caracteriza\u00e7\u00e3o das esp\u00e9cies do complexo C. neoformans tamb\u00e9m s\u00e3o \n\n\n\n26 \n \n\nimportantes para um melhor progn\u00f3sticos dos pacientes. Os autores realizaram um estudo \n\nprospectivo de 96 pacientes, enfocando aspectos cl\u00ednico-epidemiol\u00f3gico e laboratorial das \n\nesp\u00e9cies da levedura no per\u00edodo de 1996-2003.  \n\nSegundo Casali et al. (2001) e Igreja et al. (2004), a recorr\u00eancia da infec\u00e7\u00e3o por \n\nCryptococcus spp. em pacientes com AIDS, sendo esta, resultante da reativa\u00e7\u00e3o da infec\u00e7\u00e3o, \n\nou causada por linhagens novas, \u00e9 um problema crescente. Segundo Rozenbaum e Gon\u00e7alves \n\n(1994), 15 a 25% dos pacientes sem AIDS e aproximadamente 50% dos pacientes \n\nsoropositivos para o v\u00edrus (HIV) podem apresentar recorr\u00eancia da infec\u00e7\u00e3o. \n\nO fungo \u00e9 mais freq\u00fcentemente isolado de casos de criptococose em homens adultos \n\n(DARZ\u00c9 et al., 2000; FERNANDES et al., 2003; MEYER et al., 2003; PAPPALARDO; \n\nMELHEM, 2003; LITVINTSEVA et al., 2005). Por raz\u00f5es desconhecidas, Fernandes et al. \n\n(2000) afirmam que a incid\u00eancia da doen\u00e7a em crian\u00e7as \u00e9 baixa. Entretanto, no Brasil, houve \n\num incremento nos relatos da criptococose nessa faixa et\u00e1ria (CORR\u00caA et al., 1999), estando \n\nesse ligado \u00e0 migra\u00e7\u00e3o da popula\u00e7\u00e3o da \u00e1rea urbana para a \u00e1rea rural, desnutri\u00e7\u00e3o ou ao \n\naumento do n\u00famero de crian\u00e7as imunocomprometidas. Rozenbaum e Gon\u00e7alves (1994) \n\nafirmam que a exposi\u00e7\u00e3o ao agente ocorre quando os indiv\u00edduos ainda s\u00e3o jovens, havendo \n\nreativa\u00e7\u00e3o da infec\u00e7\u00e3o latente na idade adulta.  \n\nSegundo Reolon et al. (2004) e Nielsen et al. (2007), C. neoformans var. neoformans \n\npossui distribui\u00e7\u00e3o cosmopolita e tem sido isolado de v\u00e1rias fontes na natureza principalmente \n\na partir de excretas de pombos e outras aves. Parece n\u00e3o infectar as aves devido a sua \n\ntemperatura m\u00e9dia corporal (42\u00b0C) e \u00e9 capaz de sobreviver \u00e0 passagem pelo trato \n\ngastrointestinal desses animais que constituem vetores da micose. Outras fontes ambientais \n\ns\u00e3o vegetais em decomposi\u00e7\u00e3o, latic\u00ednios, solo e ocos de \u00e1rvores. C. neoformans var. \n\nneoformans tamb\u00e9m \u00e9 o agente da maioria das infec\u00e7\u00f5es criptococ\u00f3cicas em pacientes \n\nimunocomprometidos, mesmo em regi\u00f5es onde a preval\u00eancia da C. gattii \u00e9 not\u00f3ria.   \n\nV\u00e1rios autores descreveram a identifica\u00e7\u00e3o de Cryptococcus spp. em fezes e ambientes \n\nfreq\u00fcentados por pombos. Segundo Bernardo; Martins; Martins  (2001) e Baroni et al. (2006),  \n\nexcretas de pombos (Columbia l\u00edvia) s\u00e3o de maior interesse em sa\u00fade p\u00fablica. Esta ave \n\nex\u00f3tica de origem europ\u00e9ia foi introduzida no Brasil no s\u00e9culo XVI. \u00c9 encontrada em grande \n\nn\u00famero nos centros urbanos devido a diversos fatores como facilidade de encontrar abrigo e \n\nalimento. De acordo com os autores, al\u00e9m da grande capacidade de adapta\u00e7\u00e3o e de sua \n\nprolifera\u00e7\u00e3o, o principal problema \u00e9 que o fungo permanece vi\u00e1vel nas fezes secas dessa ave \n\ndurante muitos anos, tornando-se um reservat\u00f3rio de part\u00edculas infectantes pass\u00edveis de \n\ninala\u00e7\u00e3o. \n\n\n\n27 \n \n\nFili\u00fa et al. (2002) descreveram o surto de contamina\u00e7\u00e3o de aves de cativeiro por C. \n\nneoformans var. neoformans com repercuss\u00e3o na sa\u00fade p\u00fablica. Foram observadas elevadas \n\nconcentra\u00e7\u00f5es de at\u00e9 46.000 prop\u00e1gulos vi\u00e1veis do fungo por grama de material seco na \n\ncidade de Campo Grande, Mato Grosso do Sul. Segundo os autores, o n\u00edvel de contamina\u00e7\u00e3o \n\nobservado pode estar relacionado \u00e0 movimenta\u00e7\u00e3o das aves nas gaiolas, bem como a presen\u00e7a \n\nde substrato para o crescimento do fungo como sementes de N\u00edger, alpiste e girassol. \n\nReolon et al. (2004), analisando 88 amostras de excreta de aves oriundas de cinco \n\npra\u00e7as de Porto Alegre, Rio Grande do Sul, verificaram que todas as amostras foram positivas \n\npara C. neoformans var. neoformans nos cinco ambientes estudados pelos autores. A presen\u00e7a \n\nde 10 mil unidades formadoras de col\u00f4nias por grama de material confirma a exist\u00eancia de \n\nfontes ambientais do fungo. Os autores afirmam que esta observa\u00e7\u00e3o possibilita a dispers\u00e3o e \n\ninala\u00e7\u00e3o de grande quantidade de prop\u00e1gulos, o que pode determinar a doen\u00e7a em \n\nimunocompetentes e imunodeprimidos. \n\nQueiroz et al. (2008) relatam que al\u00e9m de fezes de pombos, C. neoformans var. \n\nneoformans e C. gattii podem ser encontrados em fezes de morcego e restos de colm\u00e9ia de \n\nvespas comunit\u00e1ria (Polybia occidentalis).  \n\nNo que diz respeito a C. gattii, Melo et al. (1993); Mcdougall; Fyfe (2006) e Queiroz \n\net al. (2008) relatam que  esta esp\u00e9cie apresenta distribui\u00e7\u00e3o geogr\u00e1fica mais restrita do que C. \n\nneoformans var. neoformans, e teria alcan\u00e7ado v\u00e1rias partes do mundo atrav\u00e9s de sementes do \n\nEucaliptus camaldulenses oriundos da Austr\u00e1lia. Nesse pa\u00eds, C. gattii foi isolado a partir de \n\nfolhas, sementes e cascas de eucalipto. O principal prop\u00e1gulo respons\u00e1vel pela infec\u00e7\u00e3o \n\ncorresponde aos basidiosporos encontrados nas flores dessa \u00e1rvore e que funcionaria como \n\nhospedeiro para o fungo em uma associa\u00e7\u00e3o biotr\u00f3fica. No entanto, de acordo com Fernandes \n\net al. (2000), o relato da presen\u00e7a de da levedura em ocos de diferentes \u00e1rvores como Cassia \n\ngrandis, Senna multijuga, e Ficus microcarpa, independente de sua esp\u00e9cie, indica novas \n\nfontes naturais desse fungo. Dessa forma, pode n\u00e3o haver uma rela\u00e7\u00e3o definida entre o fungo \n\ne um tipo espec\u00edfico de habitat (LAZERA et al., 1998).  \n\nCasali et al. (2003) e Abbeg et al. (2006) confirmaram a n\u00e3o especificidade de habitats \n\npelas variedades, ao realizarem no Rio Grande do Sul um estudo com 93 isolados cl\u00ednicos e \n\nambientais. Entre os isolados ambientais, os nove provenientes de eucaliptos foram \n\nidentificados como C. neoformans var. neoformans (sorotipo D) e nenhum isolado de C. gattii \n\nfoi obtido do ambiente. Outro estudo do mesmo grupo obteve 38 isolados de excretas de aves, \n\ne destes, 33 foram identificados como C. neoformans var. neoformans e cinco como C. gattii \n\n(sorotipo B), sugerindo excretas de aves pelo sorotipo B neste estado. \n\n\n\n28 \n \n\nEm Vancouver, onde houve um surto de criptococose causado por Cryptococcus gattii \n\n(MACDOUGALL; FYFE, 2006), a incid\u00eancia de infec\u00e7\u00e3o por esta variedade, entre 1999-\n\n2003, esteve entre 8,5 e 37 casos por milh\u00f5es de residentes por ano (KIDD et al., 2004). Na \n\nAustr\u00e1lia, esta taxa foi citada por Sorrel (2001) como sendo 8,5 casos por milh\u00e3o de \n\nhabitantes/ano descrito, sendo maior do que a taxa total no mesmo pa\u00eds entre 1994 e 1997, \n\nque foi de 6,6 casos por milh\u00e3o de habitantes/ano. \n\nPor raz\u00f5es desconhecidas, C. gattii raramente acomete pacientes com HIV e \n\nindiv\u00edduos imunossuprimidos. Pacientes infectados por esta esp\u00e9cie usualmente s\u00e3o \n\nimunocompetentes e respondem lentamente ao tratamento antif\u00fangico (PAPPALARDO; \n\nMELHEM, 2003; DIAZ; FELL, 2005; NIELSEN et al., 2007).  \n\n \n\n2.4 M\u00e9todos utilizados para identifica\u00e7\u00e3o de Cryptococcus spp \n\n \n\n O diagn\u00f3stico laboratorial dos agentes da criptococose baseia-se, principalmente, na \n\nvisualiza\u00e7\u00e3o de leveduras capsuladas unibrotantes, e mais raramente multibrotantes presentes \n\nno esp\u00e9cime cl\u00ednico em prepara\u00e7\u00f5es com tinta da China (figura 3-I) e no subsequente \n\nisolamento do micro-organismo em meio de cultura para sua confirma\u00e7\u00e3o (figura 3-II) \n\n(BIVANCO; MACHADO; MARTINS, 2006; OSUNA et al., 2008; QUEIROZ et al.2008). \n\n  Larsson et al. (2003); Bivanco et al. (2006) e Queiroz et al. (2008) afirmam que v\u00e1rios \n\nesp\u00e9cimes como escarro, lavado br\u00f4nquico, l\u00edquor, secre\u00e7\u00e3o de les\u00f5es cutaneomucosas, urina, \n\nmacerados de tecidos obtidos por bi\u00f3psia e sangue perif\u00e9rico, podem ser utilizados para a \n\npesquisa direta da levedura. Por\u00e9m, segundo Corr\u00eaa et al. (2002) e Moreira et al. (2006), o \n\nl\u00edquido cefalorraquidiano (LCR) representa a amostra ideal, tendo em vista que o principal \n\nagente etiol\u00f3gico apresenta tropismo pelo sistema nervoso central. \n\n De acordo com Severo et al. (1998), a prefer\u00eancia pelo SNC se deve \u00e0 alta \n\nconcentra\u00e7\u00e3o, no liquor, de nutrientes como tiamina, \u00e1cido glut\u00e2mico, glutamina, carboidratos \n\ne minerais assimil\u00e1veis pelo fungo; aus\u00eancia de atividade do complemento e a fraca ou \n\nausente resposta inflamat\u00f3ria no tecido cerebral. \n\n Kommers et al. (2005), afirmam que a observa\u00e7\u00e3o microsc\u00f3pica de C. neoformans \n\natrav\u00e9s da tinha da China, contribui um diagn\u00f3stico r\u00e1pido e barato, sendo importante \n\nespecialmente na suspeita de meningite criptococ\u00f3cica. A base para a visualiza\u00e7\u00e3o das \n\nleveduras por este m\u00e9todo \u00e9 que a c\u00e1psula afasta as part\u00edculas da tinta, formando um halo \n\nclaro ao redor da mesma. Contudo, o diagn\u00f3stico de criptococose torna-se mais dif\u00edcil quando \n\nse trata de c\u00e9lulas acapsuladas. \n\n\n\n29 \n \n\n A cultura \u00e9 o padr\u00e3o ouro dos m\u00e9todos de diagn\u00f3stico laboratorial micol\u00f3gico para \n\nCryptococcus neoformans, embora apresente como limita\u00e7\u00f5es o tempo necess\u00e1rio para o \n\ndesenvolvimento e a identifica\u00e7\u00e3o do agente etiol\u00f3gico (LACAZ et al., 2002a; QUEIROZ et \n\nal., 2008).  Por outro lado, Casadevall; Perfect (1998) afirmam que, em certas ocasi\u00f5es, como \n\npor exemplo, na meningite criptococ\u00f3cica cr\u00f4nica, o liquor pode resultar em culturas \n\nnegativas devido \u00e0 pequena concentra\u00e7\u00e3o de leveduras vi\u00e1veis ao n\u00edvel lombar (inferior a 103 \n\nUFC/mL). A baixa concentra\u00e7\u00e3o \u00e9 devido a tratamento pr\u00e9vio e torna-se um problema no \n\nmonitoramento dos pacientes cr\u00f4nicos. As prepara\u00e7\u00f5es com tinta da China, por sua vez, \n\npermanecem positivas por meses ap\u00f3s o tratamento e recupera\u00e7\u00e3o desse grupo de pacientes.  \n\nMoreira et al. (2006) afirmam que para o diagn\u00f3stico laboratorial da criptococose, a \n\npesquisa direta demonstrou a presen\u00e7a do micro-organismo em 98,3% das amostras, \n\nocorrendo 100% do isolamento da levedura. Al\u00e9m do LCR, os pesquisadores utilizaram \n\nsangue perif\u00e9rico como amostra cl\u00ednica e relataram que houve falha na detec\u00e7\u00e3o do ant\u00edgeno \n\npolissacar\u00eddico capsular do fungo em amostra da corrente sangu\u00ednea. \n\nAl\u00e9m dos testes supracitados, pode-se realizar o exame histopatol\u00f3gico para \n\nvisualiza\u00e7\u00e3o do micro-organismo e do dano tissular causado pela infec\u00e7\u00e3o. Para a an\u00e1lise \n\nhistopatol\u00f3gica, podem ser utilizadas colora\u00e7\u00f5es de rotina ou alternativas em bi\u00f3psias como \n\nHematoxilina-eosina (HE), \u00c1cido Peri\u00f3dico de Schiffer (PAS), Azul de Alciano, Metenamina \n\narg\u00eantica, Masson-Fontana, sendo eletivo o Mucicarmin de Mayer, o que cora a c\u00e1psula \n\nf\u00fangica de vermelho (NAMIQ et al., 2005). \n\nOs cortes histol\u00f3gicos corados pelo HE mostram c\u00e9lulas de C. neoformans esf\u00e9ricas, \n\novais ou el\u00edpticas com parede  fina r\u00f3sea ou azul p\u00e1lido com 5 a 15 \u00b5m de di\u00e2metro. As \n\nc\u00e1psulas n\u00e3o se coram devido a sua natureza mucopolissacar\u00eddica, permanecendo um halo \n\nclaro que envolve os blastocon\u00eddeos. Atrav\u00e9s da histopatologia \u00e9 poss\u00edvel visualizar rea\u00e7\u00e3o \n\ninflamat\u00f3ria cr\u00f4nica com linf\u00f3citos, histi\u00f3citos, macr\u00f3fagos e c\u00e9lulas gigantes, o granuloma \n\npode ser observado em alguns casos, sendo a necrose vari\u00e1vel, de m\u00ednima a abundante, assim \n\ncomo o n\u00famero de leveduras (BIVANCO; MACHADO; MARTINS, 2006; PEDROSO; \n\nCANDIDO, 2006). \n\nNos tecidos, a colora\u00e7\u00e3o com mucicarmim de Meyer \u00e9 um m\u00e9todo \u00fatil para diferenciar \n\nC. neoformans de outros fungos com tamanho e apar\u00eancias similares, pois evidencia a c\u00e1psula \n\nem vermelho, facilitando o seu reconhecimento (PEDROSO; CANDIDO, 2006). Outra \n\nt\u00e9cnica \u00fatil \u00e9 a colora\u00e7\u00e3o Fontana Masson, que pode ser utilizada para evidenciar o dep\u00f3sito \n\nde melanina na parede do C. neoformans, auxiliando na sua identifica\u00e7\u00e3o (LAZ\u00c9RA; \n\nIGREJA; WANKE, 2004; CONSENSO EM CRIPTOCOCOSE, 2008). \n\n\n\n30 \n \n\nCaso n\u00e3o seja poss\u00edvel a visualiza\u00e7\u00e3o microsc\u00f3pica de leveduras capsuladas, \n\nsugestivas de Cryptococcus, a identifica\u00e7\u00e3o pode ser realizada ou complementada por \n\nmicromorfologia e um conjunto de provas bioqu\u00edmicas da cultura f\u00fangica (DE HOOG et al., \n\n2000; LAZ\u00c9RA; IGREJA; WANKE, 2004). Mediante a prova do microcultivo em meio \u00e1gar-\n\nfub\u00e1 Tween 80 ou \u00e1gar-arroz Tween 80, \u00e9 poss\u00edvel observar c\u00e9lulas esf\u00e9ricas de tamanhos \n\nirregulares, sem hifas ou pseudo-hifas (di\u00e2metros maiores do que \u00e1s c\u00e9lulas de C. glabrata) e, \n\nalgumas vezes, separadas por material capsular.  \n\nO g\u00eanero Cryptococcus \u00e9 capaz de hidrolisar ureia (figura 3-IV), importante para \n\ndiferenciar das esp\u00e9cies do g\u00eanero Candida, que n\u00e3o possuem tal caracter\u00edstica. Cryptococcus \n\nspp. n\u00e3o possui habilidade de fermentar carboidratos, mas assimila, por metabolismo \n\noxidativo, a\u00e7\u00facares como glicose, maltose, sacarose e Lactose e como fonte de nitrog\u00eanio o \n\nsulfato de am\u00f4nio (Figura 3-V) (DE HOOG et al., 2000). A capacidade de assimilar inositol \n\ncomo \u00fanica fonte de carbono pode ser \u00fatil para diferenciar das esp\u00e9cies de Rhodotorula \n\n(WINN JR. et al., 2008).  \n\nA assimila\u00e7\u00e3o de carboidratos pode ser realizada por procedimentos semi-\n\nautomatizados e automatizados, como o API 20C (BioM\u00e9rieux) e o Vitek 2 (BioM\u00e9rieux), \n\nrespectivamente, assim como por m\u00e9todos manuais. Ademais, este g\u00eanero n\u00e3o assimila nitrato \n\ncomo \u00fanica fonte de nitrog\u00eanio inorg\u00e2nico e n\u00e3o realiza redu\u00e7\u00e3o a nitrito, bem como \u00e9 \n\nsens\u00edvel a cicloeximida, n\u00e3o crescendo em meios seletivos com sua presen\u00e7a em \n\nconcentra\u00e7\u00f5es acima de 0,2% (LAZ\u00c9RA; IGREJA; WANKE, 2004).  \n\nA habilidade do g\u00eanero Cryptococcus de produzir melanina com base em substratos \n\nfen\u00f3licos presentes em meios de cultura, conferindo \u00e0s col\u00f4nias pigmenta\u00e7\u00f5es escuras, \u00e9 \n\nespecialmente \u00fatil para isolamentos do fungo de culturas mistas e/ou ambientais (figura 3-\n\nIII) (LAZ\u00c9RA; IGREJA; WANKE, 2004; PINTO JUNIOR et al., 2006). A literatura mostra \n\nque a maioria das cepas de C. neoformans e C. gattii produz pigmento marrom quando \n\ncultivadas em meios de cultura com substratos fen\u00f3licos, enquanto para as outras esp\u00e9cies \n\nmuitas vezes esse fen\u00f4meno n\u00e3o ocorre (CARFACHIA et al., 2006a). Tal caracter\u00edstica \n\nconstitui uma prova bioqu\u00edmica \u00fatil na identifica\u00e7\u00e3o das esp\u00e9cies de import\u00e2ncia cl\u00ednica, \n\ndenominada fenoloxidase, sendo realizada inclusive em alguns laborat\u00f3rios de rotina \n\n(CAPOOR et al., 2007). H\u00e1 pesquisas que demonstram a utiliza\u00e7\u00e3o desse recurso como forma \n\nde estabelecer a diferencia\u00e7\u00e3o de C. neoformans das outras esp\u00e9cies do g\u00eanero (CHEN et al., \n\n2001; CARFACHIA et al., 2006a), contudo, existem outros estudos mostrando que isolados \n\nde C. albidus, C. laurentii e C. uniguttulatus podem apresentar produ\u00e7\u00e3o de melanina, de \n\n\n\n31 \n \n\nmaneira menos pronunciada do que para C. neoformans e C. gattii (IKEDA et al., 2002; \n\nPEDROSO et al., 2009).  \n\nA quimiotipagem de C. gattii e C. neoformans \u00e9 comumente realizada por interm\u00e9dio \n\ndo meio agar L-canavanina-glicina-azul de bromotimol (teste de CGB) (KWON-CHUNG; \n\nPOLACHECK; BENNETT, 1982). Apenas C. gattii \u00e9 resistente \u00e0 canavanina, utilizando a \n\nglicina dispon\u00edvel no meio para seu crescimento e, no per\u00edodo de at\u00e9 cinco dias, mudam a cor \n\nverde original do meio para a cor azul (figura 3-VI). J\u00e1 foram descritas, no entanto, cepas de \n\nC. neoformans com habilidade de resistir a elevadas concentra\u00e7\u00f5es de L-canavanina \n\n(NAKAMURA et al., 1998; KHAN et al., 2003). Com rela\u00e7\u00e3o \u00e0s outras esp\u00e9cies de \n\nCryptococcus, o meio de CGB geralmente n\u00e3o \u00e9 utilizado, entretanto, estudos conduzidos por \n\nBauters et al. (2001) mostram que cepas cl\u00ednicas de C. laurentii foram capazes de crescer na \n\npresen\u00e7a de L-canavanina e glicina.  \n\n \n\n \n\nFigura 3. M\u00e9todos diagn\u00f3sticos utilizados na identifica\u00e7\u00e3o de Cryptococcus spp. I) C. \n\nneoformans no l\u00edquor contra-corado com Tinta da China 40X; II) Aspecto muc\u00f3ide de C. \n\nneoformans em agar-Sabouraud 2% de glicose; III) Col\u00f4nia de C. neoformans em meio \u00c1gar \n\n\n\n32 \n \n\nSemente de Niger com forma\u00e7\u00e3o de melanina; IV) Ur\u00e9ia de Christensen. A - Teste negativo, \n\nA \u2013 Teste positivo; V) Auxonograma- Halos evidenciando crescimento f\u00fangico; VI) Meio \n\nCGB: a) C. neoformans b)  C. gattii; VII) Teste de Aglutina\u00e7\u00e3o em l\u00e1tex para detec\u00e7\u00e3o de \n\nant\u00edgeno; VIII); Gel de agarose 3% representativo de amplifica\u00e7\u00e3o utilizando primer URA5 \n\ncortado com enzimas de restri\u00e7\u00e3o Sau96Ie HhaI para identifica\u00e7\u00e3o de C. neoformans. Fonte: \n\nLaborat\u00f3rio de Micologia M\u00e9dica, 2010-2012. \n\n \n\nAs desvantagens apresentadas pelos testes fenot\u00edpicos relacionam-se principalmente \n\ncom tempo de identifica\u00e7\u00e3o e laboriosidade, al\u00e9m de ocorrer variabilidade de resultados em \n\nvirtude da subjetividade de interpreta\u00e7\u00e3o (WENGENACK; BINNICKER, 2009). Os m\u00e9todos \n\nsemiautomatizados e automatizados de identifica\u00e7\u00e3o de leveduras como API 20C AUX e \n\nVITEK, permitem a obten\u00e7\u00e3o de resultados em aproximadamente 72 horas. Muitas vezes, \n\npor\u00e9m, apresentam limita\u00e7\u00f5es por dependerem de provas suplementares para completa \n\nidentifica\u00e7\u00e3o do isolado, como teste da urease e assimila\u00e7\u00e3o de outras fontes de carbono \n\n(GUNDES; GULENC; BRINGOL, 2001; MASSONET et al., 2004).  \n\nOutras op\u00e7\u00f5es para diagn\u00f3stico da criptococose s\u00e3o os ensaios de detec\u00e7\u00e3o de ant\u00edgeno \n\npolissacar\u00eddicos capsulares, que apresentam elevada sensibilidade e r\u00e1pidos resultados. \n\nSegundo Bivanco; Machado; Martins (2006) e Queiroz et al. (2008), o teste de aglutina\u00e7\u00e3o em \n\npart\u00edculas de l\u00e1tex sensibilizadas com anticorpos espec\u00edficos (Figura 3-VII), representa uma \n\nferramenta importante no diagn\u00f3stico da criptococose. Esta prova geralmente produz alta \n\nsensibilidade e especificidade, e consiste na detec\u00e7\u00e3o de polissacar\u00eddeos capsulares \n\nsolubilizados nos fluidos corporais e que reagem com imunoglobulinas espec\u00edficas de coelho \n\nconjugadas a part\u00edculas de l\u00e1tex. Em estudo desenvolvido com 96 pacientes, foi observado \n\nque o diagn\u00f3stico atrav\u00e9s da rea\u00e7\u00e3o de aglutina\u00e7\u00e3o com part\u00edculas de l\u00e1tex mostrou \n\npositividade em 38 (97,4%) de 39 amostras, com um t\u00edtulo variando de 1:2 a 1:32 \n\n(MOREIRA et al., 2006). \n\n Pesquisas apontam que o uso de testes de aglutina\u00e7\u00e3o em l\u00e1tex para o \n\nacompanhamento da evolu\u00e7\u00e3o do tratamento requer a utiliza\u00e7\u00e3o de kits origin\u00e1rios de um \n\n\u00fanico fabricante como o CALAS\u00ae \u201cCryptocococcal Antigen Latex Agglutination System\u201d \n\n(Meridian, Bioscience, Inc.), Pastorex Crypto Plus\u00ae (Diagnostics Pasteur) e Crypto-LA \n\nTest\u00ae- (Fumouze), uma vez que h\u00e1 diferen\u00e7as na sensibilidade dos reagentes empregados. \n\nAl\u00e9m disso, a utiliza\u00e7\u00e3o desses testes para triagem, embora controverso, tem se justificado \n\npelo n\u00famero de casos com evolu\u00e7\u00e3o para a criptococose ap\u00f3s ocorrer aglutina\u00e7\u00e3o, sem \n\nqualquer achado em l\u00e2mina ou cultura (BIVANCO; MACHADO; MARTINS, 2006). Por\u00e9m, \n\nrea\u00e7\u00f5es falsopositivas podem ocorrer relacionadas ao fator reumat\u00f3ide, presen\u00e7a de c\u00e9lulas de \n\nTrichosporon spp. e bacilos Gram-negativos na amostra, devendo, ent\u00e3o, ser correlacionadas \n\n\n\n33 \n \n\ncom o quadro cl\u00ednico e laboratorial do caso sob investiga\u00e7\u00e3o (CONSENSO EM \n\nCRIPTOCOCOSE, 2008; HOUSTON; MODY, 2009).  \n\nAtualmente, apesar de n\u00e3o ser aplicado ao diagn\u00f3stico de rotina, existem m\u00e9todos \n\nmoleculares para detec\u00e7\u00e3o de sequ\u00eancias g\u00eanicas espec\u00edficas de C. neoformans e C. gattii em \n\nesp\u00e9cimes cl\u00ednicos ou com base na cultura (PASCHOAL et al., 2004; BOVERS et al., 2007). \n\nAs ferramentas moleculares (figura 3-VIII) apresentam elevadas sensibilidade e \n\nespecificidade de detec\u00e7\u00e3o, com potencial para resolver as limita\u00e7\u00f5es do diagn\u00f3stico \n\nconvencional, podendo ser empregadas tanto na identifica\u00e7\u00e3o como na tipagem e \n\nepidemiologia molecular do micro-organismo. No entanto, estes m\u00e9todos requerem \n\nnormalmente tecnologias mais sofisticadas, sendo tamb\u00e9m por este motivo mais dispendiosos, \n\ntornando-se limitados na rotina laboratorial a apenas alguns laborat\u00f3rios de diagn\u00f3stico \n\n(CARVALHO et al. 2007; LUCAS et al. 2010). \n\nV\u00e1rios m\u00e9todos moleculares baseados em PCR t\u00eam sido utilizados na caracteriza\u00e7\u00e3o e \n\nidentifica\u00e7\u00e3o de Cryptococcus spp., bem como em estudos epidemiol\u00f3gicos. Na PCR \n\nfingerprinting, s\u00e3o utilizados oligonucleot\u00eddeos iniciadores que s\u00e3o espec\u00edficos para \n\nsequ\u00eancias microssat\u00e9lites/minissat\u00e9lites ou para sequ\u00eancias repetitivas hipervari\u00e1veis de C. \n\nneoformans, permitindo que os isolados sejam tipados com sensibilidade suficiente para \n\ndetectar diferen\u00e7as inter- e intra-variedades.  Atrav\u00e9s desta t\u00e9cnica, foram identificados oito \n\ntipos moleculares [VN (VNI-VNIV) e VG (VGI-VGIV)] de C. neoformans species complex, \n\ndiferenciados atrav\u00e9s do estudo de polimorfismos de regi\u00f5es micro e minissat\u00e9lites do DNA \n\npor amplifica\u00e7\u00e3o das mesmas com primers como M13 e PCR-RFLP (restriction fragment \n\nlength polymorphism), baseado no gene URA5. Resultados indicam que os gen\u00f3tipos VNI e \n\nVNII correspondem ao sorotipo A, VNIII est\u00e1 relacionado ao sorotipo AD e VNIV ao \n\nsorotipo D de C. neoformans. Contudo, VGI-VGIV cont\u00eam isolados de dois sorotipos  (B e \n\nC) de C. gattii (MEYER et al., 1999; MEYER et al., 2003; LATOUCHE et al., 2003; \n\nESCANDON et al., 2006; DELIO et al., 2010). \n\nDe acordo com Tay et al. (2006) e Feng et al. (2008), o gen\u00f3tipo VNI \u00e9 tem \n\ndistribui\u00e7\u00e3o cosmopolita e s\u00e3o mais frequentemente isolados de pacientes com AIDS, \n\nenquanto que o VGI est\u00e1 associado a infec\u00e7\u00e3o em pacientes imunocompetentes e \u00e9 \n\nconsiderado o gen\u00f3tipo mais frequente em pa\u00edses asi\u00e1ticos. Com rela\u00e7\u00e3o ao gen\u00f3tipo VGII, \u00e9 \n\nbem distribu\u00eddo na Oceania al\u00e9m do Norte e Sul americanos (Ellis et al., 2000; Kidd et al., \n\n2004; Escand\u00f3n et al., 2006; MacDougall et al., 2007). A maior parte dos isolados cl\u00ednicos e \n\nambientais do Sul, Sudeste e Centro-Oeste brasileiros s\u00e3o VNI, enquanto o VGII predomina \n\nnas regi\u00f5es Norte e Nordeste do Brasil, especialmente em jovens adultos imunocompetentes e \n\n\n\n34 \n \n\ncrian\u00e7as (CASALI et al., 2003; IGREJA et al., 2004; MATSUMOTO et al., 2007; RIBEIRO \n\net al., 2008; SANTOS et al., 2008). \n\nEstudo realizado em 1996 comparou os perfis de amostras cl\u00ednicas e ambientais de C. \n\ngattii provenientes dos Estados Unidos e da Austr\u00e1lia. Dos 48 isolados cl\u00ednicos australianos, \n\n44 (92%) pertenciam ao gen\u00f3tipo VGI, 3 (6%), ao VGII e 1 (2%), ao VGIII. Entre as 4 \n\namostras cl\u00ednicas americanas, 3 eram VGIII, e 1, VGII. Os isolados cl\u00ednicos e ambientais \n\naustralianos apresentaram certa correla\u00e7\u00e3o (SORRELL et al., 1996). Amostras de C. \n\nneoformans originadas dos diversos continentes n\u00e3o diferem muito, geneticamente. C. gattii, \n\nno entanto, apresenta padr\u00e3o gen\u00e9tico correlacionado com a origem geogr\u00e1fica. H\u00e1 grande \n\ndiverg\u00eancia entre os isolados australianos e americanos, estando as amostras africanas e \n\nasi\u00e1ticas em posi\u00e7\u00e3o intermedi\u00e1ria (BOEKHOUT et al., 1997). \n\nEm um estudo ibero-americano, Meyer e colacoradores (2003), analisando diversos \n\nisolados provenientes de v\u00e1rios pa\u00edses, mostraram que entre as amostras de C. neoformans,  o \n\ngen\u00f3tipo VNI (68,1%) \u00e9 o mais prevalente. Com rela\u00e7\u00e3o \u00e0s amostras de C. gattii, predominou \n\no tipo molecular VGIII (44,9%). Casali et al. (2003), analisando 124 isolados (105 cl\u00ednicos e \n\n19 ambientais), verificaram que 93 amostras eram provenientes de pacientes portadores de \n\nAIDS. Entre os isolados ambientais, 52,6% eram VNI e 47,4%, VNIV. Entre os cl\u00ednicos, \n\n89,5% eram VNI e 10,5% eram VGIII, resultados estes que est\u00e3o de acordo com o estudo \n\nanterior.  \n\nJ\u00e1 Escad\u00f3n et al. (2006), obtiveram tamb\u00e9m como gen\u00f3tipo predominante VNI \n\n(62,9%), mas, entre os isolados de C. gattii, foi mais frequente VNII (99,2%). Ainda neste \n\nestudo, foi verificado grande similaridade gen\u00e9tica entre os isolados cl\u00ednicos e ambientais de \n\ngen\u00f3tipo VNI, o que corrobora a id\u00e9ia de que a criptococcose pode ser adquirida atrav\u00e9s de \n\ninala\u00e7\u00e3o do fungo presente no ambiente. Apesar disso, alguns tipos moleculares encontrados \n\nem amostras cl\u00ednicas, n\u00e3o foram isolados do ambiente. Este fato sugere que em tais pacientes \n\nhouve uma reativa\u00e7\u00e3o de uma infec\u00e7\u00e3o adquirida em uma regi\u00e3o diferente ou h\u00e1 nichos \n\necol\u00f3gicos ainda n\u00e3o bem estabelecidos. \n\nMatsumoto et al. (2007) genotiparam 47 isolados cl\u00ednicos provenientes de diversos \n\nlocais do estado de S\u00e3o Paulo-Brasil, utilizando dois m\u00e9todos: RAPD e PCR fingerprinting. \n\nQuando utilizada a t\u00e9cnica de PCR fingerprinting, observou-se certa homegeneidade entre as \n\namostras. Foram formados dois grupos, um correspondente a VNI (95,7%), e outro, a VNII \n\n(4,3%). A an\u00e1lise a partir do RAPD revelou maior heterogeneidade, com presen\u00e7a de 14 \n\nperfis de RAPD e forma\u00e7\u00e3o de 3 grupos principais: I (VNI), II(VNII) e III (VNIII), contendo, \n\nrespectivamente, 41, 2, e 4 isolados. No Esp\u00edrito Santo e Brasil, foram isoladas 10 amostras \n\n\n\n35 \n \n\nambientais, todas identificadas como VNI (RIBEIRO; NGAMSKULRUNGROJ, 2008). \n\nEstudo realizado no Par\u00e1, com amostras cl\u00ednicas, encontrou predomin\u00e2ncia de VNI (50%), \n\nseguido de VGII (44%) e VGI (6%) (DOS SANTOS et al., 2008). \n\nTrilles et al. (2008), trabalharam com 443 isolados brasileiros de Cryptococcus spp e \n\napesar de levar em considera\u00e7\u00e3o dados de um n\u00famero limitado de unidades federativas (11 \n\nestados brasileiros), esta pesquisa representa o perfil mais abrangente da epidemiologia \n\nmolecular de C. gattii e C. neoformans no Brasil. Utilizando dados de diversos estudos \n\nanteriores juntamente com dados adicionais, obteve-se os seguintes resultados: o tipos \n\nmoleculares mais comuns foram o VNI (64%) e o VGII (21%), seguidos de VNII (5%), VGIII \n\n(4%), VGI e VNIV (3% cada) e VNIII (<1%). N\u00e3o foram identificadas amostras VGIV entre \n\nos isolados brasileiros. Segundo os autores, C. gattii ocorre predominantemente no nordeste e \n\nC. neoformans, em sua maior parte, no sudeste. Foi sugerido, ainda, que o tipo molecular VGI \n\nteria uma tend\u00eancia de ocorrer em locais de latitude mais elevada.  \n\nEm um artigo recente, D\u00e9lio e colaboradores (2010) identificaram molecularmente 81 \n\nisolados de Cryptococcus obtidos de LCR de 77 pacientes com diagn\u00f3stico de meningite \n\ncriptococ\u00f3cica entre os anos de 1998 e 2007 em Uberaba, Minas Gerais, Brasil. Dos 77 \n\npacientes, 57 (74%) eram do sexo masculino com m\u00e9dia de idade de 35,6 anos. Setenta e dois \n\nisolados (88,9%) foram de 68 pacientes com AIDS e criptococose foi a doen\u00e7a prim\u00e1ria em \n\n38 (55,9%) dos pacientes. A micose e a AIDS foram diagnosticadas simultaneamente em 25 \n\n(65,8%) destes 38 pacientes. De acordo com os autores, os gen\u00f3tipos foram caracterizados \n\natrav\u00e9s da utiliza\u00e7\u00e3o do primer URA5 e a variabilidade gen\u00e9tica foi determinada utilizando \n\nPCR-fingerprinting com o primer de minissat\u00e9lite espec\u00edfico - M13. Setenta e seis dos 81 \n\nisolados foram Cryptococcus neoformans (93,8%), enquanto o restante foi identificado como \n\nC. gattii (6,1%). Isolados de C. neoformans foram gen\u00f3tipo VNI (sorotipo A), enquanto os \n\nisolados C. gattii foram VGII. Seis dos nove isolados de pacientes sem AIDS foram VNI. \n\nSegundo os autores, a ocorr\u00eancia de VGII em Minas Gerais indica uma expans\u00e3o geogr\u00e1fica \n\nno Brasil. \n\nDa mesma forma, para um diagn\u00f3stico de criptococose preciso e completo, \u00e9 \n\nimportante adicionar aos testes de rotina, a realiza\u00e7\u00e3o do perfil de sensibilidade antif\u00fangica de \n\nC. neoformans var. neoformans e C. gattii. Este m\u00e9todo \u00e9 muito utilizado para fins \n\nepidemiol\u00f3gicos e para instituir o tratamento adequado ou acompanhamento da resposta \n\nterap\u00eautica (QUEIROZ et al., 2008). \n\n \n\n \n\n\n\n36 \n \n\n2.5 Terapia na Criptococose e Teste de sensibilidade a antif\u00fangicos \n\nO tratamento de enfermidades causadas por fungos \u00e9 um desafio, uma vez que existem \n\nmuitas similaridades entre a maquinaria celular de fungos e a humana, diminuindo-se, desta \n\nforma, a disponibilidade de f\u00e1rmacos para o tratamento destas doen\u00e7as, quando comparadas a \n\ndoen\u00e7as de etiologia bacteriana ou viral (IDNUM et al., 2005). \n\nAtualmente, os antimic\u00f3ticos dispon\u00edveis constituem um pequeno grupo de f\u00e1rmacos \n\ndistribu\u00eddos entre poli\u00eanos, az\u00f3licos e alilaminas, que n\u00e3o atingem os resultados esperados \n\n(WALSH et al, 2000; WEIG et al, 2001; NUCCI; MARR, 2005).  \n\nSegundo File (2000), esta vertente na pesquisa de novos compostos com a\u00e7\u00e3o \n\nantif\u00fangica tem levado a comunidade cient\u00edfica a investigar a corrida medicamento versus \n\nmicro-organismos. Desde o in\u00edcio dos anos 80, o n\u00famero de f\u00e1rmacos em fase de \n\ndesenvolvimento diminuiu consideravelmente enquanto que a resist\u00eancia dos pat\u00f3genos aos \n\nmesmos tem crescido, porque estes est\u00e3o cada vez mais desenvolvendo uma s\u00e9rie de novos \n\nmecanismos de resist\u00eancia. \n\nDe acordo com Kanafani; Perfect (2008), apesar dos avan\u00e7os nas interven\u00e7\u00f5es \n\npreventivas, diagn\u00f3sticas e terap\u00eauticas, infec\u00e7\u00f5es f\u00fangicas invasivas causam significativa \n\nmorbidade e mortalidade em pacientes imunocomprometidos. O espectro de pat\u00f3genos, \n\nagentes de infec\u00e7\u00f5es f\u00fangicas, em imunodeprimidos est\u00e1 crescendo, no entanto, as op\u00e7\u00f5es \n\nterap\u00eauticas dispon\u00edveis s\u00e3o limitadas, e dentro deste contexto, o aumento da resist\u00eancia \n\nantif\u00fangica est\u00e1 se tornando problema de sa\u00fade p\u00fablica. \n\nDe acordo com Zanini et al. (2001) e Bianic; Harrison (2004), os principais f\u00e1rmacos \n\ncitados para o tratamento da criptococose s\u00e3o anfotericina B, associada ou n\u00e3o a 5-flucitosina, \n\ndevido a sua toxicidade principalmente renal, e fluconazol, podendo ser administrados via \n\nendovenosa e/ou oral. Segundo os autores, h\u00e1 relatos de tratamento de criptococose cut\u00e2nea \n\n(prim\u00e1ria e secund\u00e1ria), com fluconazol inicialmente endovenoso (200 mg a cada 12 h por 14 \n\ndias) e ap\u00f3s manuten\u00e7\u00e3o com a f\u00e1rmaco via oral (400 mg/dia) por no m\u00ednimo 45 dias com \n\ncura das les\u00f5es.  \n\nNo caso da criptococose pulmonar ou disseminada com comprometimento do SNC, a \n\nanfotericina B \u00e9 administrada na dose equivalente a 0,7-1 mg/kg/dia, in\u00edcio com 5 mg/dia, \n\ncom diminui\u00e7\u00e3o progressiva at\u00e9 0,5 a 1-2 mg/dia associada ou n\u00e3o com 5-fluocitosina (100-\n\n150mg/kg/dia) via oral ou endovenoso, por duas a tr\u00eas semanas, seguido pela consolida\u00e7\u00e3o da \n\nterapia com fluconazol (200-400 mg/dia via oral ou endovenosa) por 10 a 12 semanas e \n\nmanuten\u00e7\u00e3o com o mesmo f\u00e1rmaco (200 mg/dia via oral). Outros antif\u00fangicos como o \n\n\n\n37 \n \n\nitraconazol tamb\u00e9m \u00e9 citado como alternativa para o tratamento da criptococose, por\u00e9m em \n\nmenor frequ\u00eancia (BIVANCO; MACHADO; MARTINS, 2006). \n\nFilippin; Souza (2006) e Luisi et al. (2008) afirmam que a anfotericina B \u00e9 um poli\u00eano \n\nproduzido naturalmente pelo actinomiceto Streptomyces nodosus, sendo inicialmente obtida \n\nem meados de 1955 (VANDEPUTTE et al., 1956). No final dos anos 1950, a anfotericina B \n\nera utilizada em alguns casos cl\u00ednicos e em 1965 foi o primeiro agente antif\u00fangico a ser \n\naprovado pela \u201cU.S. Food and Drug Administration\u201d (FDA) (WU, 1994; DISMUKES, 2000).  \n\nEste f\u00e1rmaco \u00e9 um dos antif\u00fangicos mais antigos e considerado o f\u00e1rmaco de \n\nrefer\u00eancia para o tratamento da maioria das infec\u00e7\u00f5es f\u00fangicas mesmo com elevada \n\ntoxicidade e a introdu\u00e7\u00e3o de antimic\u00f3ticos az\u00f3licos sist\u00eamicos na d\u00e9cada de 1980. Seu efeito \n\nantif\u00fangico se d\u00e1 mediante a intera\u00e7\u00e3o direta com o ergosterol da membrana celular f\u00fangica \n\nn\u00e3o interferindo na s\u00edntese da membrana, mas sim desestabilizando e facilitando a forma\u00e7\u00e3o \n\nde fendas que permitem a perda de \u00edons e componentes celulares (DISMUKES, 2000; FICA, \n\n2004). O ergosterol \u00e9 necess\u00e1rio na manuten\u00e7\u00e3o da permeabilidade e fluidez da membrana, \n\ngarantindo a modula\u00e7\u00e3o de enzimas ligadas \u00e0 membrana plasm\u00e1tica. A aus\u00eancia do ergosterol \n\ne o ac\u00famulo de seus precursores afetam a estrutura da membrana e a absor\u00e7\u00e3o de nutrientes, \n\ntornando os fungos vulner\u00e1veis a danos (HUANG et al., 2002). \n\nO tratamento com anfotericina B quase sempre resulta em algum grau de disfun\u00e7\u00e3o \n\nrenal, que varia em gravidade de um paciente para o outro, sendo claramente uma fun\u00e7\u00e3o da \n\ndose total. Em um estudo utilizando anfotericina B, 24,8% dos pacientes tratados com 0,6-1,0 \n\nmg/Kg/dia, apresentaram nefrotoxidade comprovada atrav\u00e9s de achados laboratoriais \n\n(MORA-DUARTE et al., 2002). \n\nUm estudo com c\u00e9lulas renais de ratos conduzido por Varlam et al. (2001), sugeriu \n\nque a anfotericina B induzia apoptose das c\u00e9lulas tubulares renais e c\u00e9lulas intersticiais em \n\numa taxa diretamente proporcional a sua concentra\u00e7\u00e3o. Observou-se 90% de apoptose e \n\nnecrose com a concentra\u00e7\u00e3o m\u00e1xima tilizada de 5,0 mg/mL, reduzindo-se as les\u00f5es \u00e0 medida \n\nque esta era proporcionalmente diminu\u00edda. Estudos posteriores demonstraram que o efeito \n\nt\u00f3xico foi m\u00e1ximo nos t\u00fabulos com hipocalemia, hiposten\u00faria e diminui\u00e7\u00e3o da capacidade de \n\nexcretar \u00e1cidos, como tamb\u00e9m envolveu os glom\u00e9rulos com diminui\u00e7\u00e3o da depura\u00e7\u00e3o da \n\ncreatinina com o sem azotemia (MORA-DUARTE et al., 2002; FILIPPIN; SOUZA, 2006). \n\nBarchiesi et al. (2004) ao analisar a efic\u00e1cia terap\u00eautica da anfotericina B durante \n\ncriptococose experimental, verificou que camundongos CD1 machos infectados com 2,5x103 \n\nUFC via endovenosa apresentam redu\u00e7\u00e3o das contagens f\u00fangicas em todos os \u00f3rg\u00e3os \n\nanalisados a exce\u00e7\u00e3o do c\u00e9rebro. Os animais foram tratados com 0,3 mg/Kg/dia de \n\n\n\n38 \n \n\nanfotericina B intraperitonealmente durante 10 dias consecutivos. No c\u00e9rebro decorrido 21 \n\ndias ap\u00f3s o fim da terapia n\u00e3o foi evidenciado nenhuma diferen\u00e7a nas contagens f\u00fangicas \n\nentre o grupo tratado e o controle. \n\nPor outro lado, Larsen et al. (2004) realizaram estudo com o intuito de delinear a dose \n\nda anfotericina B na qual se obtinha melhor resultado aliado a menor toxicidade durante \n\ninfec\u00e7\u00e3o em camundongos Balb/c machos infectados com 700 UFC de C. neoformans \n\nintracerebralmente. As doses utilizadas variaram de 0,3 a 1,3 mg/Kg/dia administradas via \n\nendovenosa. Foi observado que 95% dos animais tratados com 0,5 mg/Kg/dia de anfotericina \n\nB sobreviveram at\u00e9 o final do experimento (16 dias). \u00c9 importante observar que com doses \n\niguais ou superiores a 0,7 mg/Kg/dia foi verificado n\u00famero inaceit\u00e1vel de morte nas primeiras \n\n24 horas (cerca de 40%), sendo o percentual de mortes diretamente proporcional ao aumento \n\nda dose. \n\n Apesar dos efeitos t\u00f3xicos demonstrados em pesquisas anteriores, o tratamento com \n\nanfotericina B pura ou conjugada a fluocitosina e fluconazol, \u00e9 geralmente bem sucedido na \n\ncriptococose, por\u00e9m falhas na terapia ocorrem por diversas raz\u00f5es, incluindo resist\u00eancia direta \n\naos antif\u00fangicos (PEREA;PATTERSON, 2002). \n\nAchados de resist\u00eancia antif\u00fangica in vitro em cepas cl\u00ednicas e ambientais de \n\nCryptococcus, embora raros, s\u00e3o relatados (COSTA et al., 2009). Alguns estudos descrevem \n\ntal fen\u00f4meno em cepas cl\u00ednicas de C. neoformans para fluconazol, anfotericina B e \n\nvoriconazol, bem como em isolados de C. gattii para itraconazol, flucitosina e fluconazol \n\n(CHANDENIER et al., 2004; ALMEIDA et al., 2007; SOARES et al., 2008). Em amostras \n\nambientais de C. neoformans, a resist\u00eancia antif\u00fangica prim\u00e1ria j\u00e1 foi detectada para \n\nitraconazol e fluconazol (SOARES et al. 2005; PEDROSO et al., 2006).  \n\nCom rela\u00e7\u00e3o a outras esp\u00e9cies de Cryptococcus, estudos demonstrando o perfil de \n\nsensibilidade antif\u00fangica in vitro s\u00e3o escassos, entretanto, em uma pesquisa realizada com \n\nisolados ambientais de C. neoformans var. neoformans (n=16), C. albidus (n=17), C. laurentii \n\n(n=14) e C. uniguttulatus (n=3) frente a anfotericina B, fluconazol, flucitosina e itraconazol, parte \n\ndas cepas analisadas mostrou perfil de resist\u00eancia aos f\u00e1rmacos testados com MICs variando de \n\n0,125 a 2 ?g/mL para anfotericiana B; 0,06 a 8 ?g/ mL para itraconazol, 0,5 a 64 ?g/mL para \n\nfluconazol e 5-fluorocytosina. (PEDROSO et al., 2006).  \n\nDesenvolvimento de resist\u00eancia de isolados de Cryptococcus a anfotericina B tamb\u00e9m \n\nforam descritos por Lozano-Chiu et al. (1998); Cuenca-Estrella et al. (2001); Sar et al. (2004) \n\nos quais apontam o aparecimento esp\u00e9cies de  Cryptococcus resistentes a anfotericina B \n\nassociado a casos de resist\u00eancia aos azoles, particularmente quando h\u00e1 resist\u00eancia cruzada a \n\n\n\n39 \n \n\noutros triazoles e intoler\u00e2ncia aos seus componentes, o que caracteriza grave problema para a \n\nsobrevida dos pacientes afetados pela criptococose. \n\nOutro estudo mostrando a a\u00e7\u00e3o da anfotericina B sobre isolados mutantes prop\u00f4s que a \n\nresist\u00eancia ocorria por mudan\u00e7as tanto qualitativas quando quantitativas dos ester\u00f3is, podendo \n\nocorrer uma diminui\u00e7\u00e3o do conte\u00fado de ergosterol celular ou substitui\u00e7\u00e3o de alguns ou de \n\ntodos por outros com afinidade diminu\u00edda a anfotericina. O ergosterol, colesterol e \n\nestigmasterol podem ser substitu\u00eddos por esterol 3-hidroxi ou 3-oxi ou tamb\u00e9m pode ocorrer \n\nreorienta\u00e7\u00e3o ou mascaramento do ergosterol existente, tornando a liga\u00e7\u00e3o da anfotericina \n\ntermodinamicamente menos favorecida (PEREA; PATTERSON, 2002). \n\nFilippin (2006) observaram resist\u00eancia de dois isolados de Cryptococcus neoformans a \n\nanfotericina B associada \u00e0 padr\u00e3o de ester\u00f3is. Segundo o autor, os isolados resistentes \n\npossu\u00edam um defeito na esterol isomerase, levando ao ac\u00famulo de outros ester\u00f3is e \n\ndiminui\u00e7\u00e3o do conte\u00fado de ergoster\u00f3is. \n\nPara o monitoramento do desenvolvimento de resist\u00eancia por parte de isolados de \n\nCryptococcus spp aos f\u00e1rmacos dispon\u00edveis, bem como o acompanhamento da resposta \n\nterap\u00eautica, faz-se necess\u00e1ria \u00e0 utiliza\u00e7\u00e3o dos testes de susceptibilidade. Embora a \n\nsusceptibilidade de leveduras aos antif\u00fangicos dispon\u00edveis seja vari\u00e1vel e previs\u00edvel, nem \n\nsempre uma determinada amostra isolada segue o padr\u00e3o geral. (CUENCA-ESTRELLA; \n\nRODRIGUEZ-TUDELA, 2002; PFALLER, 2012). \n\nSegundo Barchiesi et al. (2000), a avalia\u00e7\u00e3o da susceptibilidade de leveduras do \n\ng\u00eanero Cryptococcus aos antif\u00fangicos \u00e9 de grande interesse considerando a alta frequ\u00eancia em \n\npacientes imunocomprometidos e as severas manifesta\u00e7\u00f5es cl\u00ednicas da infec\u00e7\u00e3o por esta \n\nlevedura.  \n\nA utiliza\u00e7\u00e3o de v\u00e1rios m\u00e9todos pode conferir resultados diferentes (NORRIS et al., \n\n1999; JESSUP et al., 2000; FERN\u00c1NDEZ-TORRES  et al., 2002; GHANNOUM et al., 2006) \n\ne a import\u00e2ncia da padroniza\u00e7\u00e3o reflete em terap\u00eautica eficaz, a qual \u00e9 dependente da correta \n\nescolha do f\u00e1rmaco que apresente atividade em rela\u00e7\u00e3o ao fungo em quest\u00e3o (BARROS, \n\nSANTOS; HAMDAN, 2006). Os m\u00e9todos padronizados de reconhecimento nacional e \n\ninternacional para leveduras e fungos filamentosos t\u00eam contribu\u00eddo para predizer n\u00e3o somente \n\no tipo de antif\u00fangico adequado, como tamb\u00e9m a concentra\u00e7\u00e3o do f\u00e1rmaco para a terap\u00eautica \n\ninstitu\u00edda (REX et al., 2001; PFALLER et al., 2008; PFALLER, 2012).  \n\nInicialmente, para leveduras, foi proposto o documento M27-A em 1997, com segunda \n\nedi\u00e7\u00e3o aprovada em 2002 (M27-A2) e a terceira e atual em 2008 (M27-A3), todos \n\npertencentes ao Clinical and Laboratory Standards Institute (CLSI), antigo National \n\n\n\n40 \n \n\nCommittee for Clinical Laboratory Standards (NCCLS) (CUENCA-ESTRELLA et al., 2002). \n\nO documento \u00e9 composto por protocolo padronizado para avalia\u00e7\u00e3o in vitro  da atividade \n\nantif\u00fangica  de levedura que causam infec\u00e7\u00f5es invasivas, incluindo Cryptococcus \n\nneoformans. O documento inclui a sele\u00e7\u00e3o de agentes antif\u00fangicos, prepara\u00e7\u00e3o de solu\u00e7\u00f5es-\n\npadr\u00e3o e dilui\u00e7\u00f5es de antif\u00fangicos utilizadas para realiza\u00e7\u00e3o, implementa\u00e7\u00e3o e interpreta\u00e7\u00e3o \n\ndos testes. Al\u00e9m disso, esta padroniza\u00e7\u00e3o est\u00e1 relacionada com os meios de cultura utilizados \n\npara crescimento do fungo e para o teste de susceptibilidade (RPMI-1640), determina\u00e7\u00e3o da \n\nconcentra\u00e7\u00e3o inibit\u00f3ria m\u00ednima (CIM), padroniza\u00e7\u00e3o do in\u00f3culo, temperatura de incuba\u00e7\u00e3o, \n\nleitura e interpreta\u00e7\u00e3o dos resultados (CLSI, 2008). \n\nDe acordo com Brandt et al. (2001), v\u00e1rios estudos utilizando a metodologia do CLSI \n\nforam realizados para avaliar a situa\u00e7\u00e3o da resist\u00eancia a Cryptococcus. Em um estudo \n\nrealizado nos Estados Unidos com 732 isolados cl\u00ednicos obtidos nos per\u00edodos de 1992 a 1994 \n\ne 1996 a 1998, dois isolados mostraram CIMs elevadas para a anfotericina B (? 2 \u00b5g/mL), 14 \n\nisolados a fluocitosina (? 32 \u00b5g/mL), 8 isolados a fluconazol (? 64 \u00b5g/mL) e 45 isolados a \n\nitraconazol (? 1 \u00b5g/mL). \n\nSouza et al. (2005) verificaram a atividade antif\u00fangica de anfotericina B, fluconazol, \n\nitraconazol e voriconazol em 70 amostras de Cryptococcus neoformans (66 identificados \n\ncomo  C. neoformans var. neoformans e 4 como C. neoformans var. gattii) isoladas de liquido \n\nc\u00e9falo raquidiano (LCR) de pacientes com AIDS e em 40 amostras de C. neoformans obtidas \n\ndo meio ambiente.  A metodologia empregada para o teste de susceptibilidade foi o da \n\nmicrodilui\u00e7\u00e3o em caldo proposto pelo NCCLS M27-A2. As concentra\u00e7\u00f5es inibit\u00f3rias \n\nm\u00ednimas (CIMs) para os isolados cl\u00ednicos variaram de 0,06-1,0 \u00b5g/mL para anfotericina B, \n\n0,125-8 \u00b5g/mL para fluconazol, 0,03-0,5 \u00b5g/mL para itraconazol e 0,03-0,25 \u00b5g/mL para \n\nvoriconazol, enquanto que para as amostras ambientais de C. neoformans as concentra\u00e7\u00f5es \n\ninibit\u00f3rias variaram de 0,015-0,125 \u00b5g/mL, 0,25-2,0 \u00b5g/mL, 0,007-0,125 \u00b5g/mL e 0,03-0,25 \n\n\u00b5g/mL para anfotericina B, fluconazol, itraconazol e voriconazol, respectivamente. Os \n\nresultados evidenciaram que as CIMs dos isolados cl\u00ednicos tendem a ser maiores que a dos \n\nisolados ambientais. Contudo, as amostras testadas n\u00e3o apresentaram perfil de resist\u00eancia, \n\nlevando-se em considera\u00e7\u00e3o a metodologia e crit\u00e9rio de interpreta\u00e7\u00e3o estudados. \n\nOliveira et al. (2010), trabalharam com tr\u00eas agentes antif\u00fangicos: anfotericina B e \n\nfluconazol, ambos utilizados no tratamento da criptococose; e Ciclopirox olamina, um agente \n\nantif\u00fangico utilizado atualmente para infec\u00e7\u00f5es superficiais. Os autores observaram CIMs \n\nvariando de 0.03 a 1 \u00b5g/mL para anfotericina B; 2-32 \u00b5g/mL para fluconazol; e 0.25 a 1 \n\n\u00b5g/mL para a ciclopirox olamina. Com rela\u00e7\u00e3o \u00e0 concentra\u00e7\u00e3o fungicida m\u00ednima (MFC), os \n\n\n\n41 \n \n\nisolados apresentaram MFCs variando de 0.03-2 \u00b5g/mL para anfotericina B e 0.5- 4 \u00b5g/mL \n\npara Ciclopirox olamina. De acordo com os autores, cicopirox olamina representa uma \n\nalternativa em potencial para o tratamento da criptococose sist\u00eamica. \n\nEm vista da resist\u00eancia verificada e tomando por base que tratamentos prolongados \n\ngeram efeitos t\u00f3xicos ao organismo, visto que os antif\u00fangicos tamb\u00e9m agem sobre outras \n\nc\u00e9lulas eucari\u00f3ticas como as som\u00e1ticas, \u00e9 indispens\u00e1vel o desenvolvimento de novas \n\nestrat\u00e9gias terap\u00eauticas para aumentar a disponibilidade de f\u00e1rmacos com a\u00e7\u00e3o antif\u00fangica \n\nmais efetivas e menos t\u00f3xicas, contribuindo assim para a melhoria da qualidade de vida dos \n\npacientes (OLIVEIRA et al. 2010). \n\n \n\n2.6 Ciclopirox olamina \n\nDe acordo com Niewerth et al. (2003), ciclopirox olamina (originalmente HOE 296) \n\nteve seu primeiro relato como agente antif\u00fangico em 1973. Este f\u00e1rmaco \u00e9 utilizado no \n\ntratamento de micoses superficiais ou candid\u00edase vaginal e est\u00e1 dispon\u00edvel em diferentes \n\nformula\u00e7\u00f5es farmac\u00eauticas como gel, solu\u00e7\u00e3o, creme, shampoo e esmalte terap\u00eautico, sendo \n\nadministrado topicamente (JUE et al., 1985; GUPTA, 2001a,b; STAROVA; ALY, 2005; \n\nGUPTA, 2005c; GUPTA et al., 2005; ROSEN; LINGAPPAN, 2006).  \n\nA Ciclopirox olamina (CPO), conhecida quimicamente por 2-aminoetanol sal do 6-\n\nciclohexil-1-hidroxi4-metil-2-piridona (Figura 4), \u00e9 um dos f\u00e1rmacos da classe das \n\nhidroxipiridonas juntamente com octopirox (piroctona) olamina e rilopirox. Trata-se de um \n\nproduto sint\u00e9tico com peso molecular de 268, 35 g/mol (U.S. PHAMACOP\u00c9IA) e que \n\napresenta forma cristalina branco-amarelada com ponto de fus\u00e3o caracter\u00edstico entre 140 e \n\n145\u00b0C, pKa de 7.2 e Log de P de 3.42 (NOGUEIRAS-NETO et al., 2012). \n\n \n\n                           \n\nFigura 4. F\u00f3rmula estrutural da 2-aminoetanol sal do 6-ciclohexil-1-hidroxi4-metil-2-\n\npiridona \n\nDe acordo com Jones, 2003, os ensaios cl\u00ednicos com a ciclopirox olamina iniciaram \n\nem 1980 e permanecem em desenvolvimento. Atualmente, pesquisas com o f\u00e1rmaco est\u00e3o \n\n\n\n42 \n \n\nconcentradas no tratamento de infec\u00e7\u00f5es f\u00fangicas da pele e candid\u00edase vaginal, onde est\u00e1 bem \n\nestabelecido nestas indica\u00e7\u00f5es.  \n\n Segundo Niewerth et al. (2003); Walash et al. (2006), este f\u00e1rmaco \u00e9 um agente \n\nfungicida com amplo espectro de a\u00e7\u00e3o antimicrobiana e anti-inflamat\u00f3ria, demonstrando \n\nexcelente atividade fungicida contra fungos de interesse m\u00e9dico como dermat\u00f3fitos e \n\nleveduras, incluindo aquelas frequentemente azol-resistentes como Candida glabrata, C. \n\nkrusei e C. guilliermondii. Al\u00e9m disso, o f\u00e1rmaco tamb\u00e9m apresenta amplo espectro de a\u00e7\u00e3o \n\ncontra bact\u00e9rias Gram positivas e Gram negativas, al\u00e9m de atuar em tumores malignos de \n\norigem hematol\u00f3gica (WEIR et al., 2011). \n\nGupta (2001b) e Gupta; Plott (2004) afirmam que a atividade antiinflamat\u00f3ria inerente \n\na ciclopirox olamina representa um fator importante nas infec\u00e7\u00f5es f\u00fangicas, uma vez que \n\nestas podem ser complicadas na presen\u00e7a de processos inflamat\u00f3rios. \n\nCiclopirox olamina pode ser fungist\u00e1tico ou fungicida e dentre as esp\u00e9cies de \n\ndermat\u00f3fitos que s\u00e3o inibidas pelo ciclopirox, destacam-se Epidermophyton floccosum, \n\nMicrosporum canis, Trichophyton mentagrophytes e T. rubrum. Entre as leveduras, destacam-\n\nse esp\u00e9cies de Malassezia como M. restricta, M. globosa e M. furfur e esp\u00e9cies de Candida \n\ncomo C. glabrata, C. krusei e C. guilliermondii. Al\u00e9m destes, pode atuar tamb\u00e9m contra \n\nfungos dim\u00f3rficos (Blastomyces dermatitidis e Histoplasma capsulatum), e v\u00e1rios outros, \n\nincluindo esp\u00e9cies de Aspergillus, Penicillium, Phialophora e Fusarium. (NIEWERTH et al., \n\n2003; WALASH et al., 2006; Zhang et al., 2007).   \n\nHannel et al. (1988) demonstraram a a\u00e7\u00e3o fungicida de ciclopirox olamina em quatro \n\nisolados de Cryptococcus neoformans que apresentaram CIM de 6 \u00b5g/mL. Contudo, o m\u00e9todo \n\nutilizado n\u00e3o foi padronizado, com n\u00famero de isolados insuficiente para avalia\u00e7\u00e3o da a\u00e7\u00e3o \n\nantif\u00fangica do f\u00e1rmaco.  \n\nPara a maioria dos dermat\u00f3fitos e leveduras, a concentra\u00e7\u00e3o m\u00ednima fungicida se \n\nencontra dentro da faixa de 0,9 a 3,9 \u00b5g/mL quando estes micro-organismos est\u00e3o cultivados \n\nem meio \u00e1gar Sabouraud-dextrose (ABRAMS et al., 1992). \n\nContudo, Soares-Cury (2001) avaliando a atividade in vitro de antif\u00fangicos e anti-\n\ns\u00e9pticos frente a dermat\u00f3fitos isolados de amostras cl\u00ednicas de pacientes com tinea pedis, \n\nconstataram que para a CPO a CIM variou de 8 \u00b5g/mL a 32 \u00b5g/mL. No entanto, a maioria das \n\ncepas de T. rubrum e T. mentagrophytes e dois isolados de E. floccosum foram inibidas na \n\nconcentra\u00e7\u00e3o de 16 \u00b5g/mL. A CMF em rela\u00e7\u00e3o ao T. mentagrophytes foi observada nas \n\nconcentra\u00e7\u00f5es de at\u00e9 64 \u00b5g/mL. \n\n\n\n43 \n \n\nGupta; Kholi (2003) testando a atividade antif\u00fangica in vitro de ciclopirox olamina \n\ncontra dermat\u00f3fitos e outros fungos filamentosos, verificaram a excelente atividade do \n\nf\u00e1rmaco isolado e quando associado \u00e0 terbinafina, cetoconazol e itraconazol. A concentra\u00e7\u00e3o \n\nm\u00ednima inibit\u00f3ria da ciclopirox olamina ficou entre 0,015\u00b5g/mL e 0,125 \u00b5g/mL para \n\ndermat\u00f3fitos e 0,03 \u00b5g/mL a 8 \u00b5g/mL para os outros fungos. \n\nOliveira e colaboradores em 2010, demostraram pela primeira vez excelente atividade \n\nantif\u00fangica da CPO frente isolados de Cryptococcus obtidos de Liquido cefalorraquidiano de \n\npacientes com AIDS, usando anfotericina B e fluconazol como controles. A metodologia \n\nempregada foi a mais recente publicada atrav\u00e9s do documento M27-A3 do CLSI (2008). \n\nComo resultados, os autores observaram que as CIMs da CPO in vitro foram t\u00e3o eficazes \n\nquanto as da anfotericina B, f\u00e1rmaco de escolha para o tratamento da criptococose. As \n\nconcentra\u00e7\u00f5es variaram de 0,25 a 1 \u00b5g/mL para CPO e de 0,03 a 1 para a anfotericina B. Com \n\nrela\u00e7\u00e3o \u00e0 atividade fungicida, CPO apresentou MFCs mais elevados, com concentra\u00e7\u00f5es \n\nvariando de 0.5 a 4 \u00b5g/mL contra 0.03 a 2 \u00b5g/mL da anfotericina B. Os autores indicam a \n\nCPO como alvo em potencial para tratamento de micoses sist\u00eamicas.  \n\n Desde que ciclopirox foi introduzido na terap\u00eautica cl\u00ednica, h\u00e1 mais de 20 anos, v\u00e1rios \n\nestudos enfocando o mecanismo de a\u00e7\u00e3o do f\u00e1rmaco foram publicados. Segundo Gupta \n\n(2001), quando sua utiliza\u00e7\u00e3o tornou-se mais frequente, os resultados de v\u00e1rias investiga\u00e7\u00f5es \n\ne compara\u00e7\u00f5es da sua efic\u00e1cia com outros agentes antimicrobianos foram relatados. \n\nIwata; Yamaguchi (1981); Urbani et al. (1995), Gupta (2001) e Jones 2003 \n\ndescreveram que diferentemente da maioria dos agentes antif\u00fangicos, a ciclopirox olamina \n\nn\u00e3o exerce efeitos sobre a bioss\u00edntece do esterol e seu mecanismos de a\u00e7\u00e3o \u00e9 complexo, \n\ninterferindo em v\u00e1rios processos metab\u00f3licos da c\u00e9lula f\u00fangica. \n\nPesquisas realizadas por Abrams et al. (1992); Gupa (2001) e Niewerth et al. (2003), \n\ndemonstraram que o mecanismo de a\u00e7\u00e3o do f\u00e1rmaco consiste na interfer\u00eancia na recapta\u00e7\u00e3o e  \n\nacumula\u00e7\u00e3o de precursores da s\u00edntese de macromol\u00e9culas da c\u00e9lula f\u00fangica como \n\namino\u00e1cidos ou na absor\u00e7\u00e3o de \u00edons essenciais como pot\u00e1ssio e fosfato, al\u00e9m de causar \n\ninibi\u00e7\u00e3o da bioss\u00edntese de \u00e1cido ribonucl\u00e9ico (RNA) e \u00e1cido desoxirribonucl\u00e9ico (DNA) \n\ndestes micro-organismos.  \n\nAl\u00e9m desses mecanismos, Bohr; Kraemer (2000); Gupta (2001); Kokjohn et al. (2003) \n\ne Jones (2003) descrevem que ciclopirox olamina atua na quela\u00e7\u00e3o de metais trivalentes como \n\no Fe3+, por quem tem alta afinidade. Este mecanismo inibe enzimas dependentes de metal \n\ncomo catalase e peroxidase, as quais s\u00e3o importantes na degrada\u00e7\u00e3o de per\u00f3xidos t\u00f3xicos e, \n\nconsequentemente, contribuem para a integridade da c\u00e9lula f\u00fangica. Segundo Jones (2003), \n\n\n\n44 \n \n\neste mecanismo \u00fanico contribui para um potencial muito baixo no desenvolvimento de \n\nmecanismos de resist\u00eancia f\u00fangica.  \n\nSegundo Niewerth et al. (2003), a CIM de ciclopirox  aumenta efetivamente quando \n\ns\u00e3o usados meios contendo tioglicolato. Os sais de ferro presentes nesse meio antagonizam o \n\nefeito inibit\u00f3rio pela forma\u00e7\u00e3o de complexos com o antif\u00fangico.  \n\nCom base nos estudos de Bohr; Kramer (2000), a complexidade do mecanismo de \n\na\u00e7\u00e3o da ciclopirox olamina pode gerar uma diminui\u00e7\u00e3o na ocorr\u00eancia de resist\u00eancia, quando \n\ncomparado a outros agentes antif\u00fangicos. Comprovando esta afirma\u00e7\u00e3o, verifica-se que \n\nmesmo ap\u00f3s ser introduzido na terapia cl\u00ednica h\u00e1 mais de 20 anos, ainda n\u00e3o foi constatado \n\nresist\u00eancia f\u00fangica (NIEWERTH et al., 2003).  \n\nCom rela\u00e7\u00e3o \u00e0 seguran\u00e7a do f\u00e1rmaco, pesquisas confirmam que os efeitos adversos \n\ns\u00e3o raros e limitam-se a rea\u00e7\u00f5es locais ap\u00f3s aplica\u00e7\u00e3o t\u00f3pica. A toxicidade do f\u00e1rmaco foi \n\ntestada em v\u00e1rios modelos animais, assim como a sua carcinogenicidade e mutagenicidade, \n\npara os quais n\u00e3o foi demonstrada potencialidade em nenhum dos efeitos testados. Contudo, a \n\nCPO apresenta baixa biodisponibilidade e tempo de meia vida curto, o que justifica a \n\nimport\u00e2ncia da nanotecnologia terap\u00eautica para superar as desvantagens do f\u00e1rmaco e, ao \n\nmesmo tempo, possibilitar a sua aplica\u00e7\u00e3o in vivo  (ALPERMANN; SCHUTZ, 1981; COPPI; \n\nSILINGARDI, 1992; GUPTA; SKINNER, 2003).  \n\n \n\n2.7  Nanotecnologia Farmac\u00eautica \n\n \n\nA nanotecnologia \u00e9 um campo cient\u00edfico multidisciplinar que tem experimentado um \n\nincremento not\u00f3rio nas \u00faltimas d\u00e9cadas, encontrando aplica\u00e7\u00f5es em diversas \u00e1reas, \n\nprincipalmente na ind\u00fastria farmac\u00eautica atrav\u00e9s do desenvolvimento, caracteriza\u00e7\u00e3o e \n\naplica\u00e7\u00e3o de sistemas terap\u00eauticos mais eficazes e seguros para o tratamento de v\u00e1rias \n\ndoen\u00e7as, incluindo as de origem microbiana (DUR\u00c1N et al., 2006; SAKATA et al., 2007; \n\nSTEENWINKEL et al. 2007; OLSON et al., 2010; YOSHIZAWA et al., 2011).  \n\nA nanotecnologia farmac\u00eautica baseia-se na utiliza\u00e7\u00e3o de subst\u00e2ncias bioativas em \n\nescala nanom\u00e9trica ou microm\u00e9trica que apresentam propriedades f\u00edsico-qu\u00edmicas e \n\ncomportamentais diferenciadas associadas \u00e0 modifica\u00e7\u00e3o da libera\u00e7\u00e3o de f\u00e1rmacos a partir de \n\nformas farmac\u00eauticas (DAS; DAS, 2003). Ap\u00f3s estudo aprofundado sobre os impactos \n\ncomerciais desta tecnologia, estima-se que em 2015 metade do setor farmac\u00eautico depender\u00e1 \n\nda nanotecnologia, com mercado mundial em torno de U$$ 1 trilh\u00e3o. Dentre os pa\u00edses que \n\nmais investem nesta \u00e1rea est\u00e3o os Estados Unidos e o Jap\u00e3o, por\u00e9m o Brasil tem realizado \n\n\n\n45 \n \n\ninvestimentos significativos nos \u00faltimos anos em redes de pesquisa e projetos na \u00e1rea \n\n(Minist\u00e9rio de Ci\u00eancia e Tecnologia, Brasil. \u201cRelat\u00f3rio nanotecnologia: investimentos, \n\nresultados e demandas\u201d, 2006). \n\n \n\n2.7.1 Sistemas de libera\u00e7\u00e3o de f\u00e1rmacos \n\n Os f\u00e1rmacos n\u00e3o encapsulados apresentam diversas desvantagens que costumam \n\nimpedir a sua utiliza\u00e7\u00e3o, tais como r\u00e1pida metaboliza\u00e7\u00e3o no organismo e seus efeitos t\u00f3xicos \n\ndecorrentes de sua baixa solubilidade plasm\u00e1tica, bem como sua a\u00e7\u00e3o indiscriminada sobre \n\nc\u00e9lulas sadias. Al\u00e9m disso, um f\u00e1rmaco de efeito sist\u00eamico deve permanecer na circula\u00e7\u00e3o o \n\ntempo necess\u00e1rio para seu efeito terap\u00eautico, dentro de uma faixa segura de alta efic\u00e1cia \n\ncombinada \u00e0 baixa toxicidade, e um m\u00ednimo de doses repetitivas (STEENWINKEL et al., \n\n2007). \n\nDiante dessa problem\u00e1tica, os sistemas de libera\u00e7\u00e3o de f\u00e1rmacos representam um dos \n\nsetores da nanotecnologia com maior potencial de aplica\u00e7\u00e3o. Isto se deve ao fato de que o \n\ndesenvolvimento de novas mol\u00e9culas ativas gera alto custo, o que torna os sistemas \n\nnanoestruturados de libera\u00e7\u00e3o de f\u00e1rmacos uma das \u00e1reas da ind\u00fastria farmac\u00eautica mais \n\npromissoras por resgatar f\u00e1rmacos eficazes, que foram descartados ap\u00f3s descoberta de \n\npotenciais efeitos colaterais ou baixa biodisponibilidade, al\u00e9m de gerar novas patentes. Al\u00e9m \n\nde proteger o f\u00e1rmaco contra a degrada\u00e7\u00e3o prematura e promover sua solubiliza\u00e7\u00e3o, a \n\nencapsula\u00e7\u00e3o de um f\u00e1rmaco em nanossistemas apropriados pode melhorar sua cin\u00e9tica e \n\nbiodistribui\u00e7\u00e3o, bem como direcionar o f\u00e1rmaco para o seu tecido ou c\u00e9lula-alvo (SHAFFER, \n\n2005; KHAN et al., 2005).  \n\nEsses sistemas s\u00e3o capazes de modificar a distribui\u00e7\u00e3o do princ\u00edpio ativo nos sistemas \n\nbiol\u00f3gicos, e portanto, podem ser usados para melhorar a efic\u00e1cia terap\u00eautica e reduzir os \n\nefeitos t\u00f3xicos. Dentre as vantagens que estes sistemas oferecem quando comparados a outros \n\nde dosagem convencional, podemos citar: 1) maior controle da libera\u00e7\u00e3o do princ\u00edpio ativo, \n\ndiminuindo o aparecimento de concentra\u00e7\u00f5es t\u00f3xicas e subterap\u00eauticas; 2) utiliza\u00e7\u00e3o de menor \n\nquantidade do princ\u00edpio ativo 3) maior intervalo entre as doses, resultando na diminui\u00e7\u00e3o do \n\nn\u00famero de doses; 4) possibilidade de oferecer mais de um agente terap\u00eautico simultaneamente \n\n(terapia de combina\u00e7\u00e3o) 5) Direcionamento do f\u00e1rmaco para s\u00edtios espec\u00edficos 6) melhor \n\naceita\u00e7\u00e3o do tratamento pelo paciente (PEER et al., 2007; DAVIS; CHEN; SHIN, 2008; \n\nZHANG et al., 2008; OLSON et al., 2010). Al\u00e9m disso, as formula\u00e7\u00f5es na escala nanom\u00e9trica \n\npodem penetrar na c\u00e9lula hospedeira, atrav\u00e9s da endocitose, e liberar o agente antimicrobiano \n\ndiretamente nos parasitas intracelulares (WAGNER et al., 2006; ZHANG et al., 2008). \n\n\n\n46 \n \n\nOs lipossomas est\u00e3o entre os principais exemplos de sistemas nanoestruturados para \n\nencapsula\u00e7\u00e3o de f\u00e1rmacos e vacinas. Trata-se de ves\u00edculas esf\u00e9ricas de tamanho vari\u00e1vel (em \n\nescala de nm e \u00b5m) composta de uma ou mais bicamadas lip\u00eddicas conc\u00eantricas, contendo em \n\nseu interior um meio aquoso (TORCHILIN, 2005; ZHANG; GRANICK, 2006). Foram \n\ndescobertos na d\u00e9cada de 60 por Alec Bangham e colaboradores durante um estudo onde \n\nverificou que alguns fosfolip\u00eddios quando entram em contato com a \u00e1gua formam \n\nimediatamente uma esfera de bicamada (BANGHAM, 1961). Por\u00e9m, a investiga\u00e7\u00e3o quanto \u00e0 \n\ncapacidade de encapsula\u00e7\u00e3o de f\u00e1rmacos e a proposta de utiliza\u00e7\u00e3o de lipossomas como \n\nsistema transportador de f\u00e1rmaco para controlar a libera\u00e7\u00e3o surgiu na d\u00e9cada de 70 com o \n\npesquisador Gregory Gregoriadis, sendo desde ent\u00e3o extensivamente estudados (NEW; \n\nCHANCE; HEATH, 1981; FR\u00c9ZARD et al., 2005).  \n\nEstas ves\u00edculas s\u00e3o constitu\u00eddas basicamente por fosfolip\u00eddeos e ester\u00f3is. Entre \n\nfosfolip\u00eddeos mais utilizados nas formula\u00e7\u00f5es lipossomais est\u00e1 a fosfatidilcolina, \n\nfosfatidilserina, fosfatidilglicerol e esfingomielina, que tendem a formar uma bicamada \n\nest\u00e1vel em solu\u00e7\u00e3o aquosa, sendo as fosfatidilcolinas as mais empregadas nas prepara\u00e7\u00f5es \n\nlipossomais. Os fosfolip\u00eddeos s\u00e3o os principais componentes das membranas celulares \n\napresentando a capacidade de auto-organiza\u00e7\u00e3o quando em solu\u00e7\u00f5es, portanto os lipossomas \n\ns\u00e3o compostos por uma por\u00e7\u00e3o hidrof\u00edlica (cavidade interna aquosa) e outra hidrof\u00f3bica \n\n(bicamada lip\u00eddica) (Figura 5). Os f\u00e1rmacos hidrossol\u00faveis ficam encapsulados no interior da \n\ncavidade aquosa enquanto que os f\u00e1rmacos lipossol\u00faveis s\u00e3o incorporados na bicamada \n\nlip\u00eddica (BATISTA et al., 2007). \n\n \n\n\n\n47 \n \n\n   Figura 5. Estrutura do lipossoma e da bicamada lip\u00eddica (Adaptado de Chorilli et al., \n\n2004). \n\nAtualmente, os lipossomas s\u00e3o os mais utilizados nos sistemas de libera\u00e7\u00e3o de \n\nf\u00e1rmacos antimicrobianos. Uma das caracter\u00edsticas distintivas dos lipossomas \u00e9 a sua estrutura \n\nde bicamada lip\u00eddica, que mimetiza as membranas celulares e pode fundir-se facilmente com \n\noutras bicamadas lip\u00eddicas como a membrana celular dos agentes infecciosos (bact\u00e9rias e \n\nfungos), liberando o composto ativo no meio intracelular (ZHANG et al., 2010). \n\nQuanto \u00e0 composi\u00e7\u00e3o qu\u00edmica e sua intera\u00e7\u00e3o com o meio biol\u00f3gico, os lipossomas \n\npodem ser classificados em convencionais, furtivos ou Stealth, s\u00edtio-espec\u00edficos e cati\u00f4nicos \n\n(Figura 6).  \n\n \n\n \n\n \n\nFigura 6- Caracter\u00edsticas estruturais de lipossomas convencionais, furtivos, s\u00edtio-\n\nespec\u00edficos e cati\u00f4nicos (Adaptado de LASIC, 1996). \n\nDe acordo com Pinto-Alphandary et al. (2000) e Batista et al. (2007), os lipossomas \n\nconvencionais s\u00e3o constitu\u00eddos de fosfolip\u00eddeos e colesterol, al\u00e9m de um lip\u00eddeo com carga \n\nnegativa ou positiva para evitar a agrega\u00e7\u00e3o das ves\u00edculas. A camada hidrof\u00f3bica destes \n\nlipossomas in vivo \u00e9 respons\u00e1vel pelo r\u00e1pido reconhecimento pelo sistema fagocit\u00e1rio \n\nmononuclear e consequentemente r\u00e1pida remo\u00e7\u00e3o da circula\u00e7\u00e3o resultando em curta \n\nperman\u00eancia na corrente sangu\u00ednea. \n\n\n\n48 \n \n\nJ\u00e1 os lipossomas furtivos, tamb\u00e9m chamados de Stealth, ao contr\u00e1rio dos \n\nconvencionais, apresentam longa perman\u00eancia na corrente sangu\u00ednea. No desenvolvimento \n\ndestes lipossomas s\u00e3o utilizados pol\u00edmeros hidrof\u00edlicos naturais ou sint\u00e9ticos como os \n\npolietilenoglic\u00f3is (PEG), Poli (\u00f3xido de etileno) (PEO) e \u00f3xido de propileno (TORCHILIN, \n\n2005; DEHVARI; LIN, 2012). A presen\u00e7a de grupos inertes na superf\u00edcie dos lipossomas \n\nreduz as intera\u00e7\u00f5es com macromol\u00e9culas e desta forma estabilizam estas ves\u00edculas. A \n\nestabilidade biol\u00f3gica e coloidal dos lipossomas foi drasticamente aumentada pelo seu \n\nrevestimento com pol\u00edmeros hidrof\u00edlicos inertes, impedindo a penetra\u00e7\u00e3o e adsor\u00e7\u00e3o de \n\nopsoninas e promovendo um baixo reconhecimento dos lipossomas pela c\u00e9lulas do sistema \n\nret\u00edculo endotelial (ABU LILA et al., 2009; LI et al., 2009). \n\nNa tentativa de direcionar e aumentar a especificidade da intera\u00e7\u00e3o dos lipossomas \n\ncom as c\u00e9lulas alvo foram desenvolvidos lipossomas s\u00edtios-espec\u00edficos, aos quais s\u00e3o \n\nadicionados em sua superf\u00edcie, por liga\u00e7\u00e3o covalente, ligantes de reconhecimento como \n\nanticorpos monoglonais e oligossacar\u00eddeos, os quais conferem seletividade para liberar o \n\nf\u00e1rmaco no s\u00edtio de a\u00e7\u00e3o desejado, evitando com isso a a\u00e7\u00e3o t\u00f3xica do f\u00e1rmaco sobre as \n\nc\u00e9lulas adjacentes (BATISTA et al., 2007).  \n\nSharma e Sharma (1997) afirmam que a instabilidade f\u00edsica e qu\u00edmica das formula\u00e7\u00f5es \n\nlipossomais pode ocasionar um baixo tempo de meia vida. O estudo da estabilidade dos \n\nlipossomas deve incluir a caracteriza\u00e7\u00e3o do produto final. Outros fatores que devem ser \n\nlevados em considera\u00e7\u00e3o s\u00e3o: pH, estado de tamponamento e for\u00e7a i\u00f4nica. Segundo Edwards; \n\nBaeumner (2006), temperatura, luz, calor e oxig\u00eanio s\u00e3o fatores do meio ambiente que \n\nexercem influ\u00eancia na estabilidade. Tais fatores podem induzir altera\u00e7\u00f5es na distribui\u00e7\u00e3o de \n\ntamanho das ves\u00edculas, oxida\u00e7\u00e3o e hidr\u00f3lise dos lip\u00eddeos. \n\n       Samuni e colaboradores (2000) afirmam que a degrada\u00e7\u00e3o oxidativa dos lip\u00eddios em \n\ngeral pode ser minimizada pela prote\u00e7\u00e3o das prepara\u00e7\u00f5es lip\u00eddicas da exposi\u00e7\u00e3o \u00e0 luz; pelo \n\narmazenamento em baixas temperaturas, pela adi\u00e7\u00e3o de antioxidantes como o alfa-tocoferol \n\nou butil hidroxitolueno (BHT) e pela adi\u00e7\u00e3o de acido etileno diamino tetrac\u00e9tico (EDTA) \u00e0 \n\nformula\u00e7\u00e3o lip\u00eddica pra remover metais pesados. A hidr\u00f3lise lip\u00eddica leva \u00e0 forma\u00e7\u00e3o de liso-\n\nfosfatidilcolina (lyso-PC) que acentua a permeabilidade dos lipossomas, o que prejudica a \n\nintegridade da formula\u00e7\u00e3o.  \n\nAl\u00e9m da degrada\u00e7\u00e3o oxidativa dos lip\u00eddios, Edwards e Baeumner (2006) afirmam que \n\nprepara\u00e7\u00f5es de lipossomas que apresentam uma heterogeneidade em seu tamanho \n\nrepresentam um potencial problema em sua estabilidade f\u00edsica. A instabilidade f\u00edsica pode \n\nainda ser causada pela libera\u00e7\u00e3o do f\u00e1rmaco encapsulado da ves\u00edcula, e/ou agrega\u00e7\u00e3o ou fus\u00e3o \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Dehvari%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23237189\n\n\n49 \n \n\ndas ves\u00edculas para formar grandes part\u00edculas. Este processo influencia o desempenho in vivo \n\nda formula\u00e7\u00e3o, podendo afetar o \u00edndice terap\u00eautico do f\u00e1rmaco (SHARMA;  SHARMA, \n\n1997). \n\n      Muitas tentativas t\u00eam sido realizadas para aperfei\u00e7oar a estabilidade dos lipossomas. \n\nEntre elas, a modifica\u00e7\u00e3o da superf\u00edcie \u00e9 um m\u00e9todo atrativo para melhorar a estabilidade in \n\nvitro e in vivo do sistema (TAKEUCHI et al., 1998). Lasic (1998) afirma que a estabilidade \n\nbiol\u00f3gica pode ser determinada pelo tempo de circula\u00e7\u00e3o dos lipossomas na corrente \n\nsang\u00fc\u00ednea, o que est\u00e1 diretamente relacionado com a presen\u00e7a de agentes que interagem com \n\nos lipossomas. A compatibilidade sang\u00fc\u00ednea \u00e9 um importante fator na avalia\u00e7\u00e3o dos \n\nlipossomas como carreadores de f\u00e1rmaco na corrente circulat\u00f3ria, uma vez que as c\u00e9lulas \n\nsangu\u00edneas iniciam o processo de coagula\u00e7\u00e3o imediatamente quando em contato com \n\nmateriais estranhos (CEH et al., 1997; TAKEUCHI et al., 2000; ISHIHARA et al., 2002). \n\nPara exercer atividade terap\u00eautica, faz-se necess\u00e1rio que o sistema carreador contendo \n\no f\u00e1rmaco permane\u00e7a tempo suficiente na corrente sang\u00fc\u00ednea, a fim de atingir o alvo. \n\nEntretanto, quando lipossomas convencionais s\u00e3o administrados in vivo, s\u00e3o rapidamente \n\nremovidos da corrente circulat\u00f3ria atrav\u00e9s das c\u00e9lulas fagocit\u00e1rias do sistema reticulo \n\nendotelial (RES) (PINTO-ALPHANDARY et al., 2000; BATISTA et al., 2007). \n\nDe acordo com Torchilin (2005) o tamanho e a composi\u00e7\u00e3o lip\u00eddica s\u00e3o determinantes \n\nna perman\u00eancia dos lipossomas na circula\u00e7\u00e3o. Quanto ao tamanho, a redu\u00e7\u00e3o do di\u00e2metro dos \n\nlipossomas implica em um menor reconhecimento pelo Sistema Reticuloendotelial (RES) e \n\nquanto \u00e0 sua composi\u00e7\u00e3o lip\u00eddica, a inclus\u00e3o de fosfolip\u00eddios saturados e ester\u00f3is, que \n\nreduzem a fluidez da membrana resultam em uma maior perman\u00eancia desta prepara\u00e7\u00e3o na \n\ncircula\u00e7\u00e3o sang\u00fc\u00ednea.               \n\nSegundo Gabizon et al. (1997) e Torchilin (2005) o revestimento polim\u00e9rico \n\nempregando pol\u00edmeros hidrof\u00edlicos como o polietilenoglicol (PEG) \u00e9 um m\u00e9todo alternativo \n\npara a modifica\u00e7\u00e3o da superf\u00edcie dos lipossomas, conferindo prote\u00e7\u00e3o \u00e0s ves\u00edculas contra a \n\nopsoniza\u00e7\u00e3o e mecanismo de elimina\u00e7\u00e3o.  \n\nPesquisas com formula\u00e7\u00f5es lipossomais de anfotericina B com o intuito de aumentar o \n\n\u00edndice terap\u00eautico do f\u00e1rmaco, bem como reduzir sua nefrotoxicidade, v\u00eam sendo amplamente \n\nutlizadas para o tratamento de micoses por esp\u00e9cies de Candida, Aspergillus, Fusarium, \n\nCryptococcus e outros fungos de alta e baixa patogenicidade. Contudo, s\u00e3o onerosas e \n\ngeralmente n\u00e3o s\u00e3o a primeira op\u00e7\u00e3o de tratamento (KELSEY et al., 1999; WALSH et al., \n\n2001; KHAN; NASTI;OWAIS, 2005; SIONOV et al., 2006; NAHAR et al., 2008; OLSON et \n\nal., 2010; WANG et al., 2010).  \n\n\n\n50 \n \n\nEm contrapartida, ciclopirox olamina tem sido estudado e avaliado quanto a sua \n\nefic\u00e1cia em sistemas de libera\u00e7\u00e3o controlada, apesar de serem escassos os trabalhos nesta \n\n\u00e1rea. Em artigo recente, Shaikh; Pawar (2010) desenvolveram uma formula\u00e7\u00e3o lipossomal \n\ncontendo o f\u00e1rmaco com o objetivo de aumentar sua absor\u00e7\u00e3o cut\u00e2nea para tratamento de \n\ninfec\u00e7\u00f5es superficiais. Os lipossomas foram preparados pelo m\u00e9todo de inje\u00e7\u00e3o de etanol e os \n\nautores obtiveram lipossomas de tamanho variando de 196\u00b11,73 a 1040,66\u00b17,02 nm e \n\nefici\u00eancia de encapsula\u00e7\u00e3o variando de 34.28\u00b14,4 a 54,89\u00b11,9. Neste estudo, foi realizado um \n\nplanejamento fatorial 24-1 para otimizar as concentra\u00e7\u00f5es de colesterol e fosfolip\u00eddeos. \n\nSegundo os autores, encapsula\u00e7\u00e3o em lipossomas preserva a principal caracter\u00edstica da \n\nmol\u00e9cula requerida para sua a\u00e7\u00e3o antif\u00fangica, sendo os lipossomas uma ferramenta \n\nimportante para potencializar a a\u00e7\u00e3o do f\u00e1rmaco no tratamento de micoses. \n\nDevido \u00e0s limita\u00e7\u00f5es do uso da anfotericina B e o desenvolvimento de resist\u00eancia ao \n\nf\u00e1rmaco considerado de escolha, faz-se necess\u00e1rio o desenvolvimento de novas alternativas \n\nterap\u00eauticas para serem utilizadas em substitui\u00e7\u00e3o ou associadas aos f\u00e1rmacos dispon\u00edveis, \n\npodendo reduzir a toxicidade e aumentar a efic\u00e1cia terap\u00eautica. Ciclopirox olamina n\u00e3o \n\napresenta efeitos t\u00f3xicos proeminetes e sua efic\u00e1cia antif\u00fangica j\u00e1 foi demonstrada em v\u00e1rias \n\npesquisas in vitro e in vivo. Formula\u00e7\u00f5es lipossomais sist\u00eamicas contendo o referido f\u00e1rmaco \n\npara o combate \u00e0 neurocriptococose contribuir\u00e1  para uma melhor qualidade de vida de \n\npacientes imunocomprometidos, sobretudo os soropositivos para o HIV.  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n51 \n \n\nTabela 1 Caracter\u00edsticas fenot\u00edpicas, epidemiol\u00f3gicas e gen\u00e9ticas de C. neoformans e C. gattii  \n\n \nEsp\u00e9cie, \n\nvariedade, \n\nsorotipo \n\nPatogenia Termotoler\u00e2n\n\ncia in vitro \n\n(\u00b0C) \n\nSensibilidade \u00e0 \n\nglicina (Teste \n\nde CGB) \n\nSensibilidade aos \n\nantif\u00fangicos \n\nHabitats Distrib\n\nui\u00e7\u00e3o \n\ngeogr\u00e1\n\nfica \n\nTipos \n\nMolecula\n\nres \n\nC. neoformans \n\nvar. grubii \n\n(sorotipo A) \n\nOportunista (SNC) 38 - 40 Sens\u00edvel Sens\u00edvel Solo, excreta de \n\naves \n\nCosmo\n\npolita \n\nVNI \n\nC. neoformans \n\nvar. \n\nneoformans \n\n(sorotipo D) \n\nOportunista \n\n \n\n38 - 40 Sens\u00edvel Sens\u00edvel Solo, excreta de \n\naves \n\nCosmo\n\npolita \n\n(princip\nalmente \n\nEuropa\n) \n\nVNIV \n\nC. gattii \n\n(sorotipo B) \n\nInfec\u00e7\u00e3o prim\u00e1ria; \n\nles\u00f5es pulm\u00e3o e SNC \n\n35 Resistente Sensibilidade dose-\n\ndependente \n\nMaterial vegetal \n\n(Eucalyptus sp.) \n\n\u00c1reas \n\ntropicai\ns e \n\nsubtrop\n\nicais \n\nVGI \n\nC. gattii \n\n(sorotipo C) \n\nInfec\u00e7\u00e3o prim\u00e1ria; \n\nles\u00f5es pulm\u00e3o e SNC \n\n(menor preval\u00eancia) \n\n35 Resistente Sensibilidade dose-\n\ndependente \n\nMaterial vegetal \n\n(Eucalyptus sp. \n\n\u00c1reas \n\ntropicai\n\ns e \nsubtroi\n\ncais \n\nVGIII \n\nSorotipo AD \n\n(h\u00edbrido) \n\nOportunista (SNC) 38 - 40 Sens\u00edvel Sens\u00edvel Solo, excreta de \naves \n\nCosmo\npolita \n\n(Europ\n\na) \n\nVNIII \n\nVN: variedade neoformans; VG: variedade gattii; (MEYER et al., 2003; ENANCHE-\n\nANGOULVANT et al., 2007; BOVERS; HAGEN; BOEKHOUT, 2008; CONSENSO EM \n\nCRIPTOCOCOSE, 2008; HUSTON; MODY, 2009; DELIO et al., 2010; ALBUQUERQUE; \n\nRODRIGUES, 2012). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n52 \n \n\n3 REFER\u00caNCIAS  \n\n \n\nABBEG, M.A.; CELLA, F.L.; FAGANELLO, J.; VALENTE, P.; SHRANK, A.; \n\nVAINSTEIN, M.H. Cryptococcus neoformans and Cryptococcus gattii isolated from the \n\nexcreta of Psittaciformes in a Southern Brazilian Zoological Garden. Mycopathologia, v. \n\n161, p 83-91, 2006. \n\n \n\nABRAMS, B.B;  HANEL, H.; HOEHLER, T. Ciclopirox olamine: a hidroxypyridone \n\nantifungal agent. Clinics in Dermatology, v.9, p 471-477, 1992. \n\n \n\nABU-LILA, A. S.; KIZUKI, S.; DOI, Y.; SUZUKI, T.; ISHIDA, T.; KIWADA, H. Oxaliplatin \n\nencapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression \n\nvia a dual-targeting approach in a murine solid tumor model. J Control Release, v.137, p 8-14, \n\n2009. \n\n \n\nALBUQUERQUE, P.C.; RODRIGUES, M.L.  Research trends on pathogenic Cryptococcus \n\nspecies in the last 20 years: a global analysis with focus on Brazil. Future Microbiol, v.7, p \n\n319\u2013329, 2012. \n\n \n\nALMEIDA, A. M. F.; MATSUMOTO, M. T.; BAEZA, L. C.; OLIVEIRA E SILVA, R. B.; \n\nKLEINER, A. A. P.; MELHEM, M. S. C.; GIANNINI1, M. J. S. M.; The Laboratory Group \n\non Cryptococcosis. Molecular typing and antifungal susceptibilityof clinical sequential \n\nisolates of Cryptococcus neoformans from S\u00e3o Paulo State, Brazil. FEMS Yeast Res, v. 7, p \n\n152\u2013164, 2007. \n\n \n\nALPERMANN HG, SCHUTZ E. Studies on the pharmacology and toxicology of \n\nciclopiroxolamine. Arzneimittelforschung, v.31, p 1328-1332, 1981. \n\n \n\nAVERBUCH, D.; et al. Fungemia in a cancer patient caused by fluconazole-resistant \n\nCryptococcus laurentii. Med Mycol, v.40, p 479-484, 2002. \n\n \n\nBANGHAM, A. D. \u201cA correlation between surface charge and coagulant action \n\nofphospholipids\u201d. Nature, v.192, p 1197-1198, 1961. \n\n \n\n\n\n53 \n \n\n \n\nBARCHIESI, F.; SCHIMIZZI, A.M.; CASELLI, F.; NOVELLI, A.; FALLANI, S.; \n\nGIANNINI, D.; ARZENI, D.; CESARE, S.; FRANCESCO, L.F.; FORTUNA, M.; \n\nGIACOMETTI, A.; CARLE, A.; MAZZET, T.; SCALISE, G. Interactions between triazoles \n\nand amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother, \n\nv.44, p 2435-2441, 2000. \n\n \n\nBARNETT, J.A.; PAYNE, R.W.; YARROW, D. Yeast: characteristics and identification. \n\n2000. 3 ed. Cambridge: University press, 1139p.  \n\n \n\nBARONI, F.A.; et al. Cryptococcus neoformans strains islated from church towers in Rio de \n\nJaneiro city, RJ, Brazil. Rev Inst Med Trop, v.48, p 71-75, 2006. \n\n \n\nBARROS, M.E.S.; SANTOS, D.A.; HAMDAN, J.S. In vitro methods for antifungal \n\nsusceptibility testing of Trichophyton spp. Mycological Research, v. 110, n. 11, p. 1355-\n\n1360, 2006.  \n\n \n\nBATISTA, C. M.; CARVALHO, C. M. B.; SANTOS-MAGALH\u00c3ES, N. S. Lipossomas e \n\nsuas aplica\u00e7\u00f5es terap\u00eauticas: estado da arte. Braz J Pharm Sci 43, 167-179, 2007. \n\n \n\nBAUTERS, T. G. M.; SWINNE, D.; BOEKHOUT, T.; NOENS, L.; NELIS, H. J. Repeated \n\nisolation of Cryptococcus laurentii from the oropharynx of an immunocompromized patient. \n\nMycopathologia, v. 153, p. 133-135, 2001. \n\n \n\nBERNARDO, F.M.; MARTINS, H.M.; MARTINS, M.L. Urban sources of Cryptococcus sp.- \n\nLisbon (Portugal). RPCV, v. 96, p 157-160, 2001. \n\n \n\nBIANIC, T.; HARRISON, T.S. Cryptococcal meningitis. British Medical Bulletin, v.72, p \n\n99-118, 2004. \n\nBIRNBAUM, D.T.; BRANNO-PEPPAS, L. Microparticle drug delivery systems. Drug \n\nDelivery Systems, v.5, p 38-117, 2003. \n\n \n\nBIVANCO, F.C.; MACHADO, C.A.S., MARTINS, E.L. Cutaneous cryptococcosis. Arq Med \n\nABC, v.31, p 102-109, 2006. \n\n\n\n54 \n \n\n \n\nBOEKHOUT, T.; VAN BELKUM, A. Variability of karyotypes and RAPD types in \n\ngenetically related strains of Cryptococcus neoformans. Current Genetics, v. 32, p. 203-208, \n\n1997. \n\n \n\nBOHR, M.; KRAEMER, K.T. Dermatopharmacology of Ciclopirox nail lacquer topical \n\nsolution 8% in the treatment of onychomycosis. JAAD, v.43, p 57-69, 2000. \n\n \n\nBOVERS, M.; et al. Identification of genotypically diverse Cryptococcus neoformans and \n\nCryptococcus gattii isolates by Luminex xMAP technology. J Clin Microbiol, v.45, p 1874-\n\n1883. \n\n \n\nBOVERS, M.; et al. Identification of genotypically diverse Cryptococcus neoformans and \n\nCryptococcus gattii isolates by Luminex xMAP technology. J Clin Microbiol, v. 45, p. 1874-\n\n1883, 2007. \n\n \n\nBRANDT, M.E.; et al. For the Cryptococcal disease active surveillance group. Trends in \n\nantifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 \n\nto 1994 and 1996 to 1998. Antimicrob Agents Chemother, v.45, p 3065-3069, 2001. \n\n \n\nBYRNES J. E., LI, W., LEWIT, Y., MA, H., VOELZ, K., REN, P., CARTER, D.A.; \n\nCHATURVEDI, V.; BILDFELL, R.J.; MAY, R.C.; HEITMAN, J. Emergence and \n\nPathogenicity of Highly Virulent Cryptococcus gattii Genotypes in the Northwest United \n\nStates. PLoS Pathogens, v.6, p e1000850, 2010.  \n\n \n\nCAPOOR, M. R.; MANDAL, P.; DEB, M.; AGGARWAL, P.; BANERJEE, U. Current \n\nscenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for \n\nreappraisal. Mycoses, v. 51, p. 258-265, 2008. \n\n \n\nCARFARCHIA, C.; CAMARDA, A.; ROMITO, D.; CAMPOLO, M.; QUAGLIA, N. C.; \n\nTULLIO, D.; OTRANTO, D. Occurence of yeast in cloacae of migratory birds. \n\nMycopathologia, v. 161, p. 229-34, 2006a. \n\n \n\n\n\n55 \n \n\nCARVALHO, A., COSTA-DE-OLIVEIRA, S., MARTINS, M.L., VAZ-PINA, C., \n\nRODRIGUES, A.G., LUDOVICO, P., RODRIGUES, F. Multiplex PCR identification of \n\nsome clinically relevant species. Med. Mycol, v.49, p 619-627, 2007. \n\n \n\nCASADEVALL, A.; PERFECT, J.R. Cryptococcus neoformans. Washington, D.C., Amrican \n\nSociety for Microbiology Press, 1998. 541p. \n\n \n\nCASALI, A.K.; et al. Cryptococccus neoformans: aspectos moleculares e epidemiol\u00f3gicos. J \n\nClin Microbiol, v.20, p34-37, 2001. \n\n \n\nCASALI, A.K.; et al.Molecular typing of clinical and environmental Cryptococcus \n\nneoformans in the Brazilian state Rio Grande do Sul. FEMS Yeast Res, v.3, p 405-415, 2003. \n\n \n\nCAVALCANTI I.M.F, MENDON\u00c7A EAM, LIRA MCB, HONRATO SB, CAMARA CA, \n\nAMORIM RVS, FILHO, J M, RABELLO MM, HERNANDES MZ, AYALA AP, SANTOS-\n\nAGALH\u00c3ES NS. The encapsulation of b-lapachone in 2-hydroxypropyl-b-cyclodextrin \n\ninclusion complex into liposomes: A physicochemical evaluation and molecular modeling \n\napproach. Eur J Pharm Sci, doi:10.1016, 2011. \n\n \n\nCEH, B.; WINTERHALTER, M.; FREDERIK, P. M.; VALLNER, J. J.; LASIC, D. D.   \n\nStealth\u00ae liposomes: from theory to product. Adv drug deliv rev, v.24, p 165-177, 1997. \n\n \n\nCHANDENIER, J.; ADOU-BRYN, K. D.; DOUCHET, C.; SAR, B.; KOMBILA, M.; \n\nSWINNE, D.; TH\u00c9RIZOL-FERLY, M.; BUISSON, Y.; RICHARD-LENOBLE, D. In vitro \n\nactivity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus \n\nneoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis, v. 23, p. \n\n506\u2013508, 2004. \n\n \n\nCHENG, M. F.; CHIOU, C. C.; LIU, Y. C.; WANG, H. Z.; HSIEH, K. S. Cryptococcus \n\nlaurentii fungemia in a premature neonate. Journal of Clinical Microbiology, v.39, p. 1608-\n\n1611, 2001. \n\n \n\nCHORILLI M, LEONARDI GR, OLIVEIRA AG, SCARPA MV. Lipossomas em \n\nformula\u00e7\u00f5es dermocosm\u00e9ticas. Infarma, v.6, p 75-9, 2004. \n\n\n\n56 \n \n\n \n\nCHRETIEN, F.; LORTHOLARY, O.; KANSAU, I.; NEUVILLE, S.; GRAY, F.; DROMER, \n\nF. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis,  \n\nv. 186, p 522-530, 2002. \n\n \n\nCLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI).  Reference Method \n\nfor Broth Dilution Testing of Yeasts. Approved standard document M27-A3, Wayne, PA, \n\nUSA: CLSI, 2008. \n\n \n\nCONSENSO EM CRIPTOCOCOSE. Relat\u00f3rio T\u00e9cnico. Rev Soc Bras Med Trop, v. 41, p. \n\n524-544, 2008. \n\n \n\nCOPPI, G.; SILINGARDI, S. HPLC method for pharmacokinetic studies on ciclopirox \n\nolamine in rabbits after intravenous and intravaginal administrations. Farmaco, v.47, p. 779-\n\n786, 1992. \n\n \n\nCORR\u00caA, M.P.S.C.; et al. Criptococose em crian\u00e7as no estado do Par\u00e1, Brasil. Rev Soc Bras \n\nMed Trop, v.32, p 505-8, 1999. \n\n \n\nCORR\u00caA, M.P.S.C.; et al. The spectrum of computerized tomography (CT) findings in \n\ncerebral nervous system (CNS) infection due to Cryptococcus neoformans var. gattii in \n\nimmunocompetent children. Rev Inst Med Trop v. 44, p 283-287, 2002. \n\n \n\nCORTI, M., VILLAFA\u00d1E1, M.F., NEGRONI,RICARDO; ARECHAVALA, A.; MAIOLO, \n\nE.  Magnetic resonance imaging findings in AIDS patients with central nervous system \n\ncryptococcosis. Rev Iberoam Micol, v.25, p 211-214, 2008. \n\n \n\nCOSTA, A. K., SIDRIM, J. J., CORDEIRO, R. A., BRILHANTE, R. S. N., MONTEIRO, A. \n\nJ.; ROCHA, M. F. Urban pigeons (Columba livia) as a potential source of pathogenic yeast: a \n\nfocus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. \n\nMycopathologia, doi 10.1007/s11046-009-9245-1, 2009. \n\n \n\nCUENCA-ESTRELA, M.; LEE-YANG, W.; CIBLAK, M.A.; ARTHINGTON-SKAGGS, \n\nB.A.; MELLADO, E.; WARNOCK, D.W. RODRIGUEZ-TUDELA, J.L. Comparative \n\n\n\n57 \n \n\nevaluation of NCCLS M27-A and EUCATEST broth microdilution procedures for antifungal \n\nsusceptibility testing of Candida species. Antimicrob Agents Chemother, v.46, p 3644-\n\n3647, 2002. \n\n \n\nCUENCA-ESTRELLA, M.; et al. Flucytosine primary resistance in Candida species and \n\nCryptococcus neoformans. Eur J Clin Microbiol Infect Dis, v. 20, p. 276-279, 2001. \n\n \n\nDARZ\u00c9, C.; et al. Caracter\u00edsticas cl\u00ednicas laboratoriais de 104 casos de meningoencefalite \n\ncriptoc\u00f3cica. Rev Soc Bras Med Trop, v. 33, p. 21-6, 2000. \n\n \n\nDAS, N. G.; DAS, S. K. Controlled-release of oral dosage forms. Formulation, Fill &amp; \n\nFinish, v. 27, p. 10-16, 2003. \n\n \n\nDAVIS, M. E.; CHEN, Z. G.; SHIN, D. M. Nanoparticle therapeutics: an emerging treatment \n\nmodality for cancer. Nat Rev Drug Discov, v.7, p 771-782, 2008. \n\n \n\nDE HOOG, G.S. et al. 2000. Atlas of Clinical Fungi. 2 ed. Centraalbureau voor \n\nSchimmelcultures: Universitat Rovira i Virgili, 1126p. \n\nDEHVARI, K.; LIN, S. Synthesis, Characterization and Potential Applications of  \n\nMultifunctional PEO-PPOPEO- Magnetic Drug Delivery System. Curr Med Chem, v.19, p. \n\n5199-204, 2012. \n\n \n\nDIAZ, M.R.; FELL, J.M. Use of a suspension array for rapid identification of the varieties \n\nand genotypes of  the Cryptococcus neoformans species complex. J Clin Microbiol, v.43, p \n\n3662-3672, 2005. \n\n \n\nDILHUYDY, M.S.; et al. Cutaneous cryptococosis with alemtuzumab in a patient treated for \n\nchonic lymphocytic leukaemia. British J Haematol, v.137, p 490, 2007. \n\n \n\nDILLON, RF;  LASCANO,  CD;  RIERA, F.; ALBIERO, E. Cutaneous Cryptococosis in a \n\npatient with Beh\u00e7et\u2019s disease and colon cancer, Reumatol Clin, v.7, p 147\u2013148, 2011. \n\n \n\nDISMUKES, W.E. Introdution to antifungical drugs. Clin Infect Dis, v.30, p 653-657, 2000. \n\n\n\n58 \n \n\n \n\nDUIN, D.V.; CASADEVALL, A.; NOSANCHUK, J.D. 2002. Melanization of Cryptococcus \n\nneoformans and Histoplasma capsulatum Reduces Their Susceptibilities to Amphotericin B \n\nand Caspofungin. Antimicrob Agents Chemother 46(11):3394-3400. \n\n \n\nDUR\u00c1N, N.; MATTOSO, L. H. C.; MORAIS, P. C. Nanotecnologia: Introdu\u00e7\u00e3o, prepara\u00e7\u00e3o, \n\ncaracteriza\u00e7\u00e3o de nanomateriais e exemplos de aplica\u00e7\u00e3o. S\u00e3o Paulo: ArtLiber, 2006. \n\n \n\nEDWARDS, K. A.: BAEUMNER, A. J. Analysis of liposomes. Talanta, v.68, p 1432-1441, \n\n2006. \n\n \n\nEHRENSING, E.R.; SAAG, M.S. Criptococose. In: SAROSI, G.A.; DAVIES, S.F. Doen\u00e7as \n\nf\u00fangicas do pulm\u00e3o. 3ed. Rio de Janeiro: Revinter, cap 7, 89-101, 2001. \n\n \n\nENANCHE-ANGOULVANT, A., CHANDENIER, J., SYMOENS, F., LACUBE, P., \n\nBOLOGNINI, J., DOUCHET, C., POIROT, J. L. &amp; HENNEQUIN, C. Molecular \n\nidentification of Cryptococcus neoformans serotypes. J Clin Microbiol, v.45, p 1261-1265, \n\n2007. \n\n \n\nESCAND\u00d3N, P.; S\u00c1NCHEZ, A.; MART\u00cdNEZ, M.; MEYER, W.; CASTA\u00d1EDA, E. \n\nMolecular epidemiology of clinical and environmental isolates of the Cryptococcus \n\nneoformans species complex reveals a high genetic diversity and the presence of the \n\nmolecular type VGII mating type a in Colombia. FEMS Yeast Res, v. 6, p. 625-635, 2006. \n\n \n\nFENG X, YAO Z, REN D, LIAO W. Simultaneous identifi cation of molecular and mating \n\ntypes within the Cryptococcus species complex by PCR-RFLP analysis. J Med Microbiol, \n\nv.57, p 1481\u20131490, 2008. \n\n \n\nFERNANDES, O.F.L.; et al. Cryptococcus neoformans in patients with AIDS. Rev Soc Bras \n\nMed Trop, v.33, p 75-78, 2000. \n\n \n\nFERNANDES, O.F.L.; et al. In vitro susceptibility characteristics of Cryptococcus \n\nneoformans varieties from AIDS patients in Goi\u00e2nia, Brazil. Mem Inst Oswaldo Cruz, v.98, \n\np 839-41, 2003. \n\n\n\n59 \n \n\n \n\n FERN\u00c1NDEZ-TORRES, B.; CABA\u00d1ES, F.J.; CARRILLO-MU\u00d1OZ, A.J.; ESTEBAN, A.;  \n\nFICA, C.A. Tratamiento de infecciones f\u00fangicas sist\u00eamicas. III parte: anfotericina B, aspectos \n\nfarmacoecon\u00f3micos y decisiones terap\u00e9uticas. Rev Chil Infect, v.21, p 317-26, 2004. \n\n \n\nFILE, JTM. Vis\u00e3o geral sobre resit\u00eancia antimicrobiana nos anos 90. Ple Chest, v.2, p 3-8, \n\n2000.  \n\n \n\nFILIPPIN, F.B.; SOUZA, L.C. Efici\u00eancia terap\u00eautica das formula\u00e7\u00f5es lip\u00eddicas de \n\nanfotericina B. Braz J Pharm Sci, v.42, p 167-194, 2006. \n\n \n\nFILI\u00da, W.F.O.; et al.. Cativeiro de aves como fonte de Cryptococcus neoformans na Cida de \n\nCampo Grande, Mato Grosso do Sul, Brasil. Rev Soc Bras Med Trop, v.35, p 591-595, \n\n2002. \n\n \n\nFRANZOT, S. P., I. F. SALKIN, AND A. Casadevall. Cryptococcus neoformans var. grubii: \n\nseparate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol, \n\nv.37, p 838\u2013840, 1999.  \n\n \n\nFR\u00c9ZARD, F.; DEMICHELI, C.; SCHETINI, D. A.; ROCHA, O. G. F. Lipossomas: \n\npropriedades f\u00edsico-qu\u00edmicas e farmacol\u00f3gicas, aplica\u00e7\u00f5es na quimioterapia \u00e0 base de \n\nantim\u00f3nio. Qu\u00edmica Nova, v.28, p 511-518, 2005.  \n\n \n\nFRIES BC, COX GM. Cryptococcosis in AIDS. In: Cryptococcus: From Human Pathogen to \n\nModel Yeast. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (Eds). \n\nAmerican Society for Microbiology, Washington, DC, USA, p 515\u2013526, 2011.  \n\n \n\nGABIZON, A.; GOREN, D.; HOROWITZ, A. T.; TZEMACH, D.; LOSSOS, A.; SIEGAL, \n\nT. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution \n\nstudies in tumor-bearing animals. Adv drug deliv rev, v.24, p 337-344, 1997. \n\n \n\nGHANNOUM, M.A.; et al. Interlaboratory study of quality control isolates for a broth \n\nmicrodilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to \n\nantifungals. J Clin Microbiol, v.  44, p. 4353-4356, 2006.  \n\n\n\n60 \n \n\n \n\nGRAYBILL, J.R. The role of murine models in the development of antifungal therapy for \n\nsystemic mycosis. Drug Resist Updat, v.3, p 364-383, 2000. \n\n \n\nGUNDES, S. G.; GULENC, S.; BINGOL, R. Comparative performance of Fungichrom I, \n\nCandifast and API 20C AUX systems in the identification of clinically significant yeasts. J \n\nMed Microbiol, v. 50, p. 1105-1110, 2001. \n\n \n\nGUPTA AK. Ciclopirox nail lacquer: a brush with onychomycosis. Cutis, v.68, p 13-6, 2001a \n\n \n\nGUPTA AK. Ciclopirox topical solution, 8% combined with oral terbinafine to treat \n\nonychomycosis: a randomized, evalutor-blinded study. J Drugs Dermatol, v.4, p 481-5, \n\n2005c. \n\n \n\nGUPTA, A.K. Ciclopirox: an overview. Int J Dermatol, v.40, p 305\u2013310, 2001. \n\n \n\nGUPTA, A.K. Ciclopirox olamina: an overview. Inter J Dermatol, v.40, p 305-310, 2001b. \n\n \n\nGUPTA, A.K. AND SKINNER, A.R.Ciclopirox for the treatment of superficial fungal  \n\ninfections: a review. Int J Dermatol, v.42, p 3\u20139, 2003. \n\n \n\nGUPTA, A.K., Schouten, J.R.; Lynch, L.E. Ciclopirox nail lacquer 8% for the treatment of \n\nonychomycosis: a Canadian perspective. Skin Therapy Lett, v.10, p 1-3, 2005. \n\n \n\nGUPTA, A.K.; KOHLI, Y. In vitro susceptibility testing of ciclopirox, terbinafine, \n\nketoconazole and itraconazole against dermatophytes and non dermatophytes, and in vitro \n\nevaluation of combination antifungal activity. British J Dermatol, v.149, 296-305, 2003. \n\n \n\nGUPTA, A.K; PLOTT, T. Ciclopirox: abroad-spectrum with antibacterial and anti-\n\ninflammatory properties. Inter J Dermatol, v.43, p 3-8, 2004. \n\n \n\nGUPTA, G.; FRIES, B.C. Variability of phenotypic traits in Cryptococcus varieties and \n\nspecies and the resulting implications for pathogenesis. Future Microbiol, v.5, p 775-787, \n\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_AbstractPlus&amp;term=%22Gupta+AK%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_AbstractPlus&amp;term=%22Lynch+LE%22%5BAuthor%5D\njavascript:AL_get(this,%20'jour',%20'Skin%20Therapy%20Lett.');\n\n\n61 \n \n\n2010. \n\n \n\nHANNEL, H.; ROETHER, W.; DITTMAR, W. Evoluation of the fungicidal action of in vitro \n\nand in a skin model considering the influence of penetration kinetics on various standards \n\nantimycotics. J NY Acad Sci, v.544, p 329-337, 1998.  \n\n \n\nHONSHO,C.S.; et al. Generalized systemic cryptococosis in a dog after immunossupressive \n\ncorticotheray. Arq Bras Med Vet Zootec, v.55, p 155-159, 2003. \n\n \n\nHUANG, W.; ZHANG, Z.; HAN, X.; TANG, J.; WANG, J.; DONG, S.; WANG, E. Ion \n\nchannel behavior of amphotericin B in sterol-free and cholesterol or ergosterol-containing \n\nsupported bilary model membranes investigated by electrochemistry and spectroscopy. \n\nBiophys J, v.83, p 3245-3255, 2002. \n\n \n\nHULL, C.M.; HEITMAN, J. 2002. Genetics of Cryptococcus neoformans. Annu Rev Genet, \n\nv.36, p 557-615, 2002. \n\n \n\nHUSTON, S. M.; MODY, C. H. Cryptococcosis: an emerging respiratory mycosis. Clinics in \n\nChest Medicine, v. 30, p. 253-264, 2009. \n\n \n\nIDNURM, A.; BAHN, Y.S.; NIELSEN, K.; LIN, X.; FRASER, J.A.; HEITMAN, J. \n\nDeciphering the model pathogenic fungus Cryptococcus neoformans. Nat Rev Microbiol, \n\nv.3, p753-764, 2005. \n\n \n\nIGREJA, R.P.; et al. Molecular epidemiology of Cryptococcus neoformans isolates from \n\nAIDS patients of the Brazilian city, Rio de Janeiro. Med Mycol, v.42, p 229-38, 2004. \n\n \n\nIKEDA, R.; SUGITA, T.; JACOBSON, E. S.; SHINODA, T. Laccase and melanization in \n\nclinically important Cryptococcus species other than Cryptococcus neoformans. J Clin \n\nMicrobiol, v. 40, p. 1214-1218, 2002.  \n\n \n\n\n\n62 \n \n\nINZA, I.; ABARCA, L.; GUARRO, J. Collaborative evaluation of optimal antifungal \n\nsusceptibility testing conditions for dermatophytes. J Clinl Microbiol, v. 40, p 3999-4003, \n\n2002.  \n\n  \n\nISHIHARA, K.; TSUJINO, R.; HAMADA, M.; TOYODA, N.; IWASAKI, Y. Stabilized \n\nliposomes with phospholipid polymers and their interactions with blood cells. Colloids and \n\nsurfaces, v.25, p 325-333, 2002. \n\n \n\nIWATA, K.; YAMAGUCHI, H. Studies on the mechanism of antifungal action of ciclopirox \n\nolamine. Drug Res, v.31, p1323-1327, 1981. \n\n \n\nJAIN, N.; et al. Molecular epidemiology of clinical Cryptococcus neoformans strains from \n\nIndia. J Clin Microbiol, v.43, p 5733-5742, 2005. \n\n \n\nJANBON, G. Cryptococcus neoformans capsule biosynthesis and regulation.  FEMS Yeast \n\nRes, v.4, p 765-771, 2004. \n\n \n\nJESSUP, C.J.; WARNER, J.; ISHAM, N.; HASAN, I.; GHANNOUM, M.A. Antifungal \n\nSusceptibility Testing of Dermatophytes: Establishing a Medium for Inducing Conidial \n\nGrowth and Evaluation of Susceptibility of Clinical Isolates. J Clin Microbiol, v. 38, p 341\u2013\n\n344, 2000.  \n\n \n\nJONES, E.D. Onychomycosis: current treatment options. J Am Acad Nurse Pract, v.15, p \n\n165-169, 2003. \n\n \n\nJUE, S.G.; DAWSON, G.W.; BROGDEN, R.N. Ciclopirox olamine 1% cream. A preliminary \n\nreview if its antimicrobial activity and therapeutic use. Drugs, v.29, p 330-341, 1985. \n\n \n\nKANAFANI, Z.A.; PERFECT, J.R. Resistance to antifungal agents: mechanisms and clinical \n\nimpact. Clin Infect Dis, v.46, p 120-128, 2008. \n\n \n\nKELSEY, S. M.; GOLDMAN, J. M.; MCCANN, S.; et al. Liposomal amphotericin \n\n(AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, \n\ndouble-blind, placebo-controlled study. Bone Marrow Transplant, v.23, p 163-168, 1999. \n\n\n\n63 \n \n\n \n\nKHAN MA, NASTI TH, OWAIS M. Incorporation of amphotericin B in tuftsin-bearing \n\nliposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J \n\nAntimicrob Chemother, v.56, p 726\u2013731, 2005. \n\n \n\nKHAN, Z. U; AL-ANEZI, A. A.; CHANDY, R.; XU, J. Disseminated cryptococcosis in an \n\nAIDS patient caused by a canavanine-resistant strain of Cryptococcus neoformans var. grubii. \n\nJ Med Microbiol, v. 52, p. 271-275, 2003. \n\n \n\nKHAWCHAROENPORN, T.; APISARNTHANARAK, A.; MUNDY, L. M. Non-\n\nneoformans cryptococcal infections: a systematic review. Infection, v. 35, p. 51-58, 2007. \n\n \n\nKidd, S.E.; Hagen, F.; Tscharke, R.L.; Huynh, M.; Bartlett, K.H.; Fyfe, M.; Macdougall, L.; \n\nBoekhout, T.; Kwon-Chung, K.J.; Meyer, W. A rare genotype of Cryptococcus gattii caused \n\nthe cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proceedings \n\nof the National Academy of Sciences, USA 101, 17258\u201317263, 2004.  \n\n \n\nKOKJOHN, K.; BRADLEY, M.; GRIFFITHS, B. Evaluation of in vitro activity of ciclopirox \n\nolamine, butenafine HCL and Econazole nitrate against dermatophtoses, yeasts and bacteria. \n\nInter J Dermatol, v.42, p 11-17, 2003. \n\n \n\nKOMMERS, G.D.; et al. Granulomatous cryptococcal pneumonia in a hose. Cienc Rural, \n\nv.35, p 938-940, 2005. \n\n \n\nKWON-CHUNG KJ, BOEKHOUT T, FELL JW, DIAZ M 2002. (1557) Proposal to conserve \n\nthe name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, \n\nHymenomycetes, Tremellonycetidae). Taxon, v.51, p 804-806, 2002. \n\n \n\nKWON-CHUNG, K. J.; POLACHECK, I.; BENNETT, J. E. Improved diagnostic medium for \n\nseparation of Cryptococcus neoformans var. neoformans (serotype A and D) and \n\nCryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol, v. 15, p. 535-537, \n\n1982. \n\n \n\n\n\n64 \n \n\nLACAZ, C.S.; et al. Tratado de Micologia M\u00e9dica. 9 ed. S\u00e3o Paulo: Sarvier, 1104p, \n\n2002a. \n\n \n\nLARSEN, R.A.; BAUER, M.; THOMAS, A.M.; GRAYBILL, J.R.; Amphotericin B and \n\nfluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob agents \n\nchemother, v.48, p 985-991, 2004. \n\n \n\nLARSSON, C.E.; et al. Canine ocular cryptococosis: a case report. Arq Bras Med Vet \n\nZootec, v.55, p 533-538, 2003. \n\n \n\nLASIC, D. D. Novel applications of liposomes. Tibtech, v.16, p 307-321, 1998. \n\n \n\nLASIC, D. D.  Liposomes. Science &amp; Medicine, v.1, p 35-43, 1996. \n\n \n\nLATOUCHE, G.N., HUYNH, M., SORRELL, T.C. AND MEYER, W. PCR-Restriction \n\nFragment Length Polymorphism Analysis of the Phospholipase B (PLB1) Gene for Subtyping \n\nof Cryptococcus neoformans Isolates. Appl. Environ. Microbiol, v.69, p 2080-2086, 2003. \n\n \n\nLAZ\u00c9RA, M. S.; IGREJA, R. P.; WANKE, B. Criptococose. In: SIDRIM, J. J. C.; ROCHA \n\nM. F. G. Micologia M\u00e9dica: \u00c1 luz de autores contempor\u00e2neos. Rio de Janeiro: Editora \n\nGuanabara Koogan S.A., p. 89-101, 2004. \n\n \n\nLEE, Y.A. et al. First report of Cryptococcus albidus \u2013 induced disseminated cryptococcosis \n\nin a renal transplante recipient. Korean J Intern Med, v.19, p 53-57, 2004. \n\n \n\nLI, X.; DING, L.; XU, Y.; WANG, Y.; PING, Q. N.Targeted delivery of dexorubicin using \n\nstealth liposomes modified with transferrin. Int J Pharm, v. 373, p 116-123, 2009. \n\n \n\nLIN, X.; HEITMAN, J. The biology of the Cryptococcus neoformans species complex. \n\nMicrobiology, v.60, p 69-105, 2006. \n\n \n\nLITVINTSEVA, A.P.; et al. Comparative analysis of environmental and clinical populations \n\nof Cryptococcus neoformans. J Clin Microbiol, v.43, p 556-64, 2005. \n\n \n\n\n\n65 \n \n\nLOZANO-CHIU, M.; et al. Detection of resistance to amphotericin B among Cryptococcus \n\nneoformans clinical islates: performances of three different media assessed by using E-test \n\nand National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin \n\nMicrobiol, v.36, p 2817-2822, 1998. \n\n \n\nLUCAS S., MARTINS M. L., FLORES O., MEYER W., SPENCER-MARTINS I., IN\u00c1CIO \n\nJ. Differentiation of Cryptococcus neoformans varieties and Cryptococcus gattii using \n\nCAP59-based loop-mediated isothermal DNA amplification. Clin. Microbiol. Infect, v.16: \n\n711 \u2013 714., 2010. \n\n \n\nLUISI, S.B.; et al. Use of amphotericin B as antifungal agent in a culture medium for human \n\ndental pulp cells. Rev Odonto Cienc, v.23, p 58-62, 2008. \n\n \n\nMACDOUGALL, L.M.; FYFE, M. Emergence of Cryptococcus gattii in a novel enviroment \n\nprovides clues to its incubation period. J Clin Microbiol, v.44, p 1851-1852, 2006. \n\n \n\nMAJET, N.V.; KUMAR, R. Nano and Microparticles as controlled drug delivery devices. J \n\nPham Pharmaceut Sci, 3(2): 234-258, 2000. \n\n \n\nMARTINEZ, L.R.; GARCIA-RIVERA, J.; CASADEVALL, A. Cryptococcus neoformans \n\nvar. neoformans (serotype D) strains are more susceptible to heat than Cryptococcus \n\nneoformans var. gattii (serotype A) strains. J Clin Microbiol, v.39, p 3365-3367, 2001.  \n\n \n\nMASSONET, C.; ELDERE, J.V.; VANEECHOUTTE, M.; BAERE, T.; VERHAEGEN, J.; \n\nLAGROU, K. Comparison of VITEK 2 with ITS2-Fragment Length Polymorphism Analysis \n\nfor identification of yeast species. J Clin Microbiol, v. 42, p. 2209-2211, 2004. \n\n \n\nMATSUMOTO MT, FUSCO-ALMEIDA AM, BAEZA LC, et al. Genotyping, serotyping \n\nand determination of mating-type of Cryptococcus neoformans clinical isolates from Sao \n\nPaulo State, Brazil. Rev Inst Med Trop Sao Paulo, v. 49: 41\u201347, 2007. \n\n \n\nMCCURDY, L.H.; MORROW, J.D. Ventriculitis due to Cryptococcus uniguttulatus. South \n\nMed J, v.94, p 65-66, 2001. \n\n \n\n\n\n66 \n \n\nMEDEIROS, C.S.Q., LIMA-FILHO, J.V., OLIVEIRA, P. C., ANDRADE, S.L., LEAL, \n\nA.F.G., CAMARA, C.A. and NEVES, R. P. Antifungal activity of beta-lapachone against \n\ndisseminated infection by Cryptococcus neoformans var. neoformans strain 5811 on \n\nimmunosuppressed Swiss mice. Braz J Med Biol Res, v.43, p 345-349, 2010. \n\n \n\nMELO N.T., et al. Quimiotipagem do Criptococcus neoformans. Revis\u00e3o de Literatura. \n\nNovos dados epidemiol\u00f3gicos sobre a criptococose. Nossa experi\u00eancia com o emprego do \n\nmeio C.G.B. no estudo daquela levedura. Rev Inst Med Trop, v.35, p 469-478, 1993. \n\n \n\nMEYER, W.; CASTA\u00d1EDA, A.; JACKSON, S.; HUYNH, M.; CASTA\u00d1EDA, E. Molecular \n\ntyping of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis, v. 9, p. 189-\n\n195, 2003. \n\n \n\nMEYER, W.; MARSZEWSKA, K.; AMIRMOSTOFIAN, M.; IGREJA, R. P.; HARDTKE, \n\nC.; METHLING, K.; VIVIANI, M. A.; CHINDAMPORN, A.; SUKROONGREUNG, S.; \n\nJOHN, M. A.; ELLIS, D. H.; SORRELL, T. C. Molecular typing of global isolates of \n\nCryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and \n\nrandomly amplified polymorphic DNA - a pilot study to standardize techniques on which to \n\nbase a detailed epidemiological survey. Electrophoresis, v. 20, p. 1790-1799, 1999. \n\n \n\nMINIST\u00c9RIO DE CI\u00caNCIA E TECNOLOGIA, BRASIL. Relat\u00f3rio nanotecnologia: \n\ninvestimentos, resultados e demandas, 2006. \n\n \n\nMITCHELL, T.G.; PERFECT, J.R. Cryptococcosis in the Era of AIDS \u2013 100 Years after the \n\nDiscovery of Cryptococcus neoformans. Rev Clin Microbiol, v.8, p 515-548, 1995. \n\n \n\nMOHANRAJ, V.J.; CHEN, Y. Nanoparticles- A Review. Tropical Journal of \n\nPharmaceutical Research, vol.5, p 561-573, 2006. \n\n \n\nMORA, D.J.;  PEDROSA,  A.L.;  RODRIGUES, V., MAFFEI, C.M.L.; TRILLES, L.;  \n\nLAZ\u00c9RA, M.S; SILVA-VERGARA,  M.L. Genotype and mating type distribution within \n\nclinical Cryptococcus neoformans and  Cryptococcus gattii isolates from patients with \n\ncryptococcal meningitis in Uberaba, Minas Gerais, Brazil, Med Mycol, v.48, p 561\u2013569, \n\n2010. \n\n\n\n67 \n \n\n \n\nMORA, D.J.; PEDROSA, A.L.;  RODRIGUES, V.; MAFFEI, C.M.L.; TRILLES, L.; \n\nLAZ\u00c9RA, M.S.; SILVA-VERGARA, M.L. Genotype and mating type distribution within \n\nclinical Cryptococcus neoformans and Cryptococcus gattii isolates from patients with \n\ncryptococcal meningitis in Uberaba, Minas Gerais, Brazil. Med Mycol v.48, p 561\u2013569, \n\n2010.  \n\n \n\nMORA-DUARTE, J.; BETTS, R.; ROTSTEIN, C.; COLOMBO, A.L.; THOMPSON-\n\nMOYA, L.; SMIETANA; LUPINACC, R. SABLE, C.; KARTSONIS, N.; PERFECT, J.; \n\nComparison of Caspoungin and amphotericin B for invasive candidiasis. NEJM, v.347, p \n\n2020-2029, 2002. \n\n \n\nMOREIRA, T.A.; FERREIRA, R.M.R.; BORGES, A.S. Cryptococosis: clinical \n\nepidemiologycal laboratorial study and fungi varieties in 96 patients. Rev Soc Bras  Med \n\nTrop, v.39, p 255-258, 2006. \n\n \n\nNAHAR M, PHARM M, MISHRA D, DUBEY V, JAIN N K. Development, \n\ncharacterization, and toxicity evaluation of amphotericin B\u2013loaded gelatin nanoparticles. \n\nNanomedicine: Nanotechnology, Biology, and Medicine, v.4, p 252\u2013261, 2008. \n\n \n\nNAKAMURA, Y.; KANO, R.; SATO, H; WATANABE; S; TAKAHASHI; H.; \n\nHASEGAWA, A. Isolates of Cryptococcus neoformans serotype A and D developed on \n\ncanavanine-glycine-bromthymol blue medium. Mycoses, v. 41, p. 35-40, 1998. \n\n \n\nNAMIQ, A.L.; TOLLEFSON, T.; FAN, F. Cryptococcal parotidis as a cystic parotid mass: \n\nreport of a case diagnosed by fine-needle aspiration cytology. Diagn Cytolopathol, v.33, p \n\n36-38, 2005. \n\n \n\nNEW, R. R.; CHANCE, M. L.; HEATH, S. Antileshimanial activity of amphotericin and other \n\nantifungal agents entrapped in Liposomes. J Antimicrob Chemother, v.8, p 371-381, 1981. \n\n \n\nNIELSEN K.; OBALDIA,  A. L.; HEITMAN,  J. 2007. Cryptococcus neoformans Mates on \n\nPigeon Guano: Implications for the Realized Ecological Niche and Globalization. Eukaryotic \n\nCell, v.6, p 949\u2013959, 2007. \n\n\n\n68 \n \n\n \n\nNIEWERTH, M; et al. Ciclopirox Olamine treatment affects the expression pattern of \n\nCandida albicans genes encoding virulence factors, iron metabolism proteins, and drug \n\nresistance factors. Antimicrob Agents Chemother, v.47, p 1805-1817, 2003. \n\n \n\nNOGUEIRAS-NIETO L, SOBARZO-S\u00c1NCHEZ E, G\u00d3MEZ-AMOZA JL, OTERO-\n\nESPINAR FJ.  Competitive displacement of drugs from cyclodextrin inclusion complex by \n\npolypseudorotaxane formation with poloxamer: Implications in drug solubilization and \n\ndelivery. Eur. J. Pharm. Biopharm, doi:10.1016/j.ejpb.2011.12.001, 2012.  \n\n \n\nNORRIS, H.A.; ELEWSKI, B.E.; GHANNOUM, M.A. Optimal growth conditions for the  \n\ndetermination of the antifungal susceptibility of three species of dermatophytes with the use \n\nof a microdilution method. J Am Acad Dermatol, v. 40, p. Sp-S13, 1999. \n\n \n\nNUCCI, M.; MARR, K.A. Emerging fungal diseases. Clin Infect Dis, v.41, p 521-526, 2005. \n\nN\u00da\u00d1EZ, M.; et al. Pulmonary Cryptococcosis in the Immunocompetent Host : therapy with \n\nfluconazole: a report of four cases and a review of the literature. American College of Chest \n\nPhysicians, v.118, p 527-534, 2000. \n\n \n\nOLIVEIRA PC, MEDEIROS CS, MAC\u00caDO DP, ANDRADE SL, CORREIA \n\nMT, MESQUITA SD, LIMA-NETO RG, NEVES RP. Ciclopirox olamine: an antifungal \n\nalternative against cryptococcosis. Lett Appl Microbiol, v.51, p 485-9, 2010. \n\n \n\nOLSON, JA; GEORGE A; CONSTABLE, D.; SMITH, P.; PROFFITT, R.T.; ADLER-\n\nMOORE, J.P. Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential \n\nor Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus \n\nInfections. Antimicrob Agents Chemother, v.54, p 3884\u20133894, 2010. \n\n \n\nORD\u00d3\u00d1EZ, N.; CASTA\u00d1EDA, E. Varieties and serotypes of Cryptococcus neoformans \n\nclinical isolates in Colombia. Rev Iberoam Micol, v.18, p.128-130, 2001. \n\n \n\nOSUNA, P.; CARRAGOSO, A.; LEMOS, A.; MOCHO, M. L.; GASPAR, O. Criptococose, \n\nActa Medica Portuguesa, v. 21, p. 307-313, 2008. \n\n \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Oliveira%20PC%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Medeiros%20CS%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Mac%C3%AAdo%20DP%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Andrade%20SL%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Correia%20MT%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Correia%20MT%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Mesquita%20SD%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Lima-Neto%20RG%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Neves%20RP%22%5BAuthor%5D\n\n\n69 \n \n\nPAPPALARDO, M.C.S.M.; MELHEM, M.S.C. Cryptococcosis: a review of the Brazilian \n\nexperience for the disease. Rev Inst Med Trop, v.45, p 299-305, 2003. \n\n \n\nPARK BJ, WANNEMUEHLER KA, MARSTON BJ, GOVENDER N, PAPPAS PG, \n\nCHILLER TM. Estimation of the current global burden of cryptococcal meningitis among \n\npersons living with HIV/AIDS. AIDS, v.23, p 525\u2013530, 2009. \n\n \n\nPASCHOAL, R. C., HIRATA, M. H.; HIRATA, R. C.; MELHEM, M. S. C.; DIAS, A. L. T.; \n\nPAULA, C. R. Neurocryptococcosis: diagnosis by PCR method. Rev Inst Med Trop S\u00e3o \n\nPaulo, v. 46 p. 203-207, 2004. \n\n \n\nPEDROSO, R. S.; CANDIDO, R. C. Diagn\u00f3stico laboratorial da criptococose. NewsLab - \n\nedi\u00e7\u00e3o 77, p. 94-102, 2006. \n\n \n\nPEDROSO, R. S.; FERREIRA, J. C.; CANDIDO, R. C. In vitro susceptibility to antifungal \n\nagents of environmental Cryptococcus spp. isolated in the city of Ribeir\u00e3o Preto, S\u00e3o Paulo, \n\nBrazil. Mem Inst Oswaldo Cruz, v. 101, p. 239-243, 2006. \n\n \n\nPEDROSO, R. S.; FERREIRA, J. C.; CANDIDO, R. C. The isolation and characterization of \n\nvirulence factors of Cryptococcus spp. from saprophytic sources in the city of Ribeir\u00e3o Preto, \n\nS\u00e3o Paulo, Brazil. Microbiol Reserch, v. 164, p. 221-227, 2009. \n\n \n\nPEDROSO, R.S, LAVRADOR, M.AS; FERREIRA, J.C, CANDIDO, RC, MAFFEI, CML. \n\nCryptococcus neoformans var. grubii \u2013 Pathogenicity of environmental isolates correlated to \n\nvirulence factors, susceptibility to fluconazole and molecular profile. Mem Inst Oswaldo \n\nCruz, v.105, p 993-1000, 2010. \n\n \n\nPEER, D.; KARP, J. M.; HONG, S.; et al. Nanocarriers as an emerging platform for cancer \n\ntherapy. Nature Nanotechnology, v.2, p 751-60, 2007. \n\n \n\nPEREA, S.; PATTERSON, T.F.; Antifungal resistance in pathogenic fungi. Antimicrobial \n\nresistance, v.15, p 1073-1080, 2002.  \n\n \n\n\n\n70 \n \n\nPEREIRA, A.P.C.; COUTINHO, S.D.A. Criptococose em c\u00e3es e gatos- revis\u00e3o. Rev Clin \n\nVet, v.8, p 24-32, 2003. \n\n \n\nPERFECT, J.R. Cryptococcus neoformans: a sugar-coated killer with designer genes. FEMS \n\nImmunol Med Microbiol, v.45, p 395-404, 2005. \n\n \n\nPFALLER, M.A. Antifungal Drug Resistance: Mechanisms, Epidemiology, and \n\nConsequences for Treatment. Am J Med, v.125, p S3\u2013S13, 2012. \n\n \n\nPFALLER, M.A.; DIEKEMA, D.J.; GIBBS, D.L.; NEWELL, V.A.; NAGY, E.; \n\nDOBIASOVA, S.; RINALDI, M.; BARTON, R.; VESELOV, A. Candida krusei, a \n\nmultidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the \n\nartemis disk antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol, v.66, p 515-\n\n521, 2008. \n\n \n\nPINTO JUNIOR, V.L; GALHARDO, M.C.G.; LAZ\u00c9RA, M.; WANKE, B.; REIS, R. S.; \n\nPEREZ, M. Criptococose associada \u00e0 AIDS. A import\u00e2ncia do cultivo da urina no seu \n\ndiagn\u00f3stico. Revista da Sociedade Brasileira de Medicina Tropical, v. 39, p. 230-232, 2006. \n\nPINTO-ALPHANDARY, H.; ANDREMONT, A.; COUVREUR, P. Targeted delivery of \n\nantibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob \n\nAgents, v.13, p 155-168, 2000. \n\n \n\nPRADO M, SILVA MB, LAURENTI R, TRAVASSOS LR, TABORDA CP. Mortality due \n\nto systemic mycoses as a primary cause of death or in association with AIDS in Brazil: a \n\nreview from 1996 to 2006. Mem. Inst. Oswaldo Cruz, v.104, p 513\u2013521, 2009.  \n\n \n\nQUEIROZ, J.P.A.F.; et al. Criptococose- uma revis\u00e3o bibliogr\u00e1fica. Acta Vet Bras, v.2, p 32-\n\n38, 2008. \n\n \n\nREOLON, A.; PEREZ, L.R.R.; MEZZARI, A. Preval\u00eancia de Cryptococcus neoformans nos \n\npombos urbanos da cidade de Porto Alegre, Rio Grande do Sul. J Bras Patol Med Lab, v.40, \n\np 293-298, 2004. \n\n \n\n\n\n71 \n \n\nREX, J.H.; et al.. Antifungal Susceptibility Testing: Practical Aspects and Current \n\nChallenges. Clin Microbiol Rev, v.14, p 643-658, 2001. \n\n \n\nRIBEIRO, M.A.; NGAMSKULRUNGROJ, P. Molecular characterization of environmental \n\nCryptococcus neoformans isolated in Vitoria, ES, Brazil. Rev. Inst. Med. trop. S. Paulo, v. \n\n50, p 315-320, 2008. \n\n \n\nRIPPON, J.W. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. \n\n2.ed. Philadelphia: W.B. Saunders Company, 842p, 1982. \n\n \n\nRODRIGUES, C.; GAMEIRO, P.; SALETTE, R.; LIMA, J. F. L. C.; CASTRO, B. \n\nSpectrophotometric determination of drug partition coefficients in dimyristoyl-l-a-\n\nphosphatidylcholine/water: a comparative study using phase separation and liposome \n\nsuspensions. Anal Chim Acta, v. 428, p. 103-109, 2001. \n\n \n\nROSEN, T., LINGAPPAN, A. Rapid treatment of tinea nigra palmaris with ciclopirox \n\nolamine gel, 0.77%.  , v.5, p 201-3, 2006. \n\n \n\nROZENBAUM, R.; GON\u00c7ALVES, A.J. 1994. Clinical epidemiological study of 171 cases of \n\ncryptococcosis. Clin Infec Dis, v.18, p 369-80, 1994. \n\n \n\nSAKATA, S.; UCHIDA, K.; KAETSU, I.; KITA, Y. 2007. Programming control of \n\nintelligent drug releases in response to single and binary environmental stimulation signals \n\nusing sensor and electroresponsive hydrogel. Radiat Phys Chem Oxf Engl, v.76, p 733-737, \n\n2007. \n\n \n\nSAMUNI, A. M.; LIPMAN, A.; BARENHOLZ, Y. 2000. Damage to liposomal lipids: \n\nprotection by antioxidants and cholesterol-mediated dehydration. Chem Phys Lipids, v.105, \n\np 121-134, 2000.  \n\n \n\nSAN-BLAS, G.; BURGER, E. Experimental medical mycological research in Latin America - \n\na 2000-2009 overview. Rev Iberoam Micol, v.38, p 1\u201325, 2011. \n\n \n\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_AbstractPlus&amp;term=%22Rosen+T%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Search&amp;itool=pubmed_AbstractPlus&amp;term=%22Lingappan+A%22%5BAuthor%5D\njavascript:AL_get(this,%20'jour',%20'Skinmed.');\n\n\n72 \n \n\nSANTOS WR, MEYER W, WANKE B, et al. Primary endemic Cryptococcosis gattii by \n\nmolecular type VGII in the state of Para, Brazil. Mem Inst Oswaldo Cruz, v.103, p 813\u2013818, \n\n2008. \n\n \n\n \n\nSANTOS-MAGALH\u00c3ES, N. S.; PONTES, A.; PEREIRA, V. M.; CAETANO, M. N. \n\nColloidal carriers for benzathine penicillin G: Nanoemulsions and nanocapsules. Int J \n\nPharm, v. 208, p. 71-80, 2000. \n\n \n\nSAR, B.; et al. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans \n\nCambodian isolates. J Antimicrob Chemother, v.54, p 563-565, 2004. \n\n \n\nSEGAL., E.; BAUM, G.L. Pathogenic yeasts and yeasts infections. CRC Press: Boca Raton, \n\n1994, 238p. \n\n \n\nSEVERO, L.C.; OLIVEIRA, F.M.; SILVA, V.B. Diferen\u00e7as cl\u00ednicas, epidemiol\u00f3gicas, e \n\necol\u00f3gicas entre as duas variedades de Cryptococcus neoformans. Rev Med St Casa Porto \n\nAlegre, v.9, p 1672-1686, 1998. \n\n \n\nSHAFFER, C. \u201cNanomedicine transforms drug delivery\u201d. Drug Discov Today, v.10, p 1581-\n\n1582, 2005. \n\n \n\nSHARMA, A.; SHARMA, U. S. Liposome in drug delivery: progress and limitations. Int J \n\nPharm, v.154, p 123-140, 1997. \n\n \n\nSIDRIM, J.J.C; ROCHA, M.F.G. Micologia m\u00e9dica \u00e0 luz de autores contempor\u00e2neos. Rio de \n\nJaneiro: Guanabara Koogan, 2004, 388p. \n\n \n\nSILVA, P.R.; et al. Susceptibility to antifungal agents among Cryptococcus neoformans \n\nvarieties isolated from patients at a university hospital. Rev Soc Bras Med Trop, v.41, p 158-\n\n162, 2008. \n\n \n\n\n\n73 \n \n\nSIONOV E, MENDLOVIC S, SEGAL E. Efficacy of amphotericin B or amphotericin B-\n\nintralipid in combination with caspofungin against experimental aspergillosis. J. Infect, v.53, \n\np 131-139, 2006. \n\n \n\nSOARES, B. M.; SANTOS, D. A.; KOHLER, L. M.; C\u00c9SAR, G. C.; CARVALHO, I. R.; \n\nMARTINS, M. A.; CISALPINO, P. S. Cerebral infection caused by Cryptococcus gattii: a \n\ncase report and antifungal susceptibility testing. Rev Iberoam Micol, v. 25, p. 242-245, 2008.  \n\n \n\nSOARES, M. C. B.; PAULA, C. R.; DIAS, A. L. T.; CASEIRO, M. M.; PINTO DA COSTA, \n\nS. O. Environmental strains of Cryptococcus neoformans variety grubii in city of Santos, SP, \n\nBrazil. Rev Inst Med Trop S\u00e3o Paulo, v. 47, p. 31-36. 2005.  \n\n \n\nSOARES, M.M.S.R.; CURY, A.E. In vitro activity of antifungal and antiseptic agents against \n\ndermatophyte isolates from patients with tinea pedis. Braz J Microbiol, v.32, p 130-134, \n\n2001. \n\n \n\nSORREL, T.C. Cryptococcus neoformans var. gattii. Med Mycol, v.39, p 155-168, 2001. \n\n \n\nSORRELL, T.C., CHEN, S.C., RUMA, P., MEYER, W., PFEIFFER, T.J., ELLIS, D.H. and \n\nBROWNLEE, A.G. Concordance of clinical and environmental isolates of Cryptococcus \n\nneoformans var. gattii by random amplification of polymorphic DNA analysis and PCR \n\nfingerprinting. J Clin Microbiol, v.34, p 1253-1260, 1996. \n\n \n\nSOUZA, L.K.H., FERNANDES, O.F.L., KOBAYASHI, C.C.B.A., PASSOS, X.S., COSTA, \n\nC.R., LEMOS, J.A., SOUZA- JUNIOR, A.H. AND SILVA, M.R.R. (2005) Antifungal \n\nsusceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goia\u02c6nia \n\ncity, Goia\u00b4 s, Brazil. Rev Inst Med Trop Sao Paulo, v.47, p 253\u2013256, 2005. \n\n \n\nSTAROVA, A.; ALY, R. The safety and efficacy of ciclopirox olamine for the treatment of \n\nseborrheic dermatitis. Expert Opin Drug Saf, v.4, p 235-9, 2005. \n\n \n\nSTEENWINKEL, J.E.M.; VIANEN, W.V.; KATE,  M.T. T.; VERBRUGH, H.A.; \n\nAGTMAEL, M. A.; SCHIFFELERS, R.M.; BAKKER-WOUDENBERG, I.A. J. M. Targeted \n\njavascript:AL_get(this,%20'jour',%20'Expert%20Opin%20Drug%20Saf.');\n\n\n74 \n \n\ndrug delivery to enhance efficacy and shorten treatment duration in disseminated \n\nMycobacterium avium infection in mice. J Antimicrob Chemother, v.60, p 1064\u20131073, \n\n2007. \n\n \n\nTABOADA, J. Systemic Mycoses. Rev Med Trop, v.47, p 31-36, 2004. \n\n \n\nTAKEUCHI, H.; KOJIMA, H.; YAMAMOTO, H.; KAWASHIMA, Y. Polymer coating of \n\nliposomes with a modified polyvinyl alcohol and their systemic circulation and res uptake in \n\nrats. J Control Release, v.68, p 195-201, 2000. \n\n \n\nTAKEUCHI, H.; YAMAMOTO, H.; TOYODA, T.; TOYOBUKU, H.; HINO, T.; \n\nKAWASHIMA, Y. Physical stability of size controlled small unilamellar liposomes coated \n\nwith a modified polyvinyl alcohol. Int J Pharm, v.164, p 103-111, 1998. \n\n \n\nTAY ST, LIM HC, TAJUDDIN TH, et al. Determination of molecular types and genetic \n\nheterogeneity of Cryptococcus neoformans and C. gattii in Malaysia. Med Mycol, v.44, p \n\n617\u2013622, 2006. \n\n \n\nTORCHILIN, V. P. Recent advances with liposomes as pharmaceutical carrier. Nature Rev \n\nDrug Discov, v.4, p 145-160, 2005. \n\n \n\nTRILLES, et al. Regional pattern of the molecular type of Cryptococcus neoformans and \n\nCryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz, v.5, p 455\u2013462, 2008. \n\n \n\nURBANI, L.; SHERWOOD, S.W.; SCHIMKE, R.T. 1995. Dissociation of nuclear and \n\ncytoplasmic cell cycle progression by drugs employed in cell synchronization. Exp Cell Res, \n\nv.219, p 159-168, 1995. \n\n \n\nVANDEPUTTE, J.; WACHTEL, J.L.; STILLER, E.T. 1956. Amphotericin A and B \n\nantifungal antibiotics produced by a Streptomycete. II The isolation and properties of the \n\ncrystalline amphotericins. Antibiot Annu, v.1955-1956, p 587-591, 1956. \n\n \n\nVILCHEZ, R.A.; FUNG, J.; KUSNE, S. Cryptococosis in a organ transplant recipients: an \n\noverview. Am J Tranplant, v.2, p 575-580, 2002. \n\n\n\n75 \n \n\n \n\nWAGNER, V.; et al. The emerging nanomedicine landscape. Nature Biotechnology, v.24, p \n\n1211-1217, 2006. \n\n \n\nWALSH, T. J.; et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal \n\namphotericin B (AmBisome) in patients infected with Aspergillus species and other \n\nfilamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother, v.45, p \n\n3487\u20133596, 2001. \n\n \n\nWALSH, T.J.; et al. Correlation between in vitro and in vivo antifungal activities in \n\nexperimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin \n\nMicrobiol, v.38, p 2369-2373, 2000. \n\n \n\nWANG, J.L., CHANG, C.H., YOUNG-XU, Y., CHAN, K.A. Systematic review and meta-\n\nanalysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive \n\ntherapy for invasive fungal infection. Antimicrob. Agents Chemother, v.54, p 2409-2419, \n\n2010. \n\nWEIG, M.; REICHARD, U.; GROB, U. 2001. Aspergillus fumigatus-virulence and \n\nopportunism. Mycoses, v.44, p 351-355, 2001. \n\n \n\nWEIR, S.J.; PATTON, L.; CASTLE, K.; RAJEWSKI, L. KASPER, J.; SCHIMMER, A.D. \n\nThe repositioning of the antifungal agent ciclopirox olamine as a novel therapeutic agent for \n\nthe treatment of haematologic malignancy. J Clin Pharm Ther, v.36, p 128-134, 2011. \n\n \n\nWENGENACK, N. L.; BINNICKER, M. J. Fungal molecular diagnostics. Clinics in Chest \n\nMedicine, v. 30, p. 391-408, 2009. \n\n \n\nWICKES, B.L.; KNOW-CHUNG, K.J. Genetic basis of pathogenicity in Cryptococcus \n\nneoformans, p. 25-49. In: Fungal Pathogenesis: Principles and Clinical Applications. Marcel \n\nDekker, New York, p. 762, 2002. \n\n \n\nWILES, S.; WILLIAM, P.H.; FRANKEL, G.; ROBERTSON, B. Modelling infectious \n\ndisease time to think outside the box. Nat Rev Microbiol, London, 4(4):307-312, 2006. \n\n \n\n\n\n76 \n \n\nWINN, W. C.; KONEMAN, E. W. Koneman: Diagn\u00f3stico Microbiol\u00f3gico texto e atlas \n\ncolorido. 6th ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. 1535, 30 p. \n\n \n\nWU, T.C. On the development of antifungal agents: perspective of the U.S. Food and Drug \n\nAdministration. Clin Infect Dis, v.19, p 54-58, 1994. \n\n \n\nYOSHIZAWA,Y.; KONO, Y.; OGAWARA, KEN-ICHI; KIMURA T.; HIGAKI, K. PEG \n\nliposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy \n\nInternational Journal of Pharmaceutics 412:132\u2013141, 2011. \n\n \n\nZAITZ, C.; et al. 1998. Comp\u00eandio de Micologia M\u00e9dica. 1.ed. Rio de Janeiro: Medsi Editora \n\nM\u00e9dica e Cient\u00edfica, 434p. \n\n \n\nZANINI, M., MARTINS, E.L., LACAZ, C.S. \u00dalcera como primeira manifesta\u00e7\u00e3o de \n\ncriptococose sist\u00eamica em paciente aid\u00e9tico. Med Cutan Iber Lat Am, v.29, p 92-6, 2001. \n\n \n\nZARAGOSA O. et al. The polysaccharide capsule of the pathogenic fungus Cryptococcus \n\nneoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol v.59; \n\np 67-83, 2006. \n\n \n\nZHANG, A.Y.; CAMP; W.L.; ELEWSKI, B.E. Advances in topical and systemic antifungals. \n\nDermatologic clinics, v.25, p 165-183, 2007. \n\n \n\nZHANG, L.; GRANICK, S. How to stabilize phospholipid liposomes (using nanoparticles). \n\nNano Letters, v.6, p 694-698, 2006. \n\n \n\nZHANG, L.; et al. Nanoparticles in medicine: therapeutic applications and developments. Clin \n\nPharm Ther, v.83, p 761-769, 2008. \n\n \n\nZHANG, L.; PORNPATTANANANGKUL, D.; HU, C. M. J. et al. Development of \n\nnanoparticles for antimicrobial drug delivery. Curr Med Chem, v.17, p 585-594, 2010. \n\n \n\n\n\n77 \n \n\nZHU, LI-PING; SHI, YAO-ZHONG; WENG, XIN-HUA; MULLER, F.M.C. Case Reports. \n\nPulmonary Cryptococcosis associated with Cryptococcal Meningitis in non-AIDS Patients, \n\nMycoses, v.45, p 111\u2013117, 2002. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n78 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4- CAP\u00cdTULO 1 \n\n(A ser submetido \u00e0 revista Antimicrobial Agents and Chemotherapy) \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n79 \n \n\nAntifungal activity of cyclopirox olamine-loaded liposomes against \n\nCryptococcus neoformans \n\n \n\nPatr\u00edcia C. Oliveiraa,b; Rejane P. Nevesa; Pabyton G. Cadenab; Isabella M. F. Cavalcantib; \n\nSoares, P.H.S.; Nereide S. Santos-Magalhaesb,* \n\na Laborat\u00f3rio de Micologia M\u00e9dica, Centro de Ci\u00eancias Biol\u00f3gicas (CCB), Universidade Federal de Pernambuco \n\n(UFPE), Cidade Universit\u00e1ria, Av. Morais Rego s/n, 50670-910, Recife, Brazil. \n\nbLaborat\u00f3rio de Imunopatologia Keiso-Azami, UFPE, Recife, Brazil. \n\n \n\n \n\n*Corresponding author \n\nProf. Nereide Stela Santos-Magalh\u00e3es \n\nUniversidade Federal de Pernambuco \n\nLaborat\u00f3rio de Imunopatologia Keizo-Asami (LIKA) \n\nAv. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria, 50670-901, Recife-PE, Brazil. \n\nPhone: + 55 81 21268587; Fax: +55 81 21268485 \n\nE-mail: nereide.magalhaes@gmail.com \n\nmailto:nereide.magalhaes@gmail.com\n\n\n80 \n \n\nABSTRACT \n\n \n\nThe purpose of this study was to evaluate the in vitro antifungal activity of ciclopirox olamine \n\n(CPO) in its free and encapsulated liposomal forms against clinical isolates of Cryptococcus \n\nneoformans. The liposomes were prepared with soybean phosphatidylcholine (PC), \n\ncholesterol (CH) and stearylamine (SA), and distearoylphosphatidylethanolamine-\n\npolyethylene glycol for stealth liposomes. For optimization of drug/lipid ratio and liposome \n\nstability, a 24-1 fractional factorial design was carried out with mean particle size, \n\npolydispersity index (PDI) and CPO encapsulation efficiency (EE%) used as variables. In \n\nvitro kinetics was conducted to evaluate the release profiles of CPO from conventional and \n\nstealth liposomes. Antifungal susceptibility testing of CPO was evaluated on thirty clinical \n\nisolates of C. neoformans according to CLSI. The results of the factorial design of liposomes \n\nshowed a typical formulation presenting remarkable improvement of 25% in CPO amount \n\n(9.25 mM; EE%=97.36\u00b1 0.10). The particle size of 102 nm and PDI of 0.274 were found. \n\nKinetics showed a more controlled release profile of stealth liposomes as compared with \n\nconventional liposomes. C. neoformans strains were susceptible to CPO with fungistatic (0.3 \n\nand 0.61 \u00b5g/mL) and fungicidal activity (1.22 and 4.88 \u00b5g/mL). Five C. neoformans strains \n\n(5811, 5813, 5824, 5825 and 124) were susceptible to CPO encapsulated in liposomes with \n\nfungistatic and fungicidal activities of 1.22 \u00b5g/mL. The results suggest that CPO loaded-\n\nliposomes have significant antimycotic activity against Cryptoccocus spp, reinforcing its \n\npotential for in vivo studies and its application in cryptococcosis treatment.   \n\n \n\nKeywords: Ciclopirox olamine, cryptococosis, Cryptococcus neoformans, liposomes, \n\nkinetics, antifungal activity. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nviii \n\n\n\n81 \n \n\n1. Introdution \n\nDespite the widespread prophylactic use of antifungal agents, infections caused by \n\nCryptococcus spp. have increased mortality and morbidity in immunocompromised patients \n\n(1, 2). The treatment of invasive cryptococcosis with commercially available drugs such as \n\namphotericin B and fluconazole has been limited, especially because of their toxicity \n\nassociated with the emergence of resistant Cryptococcus isolates (3-7). \n\nThe treatment of choice of disseminated fungal infections in immunocompromised \n\npatients is the Amphotericin B (AmB) in sodium deoxycholate (Fungizone\u00ae), despite its \n\nnephotoxicity (8).The currently strategies used to overcome this issue are lipid formulations \n\nof AmB including liposomes (AmBisome\u00ae), AmB-lipid complex (Abelcet\u00ae) and AmB \n\ncolloidal dispersion (Amphocil\u00ae), which have been developed to enhance the therapeutic \n\nindex and to reduce the nephrotoxic side effects of amphotericin B (9-11). However, these \n\nlipid based AmB dosage forms are not stealth formulations.  \n\nIn this scenario, hydroxypyridone derivates have been synthesized and evaluated for \n\nmonitoring superficial fungal infections. Among these agents, ciclopirox olamine (CPO) [(6-\n\nCyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one and 2-aminoethanol)] (Fig. 1) is the most \n\nbroadly used in clinical applications because of its broad spectrum, no toxicity, low cost and \n\nhigh potency. It has a broad spectrum against bacterial and fungal species, inhibiting nearly \n\nall clinical relevant dermatophytes and yeasts, including Malassezia species and the \n\nfrequently azole-resistant Candida isolates (12, 13). However, antifungal activity of \n\nciclopirox olamine-loaded pegylated lipossomes against Cryptococcus spp. strains has not \n\nbeen performed yet. \n\n \n\n \n\nFig.1. Chemical Structure of 6-Cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one and 2-\n\naminoethanol. \n\n \n\nTo overcome the low bioavailability and short half-life time (2.1 h) of ciclopirox \n\nolamine [13], the liposomal formulations are proposed to allow CPO systemic use. The \n\npresent study, thus, aims to develop and characterize CPO-loaded liposomes, as well as to \n\n\n\n82 \n \n\nevaluate its in vitro antifungal activity against thirty Cryptococcus clinical isolates obtained \n\nfrom the cerebrospinal fluid of immunocompromised patients.                    \n\nBased on these findings, herein, we describe the in vitro antifungal activity of CPO \n\nencapsulated in conventional and stealth liposomes. Indeed, the preparation and the \n\ncharacterization of CPO-loaded liposomes was performed using experimental fractional \n\ndesign, as well as the in vitro kinetic studies of these liposomal formulations were carried out. \n\n2. Material and methods \n\nReagents. Soya phosphatidylcholine (PC), distearoylphosphatidylethanolamine-polyethylene \n\nglycol 2000 (DSPE-PEG2000) were supplied by Lipoid GmBH (Ludwigshafen, Germany). \n\nCholesterol (CH), stearylamine (SA), ciclopirox olamine (97% purity), Roswell Park \n\nMemorial Institute Medium (RPMI) and morpholine-propanesulfonic acid (MOPS) were \n\npurchased from Sigma-Aldrich (St. Louis, Missouri, US). Sabouraud dextrose agar medium \n\n(SDA) was obtained from Difco (Detroit, US). Microtiter plates were furnished by TPP \n\n(Trasadingen, Switzerland) and 0.22-\u00b5m membranes were purchased from Millipore \n\n(Darmstadt, Germany). All chemicals were of reagent grade.  \n\nCryptococcus strains. The experimental protocol was previously approved by the \n\nEthical Committee of the Human Care and Use of the Federal University of Pernambuco \n\n(UFPE), Recife, Brazil (#080/09).  Thirty clinical strains of Cryptococcus neoformans were \n\nisolated from 300 samples of cerebro spinal fluid (CSF) of immunocompromised patients \n\nobtained by lumbar punctures at the Pernambuco Neurological Diagnosis Service. The \n\nclinical samples were processed for mycological diagnosis using standard methods, direct \n\nexamination with China ink staining and isolation in culture, at the Medical Mycology \n\nLaboratory, UFPE, Brazil. Cultures were prepared in duplicate using SDA medium with \n\nchloramphenicol (50 mg/mL) and incubated at 28\u00b12\u00b0C or 35\u00b12\u00b0C in an aerobic atmosphere \n\nfor 5 days. Pure cultures were transferred onto the surface of SDA for taxonomic \n\nidentification (14, 15). \n\n  Preparation of ciclopirox olamine-loaded liposomes. Ciclopirox olamine was \n\nencapsulated in conventional (CPO-Lipo C) and stealth liposomes (CPO-Lipo S) were \n\nprepared using the dried-lipid film hydration method (16). Initially, a pre-formulation study \n\nwas carried out using PC, CH and SA at 7:2:1 molar ratio, with total lipid concentrations \n\nvarying from 37.3 mM to 117.6 mM, drug:lipid ratio ranging from 1:50 to 1:317, and CPO \n\nconcentrations at 1-2 mg/mL. Stealth liposomes were prepared by replacing 5% of PC for \n\nDSPE-PEG2000. From the pre-formulation studies, a two-level 24-1 experimental fractional \n\ndesign was carried out to optimize the CPO encapsulation in liposomes evaluating the \n\n\n\n83 \n \n\ninfluence of lipid concentrations and drug:lipid molar ratio on the variables mean particle \n\nsize, polidispersity index (PDI) and drug encapsulation efficiency (EE%). The factors were \n\ndefined as follows: Factor A = PC (41.16, 61.74 and 82.32 mM); Factor B = CH (11.76, 23.52 \n\nand 35.28 mM); Factor C = SA (0.0; 5.88 and 11.76mM) and Factor D = CPO (2.0; 2.5 and \n\n3.0 mg). Experiments were randomly assayed in order to nullify the effect of inappropriate \n\nnuisance variables. The central point was employed in triplicate.   \n\n  Characterization and physicochemical evaluation of CPO-LIPO. The \n\nphysicochemical analysis was carried out after preparation of liposomes. Parameters such as \n\nthe macroscopic appearance, morphological examination, particle mean diameter, pH \n\nchanges, CPO content and encapsulation efficiency were analyzed. To determine CPO content \n\nan aliquot of liposomes (20 \u00b5L) was diluted with methanol to 5 mL and then sonicated for 5 \n\nminutes. Measurements were carried out at 304 nm (13) using a CPO standard curve with \n\nconcentrations varying from 5 to 80 \u00b5g/mL.  Drug-encapsulation efficiency of CPO in \n\nliposomes was determined by the ultrafiltration/ultracentrifugation technique using \n\nUltrafree? units (Millipore, USA). After centrifugation of the CPO-Lipo samples \n\n(Ultracentrifuge KT 20000, Kubota, Japan) at 8.776 g for 1 h at 4 ?C, the CPO concentration \n\nin the supernatant was also measured at 304 nm and the CPO encapsulation ratio calculated in \n\nrelation to its initial content in the liposome formulation.  \n\nIn vitro release kinetics of CPO from convencional and stealth liposomes. The in \n\nvitro release kinetics of CPO from conventional and stealth liposomes were carried out using \n\nthe dialysis technique under sink conditions at pH 7.4 phosphate buffer solution at 37\u00b0C. \n\nBriefly, an aliquot of the liposomal formulation (1 mL) containing CPO was inserted into a \n\ndialysis membrane bag (MW cut-off 12,400), which was subsequently sealed and suspended \n\nin the release medium (50 mL). The system was maintained under magnetic stirring at 37\u00b0C. \n\nAt appropriate intervals, samples of the release medium (1 mL) were removed and assessed \n\nfor CPO content. At each withdraw the release medium was replaced by fresh phosphate \n\nbuffer solution (1 mL).  \n\n Antifungal susceptibility testing.  Antifungal activity of CPO against Cryptococcus \n\nstrains was determined according to CLSI (guide M27-A3) with some modifications (18). The \n\nculture medium RPMI 1640 with L-glutamine, without sodium bicarbonate (pH 7.0 \u00b1 0.1) and \n\nsupplemented with MOPS (0.165 mol-1),  was filter-sterilized in 0.22\u00b5 membranes (Millipore, \n\nDarmstadt, Germany). Stock solutions of CPO diluted in DMSO at concentrations of 1600 \n\nmg/mL were prepared. The concentrations of CPO in solution or in conventional and stealth \n\nliposomes ranged from 0.3 to 625 \u00b5g/mL.  \n\n\n\n84 \n \n\nThe Cryptococcus strains were maintained on SDA medium and incubated for 48h. \n\nSuspensions of the isolates were prepared and their density was adjusted according to the 0.5 \n\nMacFarland scale for 90% transmission using a spectrophotometer. The volume of the \n\ninoculum was adjusted with steril saline to 5.0 mL of and was then diluted in RPMI 1640 to \n\nattain a concentration of 2-5 \u00d7103 cells/mL. \n\nFor the susceptibility tests, sterilized flat-bottomed 96-well microtiter plates were used \n\nand the procedures followed the CLSI protocols [17,18]. The inoculum was added to the wells \n\nwith the tested drug, and the plates were incubated at 35\u00b0C for 3 days before reading the \n\nresults to determine the minimal inhibitory concentration (MIC) of the CPO. The \n\nmicroorganism growth inhibition was evaluated by visual observation. Candida parapsilosis \n\n(ATTC 22019) and Candida krusei (ATCC 6528) strains were used as quality controls. \n\nThe minimal inhibitory concentration (MIC) values of CPO against C. neoformans  \n\nwere determined as the concentration able to inhibit fungal growth ?80% [17]. To determine \n\nthe minimal fungicide concentration (MFC) of CPO the content of the well that showed 80% \n\nand 100% fungal growth inhibition was transferred onto SDA in Petri dishes. The dishes were \n\nthen incubated at 35\u00b0C for 3 days to determine the fungal viability. The MFC was confirmed \n\nby the absence of fungal growth. The CPO activity was determined according to the CLSI \n\ndocument M27-A3 [18] based on the susceptibility range of AmB (? 1 \u00b5g/mL), which is the \n\ndrug reference. In addition, the evaluation was also based on the new CLSI document M38-\n\nA2 [17], which includes tests with CPO for dermatophytes, suggesting that MICs ? 1 \u00b5g/mL \n\nare considered susceptible. Each experiment was performed in duplicate.  \n\nStatistical analysis. Statistical analysis of data of stealth and conventional liposomes \n\nformulations was carried out using the Tukey's Multiple Comparison test with a significance \n\nlevel defined as p &lt;0.05. Data were analyzed using Statistica 8.0\u00ae software (Statsoft Inc, \n\nTulsa, OK, USA) and GraphPad Prism 4\u00ae (GraphPad software, California, US). \n\n3. Results  \n\nPre-formulation study of CPO-loaded liposomes. Different batches of CPO-loaded \n\nliposomes were presented in the pre-formulation study, presenting mean size diameter and \n\nPDI ranging from 97.3 nm to 156 nm and 0.293 to 0.360, respectively (Table 1). After \n\npreparation, liposomal formulations exhibited a bluish reflection characteristic of small \n\nunilamellar vesicles, independently of the encapsulated CPO concentration (1\u20132 mg/mL). \n\nLiposomes presented CPO encapsulation efficiency ranging from 89.65 \u00b1 0.10% to 99.75 \u00b1 \n\n0.51%, calculated using the standard curve of CPO concentrations ranging from 5 to 80 \n\n\n\n85 \n \n\n\u00b5g/mL (Abs=0.0252[CPO] \u2013 0.0286; r2= 0.9994). A typical CPO-loaded liposomal \n\nformulation (L4) was obtained with a 1:79 drug/lipid molar ratio (CPO=7.4 mM: PC:CH:SA= \n\n41.16:11.76:5.88), EE% of 99.6\u00b1 0.21%, particle size of 123 nm and PDI of 0.312. The others \n\nliposome formulations were unstable, exhibiting drug precipitation and lipid flocculation after \n\none week of preparation. The formulation L4 was chosen for further fractional factorial \n\ndesign. \n\nFractional Factorial design. Eleven runs of two-level 24-1 fractional experimental \n\ndesign and their responses are shown in Table 2. The variable PC concentrations at higher \n\nlevels (61.74 and 82.32 mM) reduced the mean size (from  156 to 90.5 nm). The higher CH \n\nconcentrations reduced the mean size (from  154 to 133 nm) and EE% (from 95.8\u00b10.45 to \n\n93.6\u00b10.98), however, increased the PDI values from 0.319 to 0.472 of the liposomes. The \n\nenhancement of SA concentrations (5.88 and 11.76) increased the mean size (from 90.5 to \n\n119 nm ) and PDI values (from 0.274 to 0.301) and reduced EE% from 98.7\u00b10.97% to \n\n89.7\u00b10.2%. But the absence of SA induced drug precipitation after 48 h of storage at 4\u00b0C of \n\nformulations.  Finally, the higher CPO concentrations (11.1 mM) reduced the EE% (from \n\n95.56\u00b10.45% \u2013 90.56\u00b10.31%).  \n\nBased on factorial results, the formulations of the central point presented stability with \n\nthe lowest values of the mean size diameter 102.7 nm, PDI 0.264 and EE% of 97.36% (L11) \n\n(Fig. 2, Table 2). This formulation was chosen to prepare stealth liposomes using DSPE-\n\nPEG2000. The stealth liposomes present a mean size diameter, PDI, EE% values of 101.4\u00b1 \n\n0.74 nm, 0.307 and 96.45\u00b10.89%, respectively.  \n\nNo statistical difference was found between physicochemical parameters (mean particle \n\nsize, PDI and drug encapsulation efficiency) of conventional (L11) and stealth (L11\u2019) \n\nliposomes formulations by the Turkey Test (p &lt;0.05). \n\nKinetics of CPO-loaded in conventional and stealth liposomes. A slower release \n\npattern of CPO from the stealth liposomal formulation was found when compared with the \n\nconventional liposomes (Fig. 3). The release profile from CPO-loaded conventional and \n\nstealth liposomes showed burst effects of 65.95\u00b10.5 and 41.09\u00b10.3%, respectively, after the \n\nfirst 2h. The maximum release and the release rate of CPO from conventional and stealth \n\nliposomes at 96 h were approximately 99.9\u00b10.6% and 94.6\u00b10.3%; 634.2\u00b10.0 \u00b5g/mL and \n\n109.02\u00b1 2.8 \u00b5g/mL, respectively.  \n\nAntifungal activity of CPO-loaded liposomes.  All the analyzed Cryptococcus strains \n\nwere susceptible to CPO with fungistatic concentrations ranging from 0.30 to 0.61 ?g/mL and \n\nfungicidal activity from 1.22 to 4.88 \u00b5g/mL (Table 3). On the other hand, the conventional \n\n\n\n86 \n \n\nand stealth CPO-loaded liposomes had the same fungistatic activity with MIC values ranging \n\nfrom 1.22 to 2.44 \u00b5g/mL, and fungicidal activity between 1.22 and 9.76 \u00b5g/mL. Moreover, \n\nfive C. neoformans strains (5811, 5813, 5824, 5825 and 6897) were more susceptible to CPO \n\nencapsulated in liposomes with fungistatic and fungicidal activities of 1.22 \u00b5g/mL. \n\n4. Discussion    \n\nCryptococosis, a mycosis caused by Cryptococcus spp, is one of the most important HIV-\n\nrelated opportunist fungal infections (7). High rates of fungal persistence and recurrence \n\ncaused growing concern among physicians about the potential emergence of resistance of \n\ncapsulated yeasts (6).  \n\nThe micellar suspension of amphotericin B (AmB) with sodium desoxycholate \n\n(Fungizone\u00ae) is the antifungal agent of choice for the treatment of cryptococosis. It can be \n\nnotice that both activity and the toxicity of AmB are related to its structure and tendency to \n\nform pores in ergosterol-containing membranes, leading to toxicity towards host cells (8). In \n\nthe literature, several studies have been proposed the encapsulation of antibacterial and \n\nantifungal agents in drug delivery systems, particularly liposomes, due to their ability to \n\nreduce drug toxicity and improve their therapeutic index (19-21). \n\nIn this study it was possible to evaluate the in vitro antifungal activity of free CPO and \n\nencapsulated into conventional and stealth liposomes. The mean size, index polydispersity  \n\nand drug encapsulation efficiency as well as the lipid constituents of the liposomes were \n\nevaluated, given that these parameters are prominent aspects for drug delivery effectiveness \n\n(22). \n\nThe antifungal drug used in this work, CPO is a broad-spectrum agent used in the  \n\ntreatment of topical fungal infections. Nevertheless CPO systemic use is limited due to its \n\nshort half-life time of 2.1 h (13, 23). To the best of our knowledge, no previous report on the \n\nimprovement of systemic delivery systems containing ciclopirox olamine was found. In order \n\nto rise above these issues and improve the CPO bioavailability the use of liposomes as \n\nnanocarriers for systemic administration was proposed in the present study.   \n\nCiclopirox olamine-loaded liposomes (CPO-Lipo) were previously developed using the \n\ndried-lipid film hydration method by varying drug concentrations from 1 to 2 mg/mL. CPO-\n\nLipo were characterized with respect to macroscopic appearance, mean size diameter, \n\npolidispersity index and encapsulation efficiency from the initial formulation (L1) with \n\nconcentrations of PC=82.32, CH=23.52, SA=5.88 and 1 mg/mL of CPO (Table 1). According \n\nto the pre-formulation study, the L4 formulation prepared with 117,6 mM of lipids (PC= \n\n82.32, CH=23.52, SA=11.76) was chosen as a typical CPO liposomal formulation for having  \n\n\n\n87 \n \n\nbetter physicochemical aspect, no drug precipitation, greater amount of drug encapsulated (2 \n\nmg/mL) and encapsulation efficiency of 99.6 \u00b1 0.01%. The others formulations showed drug \n\nprecipitation up to seven days after preparation. In addition, CPO-loaded liposomes without \n\nstearylamine were equally unstable (L7 formulation). From the L4 formulation, a 24-1 \n\nfractional factorial design was carried out to verify the influence of the lipid concentrations \n\nand the positively charged lipid, stearylamine, on the stability and drug entrapment efficiency \n\nof liposomes (Table 2). Despite of the central point of the factorial design have increased the \n\ntotal lipids amount in 35.52%, it showed prominent characteristics when compared with the \n\nL4 formulation with improvement of the mean size in 17.1%, PDI in 15.34%  and CPO \n\namount in 25%. The minimum concentrations of stearylamine to obtain the stable formulation \n\nfor one month was 5.88 mM. \n\nTo develop a therapeutically efficient nanocarrier system, the constituents of liposomes \n\nhas to be optimized because it is the crucial factor in preparing stable liposomes incorporated \n\nby maximum of drug concentration. The use of a 24-1 fractional factorial design can \n\nconsiderably reduce the number of preparations. In our study, the factors content of PC, CH, \n\nSA were examined at two levels. Cholesterol is often used as a main component of the lipid \n\nmembrane. It has been shown to modify the order and mobility of the phospholipids in the \n\nbilayer and as a consequence, it alters the bilayer fluidity (24). According to Shaikh and \n\nPawar (25) the amounts of CH  are primarily responsible for the stability of topic liposomes \n\ncontaining CPO.  SA liposomes have previously demonstrated efficacy in animal models for \n\nhuman diseases and are currently being evaluated in human clinical studies. However, toxic \n\neffects have also been reported for SA liposomes (26). In our study, it was observed that high \n\nSA concentrations result in unstable liposomes. The amount of SA was maintained to a \n\nminimum concentration after the fractional factorial designer (5.88 mM).  \n\nRecently, the design of CPO-loaded liposomes to enhance availability of this drug in \n\ncutaneous mycosis treatment was reported by Shaikh; Pawar (25). In this previous study \n\nspherical unilamellar , CPO-lipo were obtained using a method based on ethanol injection. \n\nThe vesicles size and drug entrapment efficiency ranged from 196\u00b11.73 nm to 1040.66 \u00b1 7.02 \n\nnm and from 34.28 \u00b1 4.4% to 54.89 \u00b1 1.9%, respectively. The method used by these authors \n\nis not applicable for systemic use due to high particle size and low drug entrapment \n\nefficiency. In our study, the liposome formulations presented after experimental design a \n\nvesicle size ranging from 90,5 \u00b1 0,96 nm to 189.1 \u00b1 4.50 nm and % entrapment efficiency \n\nranging from 89,56\u00b10,47% to 98,75\u00b10,51%.  \n\n\n\n88 \n \n\nBased on the results of the 24-1 fractional factorial design, the lipids concentrations \n\nobtained from the central point were used for stealth liposome preparation. The results \n\nindicated that there is no statistical difference between conventional and stealth formulations \n\non the physico-chemical parameters by the Turkey Test (p &lt;0.05).  \n\nFrom the prominent formulation observed on the experimental designer, kinetic release \n\nwas carried out in vitro using conventional and stealth systems for comparison. Comparing \n\nthe release kinetic of CPO-loaded conventional and stealth liposomes, the both systems \n\npresented a released profile in a controlled manner, however, it was observed that stealth \n\nliposomes showed considerable decrease in the CPO release profile, probably due to the \n\npresence of PEG, so the stealth liposomes perhaps may be effective in the treatment of \n\ncryptococosis avoiding repeated doses and adverse effects (27).  \n\nRegarding biological activity, the antifungal testing was realized with both conventional \n\nand stealth liposomes from the central point formulation of the experimental designer. It has \n\nbeen establish that the in vitro activity of CPO occurs against a broad spectrum of fungi, \n\nincluding pathogenic yeasts. Furthermore, free CPO can be considered both fungistatic and \n\nfungicidal with MICs ranging from 0.9 to 3.9 \u00b5g/mL for Candida species such as Candida \n\nalbicans and C. glabrata. The MIC range of pathogenic yeast including Cryptococcus strains \n\nand dermatophytes is between 0.25 and 31.3 \u00b5g/mL (7, 12, 28, 29, 30). Hannel et al. (31) \n\nusing a non-reference method, obtained the antifungal activity of CPO around 6 \u00b5g/mL. The \n\nMICs values obtained from our data with free CPO are lower than those reported in literature \n\nwith concentrations ranging from 0.30 to 0.61 \u00b5g/mL.  \n\nAccording to the reference method (17), dermatophytes are considered sensitive to CPO \n\nwhen MICs are ? 1 \u00b5g/mL. Regarding Cryptococcus strains, only one research focus on the \n\nantifungal activity of CPO was performed according to CLSI protocol (7). In the present \n\nstudy, all the thirty tested strains presented MICs ? 1 \u00b5g/mL and were considered sensitive to \n\nCPO treatment.  \n\nWith respect to free CPO fungicidal activity, thirty Cryptococcus isolates showed \n\nfungicidal concentrations of 1.22, 2.44, 4.88 \u00b5g/mL.  Oliveira et al. (7) working with sixteen \n\nCryptococcus isolates also observed similar results with fungicidal activity of CPO free in \n\nconcentrations from 1 to 4 \u00b5g/mL.  \n\nRegarding the conventional and stealth CPO-loaded conventional and stealth liposomes, \n\nno difference in terms of in vitro fungistatic activity was observed. The MICs varied between \n\n1.22 and 2.44\u00b5g/mL. Despite drugs routinely used in clinical practice for cryptococosis \n\ntreatment such as amphotericin B and Fluconazole, exhibit MIC values lower than the MICs \n\n\n\n89 \n \n\nobserved in our study, these drugs showed some disadvantages due to side effects such as \n\nhypertension, nausea, gastrointestinal intolerance, hepatotoxicity and nephrotoxicity (32, 33). \n\nFurthermore, Fluconazole is an antifungal drug which shows only fungistatic activity and our \n\nliposomes showed both fungistatic and fungicidal activity with MFC/MIC ? 9.76 \u00b5g/mL. \n\nSeveral reports described liposomes as a drug delivery tool in experimental models of \n\ncryptococcal infections (34-38).  \n\nIt is also possible to observed in our study that the most MIC and MFC of CPO-loaded \n\nconventional and stealth liposomes (1.22 to 2.44 \u00b5g/mL and 1.22 to 9.76 \u00b5g/mL, respectively) \n\nshowed promising values when compared with those obtained by Ambisome\u00ae against clinical \n\nCryptococcus neoformans isolates with MIC and MFC values of 8 and ? 8\u00b5g/mL, \n\nrespectively (39).  \n\nThe present study shows a prospective application of the CPO-loaded liposomes  \n\nfor the management of AIDS-associated cryptococcal meningitis, although this drug show \n\nlow bioavailability. Thus, the liposomes may overcome these limitations of the CPOin a free \n\nform and improve its antifungal activity. The ciclopirox olamine liposomal formulation is an \n\ninteresting approach to afford commercially available efficient antifungal systems. Although \n\nCPO-loaded liposomes exhibited excellent in vitro antifungicidal activity, further in vivo \n\nexperiments are still required to consider this drug as promising treatment option for \n\ncryptococcosis. These experiments are being performed by our research group.  \n\n \n\nAcknowledgments \n\nWe thank the Brazilian Council for Scientific and technological Development (CNPq) for \n\nfinancial support and the grant fellowship of the first author. \n\n \n\nReferences \n\n1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. \n\n2009. Estimation of the current global burden of cryptococcal meningitis among persons \n\nliving with HIV/AIDS. AIDS. 23:525\u2013530.  \n\n2. Albuquerque PC, Rodrigues ML. 2012. Research trends on pathogenic Cryptococcus \n\nspecies in the last 20 years: a global analysis with focus on Brazil. Future Microbiol. 7:319\u2013\n\n329.  \n\n\n\n90 \n \n\n3. Joseph-Horne T, Loeffler RST, Hollomon DW, Kelly SL. 1996. Amphotericin B resistant \n\nisolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J. med. vet. \n\nMycol. 34:223\u2013225. \n\n4. Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. 1998. Detection of resistance \n\nto amphotericin B among Cryptococcus neoformans clinical isolates: performances of three \n\ndifferent media assessed by using E-test and National Committee for Clinical Laboratory \n\nStandards M27-A methodologies. J. Clin. Microbiol. 36:2817\u20132822. \n\n5. Sar B, Monchy D, Vann M, Chantary K, Sarthou JL, Buisson Y. 2004. Increasing in \n\nvitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates. J. \n\nAntimicrob. Chemother. 54:563-565.  \n\n6. Cowen LE, Steinbach WJ. 2008. Minireviews: stress, drugs, and evolution: the role of \n\ncellular signaling in fungal drug resistance. Eukaryot Cell 7:747\u2013764. \n\n7. Oliveira PC, Medeiros CS, Macedo DP, Andrade SL, Correia MT, Mesquita \n\nSD, Lima-Neto RG, Neves RP. 2010. Ciclopirox olamine: an antifungal alternative against \n\ncryptococcosis. Lett. Appl. Microbiol. 51:485-9. \n\n8. Labari M, Gulik A, Dedjeu LP, Legrand P, Barratt G, Cheron M. 2004. New lipid \n\nformulation of amphotericin B: spectral and microscopic analysis. Biochim Biophys Acta \n\n1664:172-181. \n\n9. Sionov E, Mendlovic S, Segal E. 2006. Efficacy of amphotericin B or amphotericin B-\n\nintralipid in combination with caspofungin against experimental aspergillosis. J. Infect. \n\n53:131-139. \n\n10. Nahar M, Pharm M, Mishra D, Dubey V, Jain NK. 2008. Development, \n\ncharacterization, and toxicity evaluation of amphotericin B\u2013loaded gelatin nanoparticles. \n\nNanomedicine 4:252\u2013261. \n\n11. Wang JL, Chang CH, Young-Xu Y, Chan KA. 2010. Systematic review and meta-\n\nanalysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive \n\ntherapy for invasive fungal infection. Antimicrob. Agents Chemother. 54:2409-2419. \n\n12. Niewerth M, Kunze D, Seibold M, Shaller M, Korting HC, Hubel B. 2003. Ciclopirox \n\nOlamine treatment affects the expression pattern of Candida albicans genesencoding virulence \n\nfactors, iron metabolism proteins, and drug resistance factors. Antimicrob. Agents \n\nChemother. 47:1805\u20131817. \n\n13. Coppi G, Silingardi S. 1992. HPLC method for pharmacokinetic studies on ciclopirox \n\nolamine in rabbits after intravenous and intravaginal administrations. Farmaco 47:779-786. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Oliveira%20PC%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Medeiros%20CS%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Mac%C3%AAdo%20DP%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Andrade%20SL%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Correia%20MT%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Mesquita%20SD%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Lima-Neto%20RG%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Neves%20RP%22%5BAuthor%5D\n\n\n91 \n \n\n14. Barnett JA, Paine RW, Yarrow D. 2000. Yeasts: Characteristics and Identification, 3 \n\nedn. Cambridge: Cambridge- University Press. \n\n15. De Hoog GS, Guarro J, Gene J, Figueras MJ. 2000. Atlas of Clinical Fungi. 2rd edn. \n\nCentraalbureau voor Schimmelcultures: Universitat Rovira Virgili.  \n\n16. Cavalcanti IMF, Mendon\u00e7a EAM, Lira MCB, Honrato SB, Camara CA, Amorim \n\nRVS, Filho, J M, Rabello MM, Hernandes MZ, Ayala AP, Santos-Magalh\u00e3es NS. 2011. \n\nThe encapsulation of b-lapachone in 2-hydroxypropyl-b-cyclodextrin inclusion complex into \n\nliposomes: A physicochemical evaluation and molecular modeling approach. Eur. J. Pharm. \n\nSci. 44:332-40. \n\n17. Clinical and Laboratory Standards Institute (CLSI). 2008. Reference Method for \n\nBroth Dilution Antifungal Susceptibility Testing of Filamentous Fungi (M38-A2). 2 ed. \n\nWayne, PA, USA. \n\n18. Clinical and Laboratory Standards Institute (CLSI). 2008. Reference method for broth \n\ndilution Antifungal susceptibility testing of yeasts (M27-A3). 3rd edn. Wayne: USA. \n\n 19. Adler-Moore JP, Olson JA, Proffitt RT. 2004 Alternative dosing regimens of \n\nliposomal amphotericin B (Ambisome) effective in treating murine systemic candidiasis. J. \n\nAntimicrob. Chemother. 54:1096-1102. \n\n20. Rukholm G, Mugabe C, Azghani AO, Omri A. 2006. Antibacterial activity of \n\nliposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int. J. Antimicrob. \n\nagents 27:247-252. \n\n21. Nicolosi D, Scalia M, Nicolosi VM, Pignatello R. 2010. Encapsulation in fusogenic \n\nliposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. \n\nInt. J. Antimicrob. Agents 35:553-558. \n\n22. Bakker-Woudenberg IAJM. 2002. Long-circulating sterically stabilized liposomes as \n\ncarries of agents for treatment of infection or for imaging infectious foci. Int. J. Antimicrob. \n\nAgents 19:299-311.  \n\n23. Nogueiras-Nieto L, Sobarzo-S\u00e1nchez E, G\u00f3mez-Amoza JL, Otero-Espinar FJ. 2012.  \n\nCompetitive displacement of drugs from cyclodextrin inclusion complex by \n\npolypseudorotaxane formation with poloxamer: Implications in drug solubilization and \n\ndelivery. Eur. J. Pharm. Biopharm. 80:585-95. \n\n24. Braun E, Wagner A,  Furnschlief E,  Katinger H,  Vorauer-Uhl, K. 2006. \n\nExperimental design for in vitro skin penetration study of liposomal superoxide dismutase. J. \n\nPharm. Biomed. Anal. 40:1187\u20131197. \n\n\n\n92 \n \n\n25. Shaikh KS, Pawar AP. 2010. Lipossomal delivery enhances cutaneous availability of \n\nCiclopirox olamine. Lat. Am. J. Pharm. 29:763-70. \n\n26. Nishiya T, Lam RT, Enq F, Zerey M, Lau S. 1995. Mechanistic study on toxicity of \n\npositively charged liposomes containing stearylamine to blood.  Artif. Cells Blood Substit. \n\nImmobil. Biotechnol. 23: 505-512. \n\n27. Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K. 2011. PEG liposomalization \n\nof paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm. 412:132-\n\n141. \n\n28. Dittmar W, Lohaus G. 1973. HOE 296, a new antimycotic compound with a broad \n\nantimicrobial spectrum: laboratory results. Arzneimittelforschung 23:670-674. \n\n29. Figueiredo VT, Santos DA, Resende MA, Hamdan JS. 2007. Identification and in vitro \n\nantifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for \n\nfingernail infections. Mycopathologia 164:27\u201333. \n\n30. Biancalana FSC, Telles PFG, Lyra L, Zaninelli A. 2008. Preanalytical conditions for \n\nbroth microdilution antifungal susceptibility of Microsporum spp. Mycoses 51:313\u2013317. \n\n31. Hannel H, Roether W, Dittmar W. 1988. Evaluation of the fungicidal action of in vitro \n\nand in a skin model considering the influence of penetration kinetics on various standards \n\nantimycotics. Ann. NY Acad. Sci. 544:329\u2013337. \n\n32. Pathak A, Pien FD, Carvalho L. 1998. Amphotericin B use in a community hospital, \n\nwith special emphasis on side effects. Clin. Infect. Dis. 26:334-338. \n\n33. Vandeputte P, Ferrari S, Coste AT. 2012. Antifungal Resistance and New Strategies to \n\nControl Fungal Infections. Int. J. Microbiol. doi: 10.1155/2012/713687. \n\n34. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, \n\nMildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC, Simberkoff MS, Wolf J, \n\nMeyer RD, Gupta R, Lee LW, Gordon DS. 1996. Amphotericin B complex compared with \n\namphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. \n\nInfect. Dis. 22:315-321. \n\n35. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, Borleffs JC, Allmorth \n\nT, Kauffmann RH, Jones P, Kroon FP, Verbrugh HA, Marie S. 1997. Lipossomal \n\namphotericin B (Ambisome) compared with amphotericin B both followed by oral \n\nfluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11: 1463-\n\n1471.  \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/7581836\nhttp://www.ncbi.nlm.nih.gov/pubmed/7581836\n\n\n93 \n \n\n36. Clemons KV, Stevens DA. 1998. Comparison of Fungizone, Amphotec, AmBisome, and \n\nAbelcet for Treatment of Systemic Murine Cryptococcosis. Antimicrob. Agents Chemother. \n\n42: 899\u2013902. \n\n37. Baddour LM, Perfect JR, Ostrosky-Zechener I. 2005. Successful use of amphotericin \n\nB lipid complex in the treatment of cryptococcosis. Clin. Infect Dis. 40:409-413. \n\n38. Khan MA, Nasti TH, Owais M. 2005. Incorporation of amphotericin B in tuftsin-bearing \n\nliposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J. \n\nAntimicrob. Chemother. 56:726\u2013731. \n\n39. Johnson EM, Ojawang JO, Szekely A, Wallace TL, Warnock DW. 2005. \n\nComparizon of in vitro antifungal activities of free and liposome-encapsulated nystatin \n\nwith those of four amphotericin B formulations. Antimicrob. Agents Chemother. 49:4867-\n\n4875. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n94 \n \n\n \n\n  \n\n \n\n \n\n \n\n                                          5- CAP\u00cdTULO 2 \n\n(A ser submetido \u00e0 revista Mycopathologia) \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n95 \n \n\nPhenotypic and Genotypic determination of Cryptococcus \n\nneoformans clinical isolates \n\nPatricia de Oliveira Kocerginskya. Delio Jos\u00e9 Morab. Neiva Tinti de Oliveiraa. \n\nMariele Carneiro Portoa. Pedro Henrique dos Santos Soaresc . Rejane Pereira Nevesa*. \n\nNereide Stela Santos Magalh\u00e3esc \n\n \n\na Departamento de Micologia, Centro de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de \n\nPernambuco (UFPE), Av. Prof. Nelson Chaves, s/n, Cidade Universit\u00e1ria, 50670-420 Recife, \n\nPE, Brasil. \n\nb Disciplina de Doen\u00e7as Infecciosas e Parasit\u00e1rias, Universidade Federal do Tri\u00e2ngulo \n\nMineiro (UFTM), Av. Frei Paulino, 30, Abadia, 38025-180, Uberaba, MG, Brasil. \n\nb Departamento de Biologia, Universidade Federal Rural de Pernambuco (UFRPE), Rua \n\nManoel de Medeiros, s/n, Dois irm\u00e3os, 52171-900, Recife, PE, Brasil.  \n\nc Laborat\u00f3rio de Imunopatologia Keizo-Asami (LIKA), Universidade Federal de Pernambuco \n\n(UFPE), Av. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria, 50670-901, Recife, PE, Brasil. \n\n \n\n*Corresponding author: rejadel@yahoo.com.br, telephone: (+5581) 2126-8570, fax: (+5581) \n\n2126-8482 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n96 \n \n\nAbstract \n\nOn this work was developed a strategy to compare the classical phenotypical approach with \n\nthe minisatellite-specific primer M13 in the diagnosis of Cryptococcus. From a total of 300 \n\ncerebrospinal fluid samples of patients with suspected cryptococcal meningitis, thirty cases \n\n(10%) were diagnosed with neurocryptococcosis. All patients except one, who presented \n\nAdult T-Cell Leukaemia, were HIV seropositive. The phenotypic identification was realized \n\nby colonial aspects, cellular morphologies, microscopic appearance, physiological and \n\nbiochemical tests. Genotypes were characterized through the use of URA5 restriction \n\nfragment length polymorphisms analysis and the genetic variability was determined using \n\nPCR-fingerprinting with the minisatellite specific primer M13. The yeasts presented \n\nmorphological and physiological characteristics compatible with the genus Cryptococcus. All \n\n30 isolates were sensitive to canavanine and showed VNI genotype representing C. \n\nneoformans var. grubii (serotype A). According to M13 analysis, all isolates showed 100% \n\nsimilarity in their PCR fingerprinting patterns, which may suggest a possible clonal origin. \n\nThere was no incongruence observed between the classical phenotypical approach results and \n\nthe molecular identification data. These results reinforce the importance of biochemical tests, \n\nas an inexpensive and efficient tool, for a rapid identification and diagnosis of cryptococcosis \n\nin the routine analyses in health centers and hospitals. The molecular tests can be employed \n\nfor identification, typing and molecular epidemiology studies in order to understand \n\ngeographical expansion and global distribution of Cryptococcus. \n\n \n\nKeywords: Cryptococcus neoformans; cryptococcal meningitis; clinical isolates; genotype; \n\nphenotype. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n97 \n \n\nIntroduction \n\nNewly emerging and reemerging infectious diseases have become a major focus of \n\nresearch in the 21st century. Among opportunistic fungal infections, cryptococcosis is the \n\nmost prevalent systemic mycosis in HIV patients, caused primarily by Cryptococcus \n\nneoformans species complex, whose members are C. gattii and C. neoformans [1, 2]. The \n\netiologic agents of cryptococcosis differ in their virulence, geographical distribution, \n\npathogenicity, clinical picture and therapeutic outcome [3-5]. \n\nCryptococcus gattii is distinct from its sibling species Cryptococcus neoformans [4]. \n\nClassically, C. gattii affects healthy hosts living in tropical and subtropical rural areas and it is \n\noccasionally isolated from AIDS patients. However, in some African regions it may be the \n\netiologic agent in up to 10% of the cases [6-8]. C. gattii can be classified into four discrete \n\nmolecular types (VGI-VGIV), which represent cryptic species as no nuclear allelic exchange \n\nbetween groups has been observed [9]. \n\nCryptococcus neoformans more commonly infects immunosuppressed hosts and \n\ninfects almost one million people annually with over 620,000 attributable mortalities [2, 10]. \n\nThe yeast has been found to be composed of two varieties and three serotypes based on \n\nmolecular analysis, genome sequence and serological tests,  specifically, C. neoformans var. \n\ngrubii (serotype A), C. neoformans var. neoformans (serotype D) and the hybrid (serotype \n\nAD) [11].  \n\nThe prevailing laboratory investigation model for cryptococcosis includes direct \n\nexamination, standardized morphological criteria, biochemical and physiological tests, such \n\nas L-Canavanine\u2013Glycine\u2013Bromothymol blue media (CGB). This medium was proposed by \n\nKwon-Chung et al. (1982) and C. neoformans is distinguished from C. gattii by enzymatic \n\ndifferences. Beyond classical identification, molecular techniques have been applied as \n\nadditional tools for the diagnosis of C. neoformans complex [12].  \n\nThe Cryptococcus species complex has been divided into eight major molecular types \n\nby PCR-fingerprinting using single primers specific to ISSR (M13) and PCR-RFLP of URA5 \n\ngene from clinical cultures. Results indicate that VNI and VNII genotypes correspond to \n\nserotype A, VNIII is related to serotype AD and VNIV to serotype D of C. neoformans. \n\nHowever, VGI-VGIV contains isolates of both serotypes (B and C) of C. gattii [8, 13, 14]. \n\nThe molecular tests have high sensitivity and specificity, with the potential to overcome the \n\nlimitations of conventional diagnosis, in addition, can be employed for identification, typing \n\nand molecular epidemiology studies [2, 15]. \n\n\n\n98 \n \n\nIn the present study, thirty clinical isolates of Cryptococcus spp obtained from the \n\ncerebrospinal fluid (CSF) of immunocompromised patients, admitted in public hospitals of \n\nRecife-PE, have been identified and compared with each other by classical and molecular \n\nmethods.   \n\n \n\nMaterials and Methods \n\nThe protocol was approved by the Ethical Committee for Research in Humans of the \n\nFederal University of Pernambuco (Centro de Ci\u00eancias da Sa\u00fade-UFPE, permit number \n\n080/09). \n\nIsolation and classical identification  \n\nA total of 300 CSF samples were obtained from patients with suspected cryptococcal \n\nmeningitis over the last four years (2008-2012) at public hospitals of Recife, Pernambuco- \n\nBrazil. All the isolates obtained were submitted to phenotypic and molecular identification. \n\nThe phenotypic identification was realized by colonial aspects on Sabouraud Dextrose Agar-\n\nSDA (Difco) plates, cellular morphologies, microscopic appearance using India ink, \n\nphysiological and biochemical tests [16-18]. The different species were distinguished by \n\ncanavanine-glycine-bromothymol blue agar medium (CGB) as proposed by Kwon-Chung et \n\nal. [18]. The isolates were cultured in plates containing 20 mL of L-canavanine-glycine-\n\nbromothymol blue agar medium (CGB) at 37\u00b0C. All the plates were observed daily for up to \n\nfive days.  \n\nMolecular Identification  \n\nDNA extraction \n\nYeast were grown on plates containing SDA plus chloramphenicol (50 mg ml-1) at \n\n37\u00b0C for 72h and DNA protocol extraction was carried out according to described by Mora et \n\nal. (2010).  The DNA concentration was determined spectrophotometrically at 260/280 nm. \n\nThe integrity of the extracted DNA was detected on a 1% agarose gel, visualized under UV \n\nlight. \n\nGenotype determination by URA5-RFLP \n\nStandard PCR amplification reactions of the URA5 primer were performed with 1.5U of \n\nTaq DNA polymerase and 50 ng of each primer URA5 (5\u2019- \n\nATGTCCTCCAAGCCCTCGACTCCG-3\u2019) and SJ01 (5\u2019-TTAAGACCTCTGAACACC) \n\n(Invitrogen, Brazil). The parameters used  were: initial denaturation at 95\u00b0C for 4 min followed \n\nby 34 cycles amplification: 45s of denaturation at 94\u00b0C, 1 min of annealing at 57\u00b0C, 1 min of \n\nextension at 72\u00b0C. A final extension step was applied at 72\u00b0C for 10 min. A volume of 30 ?L of \n\n\n\n99 \n \n\nthe PCR amplicons was double digested with Sau96I (10 U/ ?L) and HhaI (20 U/?L) (New \n\nEngland Biolabs, USA), and then incubated in a dry bath at 37\u00b0C for 3h [19]. The molecular \n\ntypes (VNI\u2013VNIV and VGI\u2013VGIV) were assigned by comparison to the reference strains of the \n\neight major molecular types [8, 14]. The PCR fingerprinting profiles were analyzed on the basis \n\nof the presence or absence of clear and defined bands in the digitalized gel images.  \n\nM13 analysis \n\nThe minisatellite-specific core sequence of the wild-type phage M13 (5?-\n\nGAGGGTGGCGGTTCT-3?) was used as single primer in the PCR-fingerprinting [8]. Briefly, \n\nthe amplification reaction was conducted in a volume of 50 ?L containing 100 ng of DNA, 1 \n\n\u00d7 PCR buffer (10 mM Tris-HCl, pH 8.0, 50 mM KCl), 0.2 mM each of dATP, dCTP, dGTP \n\nand dTTP, 2.0 mM of MgCl2, 0.5 ?M  of primer (Invitrogen, Brazil) and 2.5 U of Taq DNA \n\npolymerase (Invitrogen, Brazil). The PCR consisted of an initial denaturation at 94\u00b0C for 10 \n\nmin, followed by 36 cycles amplification: 1 min of denaturation at 94\u00b0C, 1 min of annealing \n\nat 50\u00b0C, 1 min of extension at 72\u00b0C. A final extension step was applied at 72\u00b0C for 10 min. \n\nAmplification products were separated by electrophoresis in 2% agarose gels in 1 \u00d7 Tris-\n\nAcetate EDTA (TAE) buffer at 3V/cm of electrodes distance, stained with GelRed\u00ae for 30 \n\nmin and visualized under UV light.  \n\n \n\nResults \n\nIsolation, morphological and physiological identification \n\nAll the isolates showed colonial aspects on Sabouraud Dextrose Agar-SDA (Difco) \n\nplates, microscopic appearance  in India ink and physiological tests compatible with those \n\ndescribed in the literature for yeasts of the genus Cryptococcus [16, 17].  \n\nIdentification of the Cryptococcus isolates by canavanine-glycine-bromothymol blue agar \n\nmedium (CGB) \n\nAll 30 isolates were sensitive to canavanine, resulting in no growth or coloration in \n\nthis selective indicator medium. Base on this result, the Cryptococcus isolates were identified \n\nas C. neoformans [Table 1]. \n\nClinical isolates \n\nFrom a total of 300 CSF samples of patients with suspected cryptococcal meningitis, \n\nthirty cases (10%) were diagnosed with neurocryptococcosis. All patients except one were \n\nHIV seropositive. Only one patient presented Adult T-Cell Leukaemia with negative latex \n\nagglutination test and with a fatal outcome during treatment. Fifteen (50%) were male, with a \n\nmean age of 42.17 (20\u201365) years. \n\n\n\n100 \n \n\nMolecular Identification \n\n According to URA5-RFLP analysis, all thirty isolates of Cryptococcus showed VNI \n\ngenotype representing C. neoformans var. grubii (serotype A) as showed on Fig. 1. \n\nAccording to M13 PCR-fingerprinting analysis, all Cryptococcus neoformans var. \n\ngrubii isolates, prior characterized by PCR-RFLP of amplification products of the URA5 \n\ngene,  showed 100% similarity in their PCR fingerprinting patterns , not revealing genetic \n\nvariability  among these isolates as showed on  Fig. 2. \n\n \n\nDiscussion \n\nEncapsulated yeasts as those of the genus Cryptococcus are the major cause of \n\ninvasive fungal diseases. Cryptococcosis emerged as an important opportunistic infection in \n\nthe early years of the HIV epidemic, affecting approximately 12% of patients with AIDS [20]. \n\nThe last four decades have witnessed a global steady increase in the incidence and prevalence \n\nof cryptococcal diseases [21-23].  \n\nIn this study we diagnosed thirty cases of neurocryptococcosis. One patient presented \n\nAdult T-Cell Leukaemia whereas the remaining 29 were HIV-infected. According to Nguyen \n\net al. [24], Central Nervous System (CNS) cryptococcosis is defined as the isolation of \n\nCryptococcus species from the CNS or CSF and patients are classified into three categories: \n\n1) HIV- infected: cryptococcosis occurs in 6% to 13% of patients with AIDS, especially when \n\ntheir CD4+ lymphocyte count is below 200/mm3 [21, 25, 26] 2) HIV-uninfected but otherwise \n\nimmunosuppressed  with chronic diseases (lymphoma, leukemia, diabetes, tuberculosis and \n\nothers); long-term use of antimicrobial drugs and  immunosuppressive agents such as \n\ncorticosteroids [25, 27, 28] 3) HIV- uninfected and nonimmunosuppressed [29-32].  \n\nDisease in HIV patients is most usually due to infection with either C. neoformans var. \n\nneoformans or C. neoformans var. grubii [20]. In this study, we confirmed 30 different \n\nclinical isolates of C. neoformans using phenotypic tests and identification by molecular \n\nmethods. According to our results, only the C. neoformans specie was founded in both \n\nmethods analysed. The gold standard for laboratory diagnosis of cryptococcosis has been \n\nbased on direct microscopy, culture, subsequently biochemical identification and \n\nimmunodiagnosis, despite some limitations such as the time and labor required for \n\nidentification [33]. Automated and semi-automated methods can be inconclusive owing to the \n\nfrequency dependence on supplementary tests for complete microorganism identification [34-\n\n38]. \n\n\n\n101 \n \n\n Immunodiagnosis tests such as latex agglutination can return false- negative or false-\n\npositive results [33]. We had a patient with Adult T Cell Leukemia who exhibited a negative \n\ntest for latex agglutination. Xiao-guang et al. [22] reported an unusual case of disseminated \n\ncryptococcal lymphadenitis in an immunocompetent host who presented fever and \n\nlymphadenopathy. Latex agglutination test of serum and cerebrospinal fluid (CSF) were \n\nnegative, while lymph node biopsy showed C. neoformans. According to the authors, the \n\nlatex agglutination test for detection of cryptococcal is a rapid and reliable method for \n\nimmunodiagnosis of C. neoformans infection, whose sensitivity and specificity were about \n\n98% and 99% respectively. Nevertheless, it still demonstrates certain limitations of false-\n\npositivity and false-negativity due to the presence of a malignancy, sarcoidosis, systemic \n\nlupus erythematosus or rheumatoid factor, infection with Trichosporon beigelii, \n\nCapnocytophaga canimorsus, acid-fast bacillus or HIV, and contamination with agar \n\nsyneresis fluid during laboratory pipetting.  \n\nRegarding biochemical tests, the canavanine-glycine-bromothymol blue agar medium \n\nhas been used to differentiate C. neoformans and C. gattii. It\u2019s considered by some authors a \n\nuseful and rapid method for cryptococcosis diagnosis, although there are few reports of its \n\nperformance in routine clinical practice [39-41]. Growth on CGB agar indicates that isolates \n\nare canavanine resistant, and able to use glycine as a sole carbon source, triggering a \n\nbromothymol blue color reaction indicative of C. gattii, whereas C. neoformans is sensitive to \n\ncanavanine, and cannot use glycine as a sole carbon source, resulting in no growth or \n\ncoloration in this selective indicator medium. All the tested isolates have not turned the color \n\nto blue, which is indicative of C. neoformans strains. Previous reports from southeast Brazil \n\nalso showed the high prevalence of C. neoformans isolates (93.83%) among HIV patients [8]. \n\nIn contrast, the authors observed five isolates of C. gattii which were equally recovered from \n\nthe patients included in the study.  \n\nRegarding molecular methods for detection of C. neoformans and C. gattii, specific \n\ngene sequences from clinical specimens and cultures have been available and gradually have \n\nbeen implemented into clinical practice [1, 42, 43]. In our study, genotypes were \n\ncharacterized through the use of URA5 restriction fragment length polymorphisms analysis \n\nand the genetic variability was determined using PCR-fingerprinting with the minisatellite \n\nspecific primer M13. PCR fingerprinting and RAPD (Random Amplification of Polymorphic \n\nDNA) are two of the most useful molecular methods for identification of the C. neoformans \n\ncomplex. Many authors have successfully employed URA5 and M13 as target sequences for \n\ntyping C. neoformans and C. gattii [8, 11, 44]. In our study, VNI genotype was found in all \n\n\n\n102 \n \n\nthe clinical isolates. Previous reports have demonstrated that the VNI molecular type is the \n\nmost isolated from both clinical and environmental sources, furthermore is found in various \n\nregions worldwide, with emphasis on Latin America [14, 45], including  Brazil [19, 46, 47] \n\nand Colombia [48]. This genotype also corresponds to the majority isolates of C. neoformans \n\nfrom Asian countries as Taiwan [49, 50]. In addition, most of the cryptococcal infections in \n\nAIDS patients from other parts of the world are caused by the VNI genotype (serotype A) [8].  \n\nRegarding M13 primer results, we have not observed genetic variability among \n\nCryptococcus neoformans isolates obtained from immunocompromised patients admitted in \n\npublic hospital of Recife, Pernambuco, Brasil.  Within isolates from HIV patients, we \n\nobserved 100% similarity of their PCR fingerprinting patterns. The finding of 100% similarity \n\nof their PCR fingerprinting patterns may suggest a possible clonal origin. Mora et al. [8] \n\ncharacterized molecularly 77 Cryptococcus isolates recovered obtained in cerebrospinal fluid \n\nfrom AIDS patients between 1998 and 2007 in Uberaba Minas Gerais, Brazil. Genotypes \n\nwere characterized also through the use of URA5 restriction fragment length polymorphisms \n\nanalysis, the genetic variability was determined using PCR-fingerprinting with the \n\nminisatellite- specific primer M13. The authors also observed two of the three AIDS isolates \n\nwho relapsed two years or more after the first episode were VNI and 100% identical, \n\nsuggesting, according to the authors, an endogenous reactivation or a re-infection source. Da \n\nSilva et al. [51], as well, observed the same band patterns among Candida strains obtained \n\nfrom infants hospitalized in a neonatal intensive care unit from a hospital in Recife-PE, after \n\nPCR amplification using M13 primer. Additionally, the authors suggest a possible clonal \n\norigin of the four isolates of Candida pelliculosa. \n\nOn this work was developed a strategy to compare the capability of the classical \n\nphenotypical approach (biochemical analysis by CGB agar, molecular methods, such as URA5 \n\nrestriction fragment length polymorphisms analysis, and PCR-fingerprinting) with the \n\nminisatellite-specific primer M13 in the identification and diagnosis of Cryptococcus isolates \n\nfrom clinical cases. All 30 isolates were classified by these two approaches as C. neoformans. \n\nLikewise, similar results were found by Mora et al. [8] and Byrnes et al. [2].  \n\nFrom the comparative analysis of the Table 1, it is possible to observe that there was \n\nno incongruence between the classical phenotypical approach results and the molecular \n\nidentification data. These results reinforce the importance of biochemical tests, as an \n\ninexpensive and efficient tool, for a rapid identification and diagnosis of cryptococcosis in the \n\nroutine analyses in health centers and hospitals.  \n\n\n\n103 \n \n\nIn conclusion, the use of different techniques for various purposes can either \n\ncontribute to epidemiological studies [52] or emphasize the relevance to characterization of \n\nclinical Cryptococcus isolates, in order to understand its geographical expansion and its \n\ndistribution among HIV patients [8]. \n\n \n\nAcknowledgements   \n\nWe thank the Brazilian Council of Research (CNPQ) for granting the fellowship and the \n\nFederal University of Pernambuco (UFPE) for providing the infrastructure.  \n\n \n\nReferences \n\n1. Bovers M, Diaz MR, Hagen F, Spanjaard L, Duim B, Visser CE, Oogveld HL, Scharringa \n\nJ, Hoepelman IM, Fell JW, Boekhout T. Identification of genotypically diverse Cryptococcus \n\nneoformans and Cryptococcus gattii isolates by Luminex xMAP technology. J Clin \n\nMicrobiol. 2007;45:1874\u201383. \n\n2. Byrnes JE, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chaturvedi V, Bildfell RJ, \n\nMay RC, Heitman J. Emergence and pathogenicity of highly virulent Cryptococcus gattii \n\ngenotypes in the northwest United States. PLoS Pathog. 2010;6:e1000850. \n\n3. Diaz MR, Boekhout T, Theelen B, Fell JW. Molecular sequence analyses of the   intergenic \n\nspacer (IGS) associated with rDNA of the two varieties of the pathogenic yeast, Cryptococcus \n\nneoformans. Syst Appl Microbiol. 2000;23:535\u201345. \n\n4. Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M. Proposal to conserve the name \n\nCryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, \n\nHymenomycetes, Tremellomycetidae). Taxon. 2002;51:804\u20136. \n\n5. Kwon-Chung K, Varma A. Do major species concepts support one, two or more species \n\nwithin Cryptococcus neoformans. FEMS Yeast Res. 2006;6:574\u201387. \n\n6. Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol. 2001;39:155\u201368. \n\n7. Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of \n\nCryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect \n\nDis. 2005;192:888\u201392. \n\n8. Mora DJ, Pedrosa AL, Rodrigues V, Maffei CML, Trilles L, Laz\u00e9ra MS, Silva-Vergara \n\nML. Genotype and mating type distribution within clinical Cryptococcus neoformans and \n\nCryptococcus gattii isolates from patients with cryptococcal meningitis in Uberaba, Minas \n\nGerais, Brazil. Med Mycol. 2010;48:561\u20139. \n\n\n\n104 \n \n\n9. Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, Allen A, \n\nStajich JE, Dietrich FS, Perfect JR, Heitman J. Same-sex mating and the origin of the \n\nVancouver Island Cryptococcus gattii outbreak. Nat. 2005;437:1360\u20134. \n\n10. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. \n\nEstimation of the current global burden of cryptococcal meningitis among persons living with \n\nHIV/AIDS. AIDS 2009;23:525\u201330. \n\n11. Pedroso RS, Lavrador MAS, Ferreira JC, Candido RC, Maffei CML. Cryptococcus \n\nneoformans var. grubii \u2013 Pathogenicity of environmental isolates correlated to virulence \n\nfactors, susceptibility to fluconazole and molecular profile. Mem Inst Oswaldo Cruz \n\n2010;105:993\u20131000. \n\n12. Sidrim JJ, Costa AK, Cordeiro RA, Brilhante RS, Moura FE, Castelo-Branco DS, Neto \n\nMP, Rocha MF. Molecular methods for the diagnosis and characterization of Cryptococcus: a \n\nreview. Can J Microbiol. 2010;56:445\u201358. \n\n13. Latouche GN, Huynh M, Sorrell TC, Meyer W. PCR-restriction fragment polymorphism \n\nanalysis of the phospholipase B (PLB1) gene for subtyping of Cryptococcus neoformans \n\nisolates. Appl Environ Microbiol. 2003;69:2080\u20135. \n\n14. Meyer W, Castaneda A, Jackson S, Huynh M, Casta\u00f1eda E, IberoAmerican Cryptococcal \n\nStudy Group. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg \n\nInfect Dis. 2003;9:189\u201395. \n\n15. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara J, Chang TC. Identification of \n\nmedically important yeast species by sequence analysis of the internal transcribed spacer \n\nregions. J Clin Microbiol. 2006;44:693\u20139. \n\n16. Barnett JA, Paine RW, Yarrow D. Yeasts: characteristics and identification. 3rd ed. \n\nCambridge: Cambridge University Press; 2000. \n\n17. De Hoog GS, Guarro J, Gene J, Figueras MJ. Atlas of clinical fungi. 2nd ed. Holland: \n\nCBS; 2000. \n\n18. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of \n\nCryptococcus neoformans var.  neoformans (serotypes A and D) and Cryptococcus \n\nneoformans var. gatti (serotypes B and C). J Clin Microbiol. 1982;15:535\u20137. \n\n19. Igreja RP, Lazera MS, Wanke B, Galhardo MC, Kidd SE, Meyer W. Molecular \n\nepidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, \n\nRio de Janeiro. Med Mycol. 2004;42:229\u201338. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Diezmann%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16222245\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Allen%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16222245\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Stajich%20JE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16222245\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Dietrich%20FS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16222245\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Perfect%20JR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16222245\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Heitman%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16222245\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Huynh%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12603989\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Casta%C3%B1eda%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12603989\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=IberoAmerican%20Cryptococcal%20Study%20Group%5BCorporate%20Author%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=IberoAmerican%20Cryptococcal%20Study%20Group%5BCorporate%20Author%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Galhardo%20MC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=15283237\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Kidd%20SE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=15283237\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Meyer%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=15283237\n\n\n105 \n \n\n20. Chau TTH, Mai NH, Phu NH, Nghia HD, Chuong LV, Sinh DX, Duong VA, Diep PT, \n\nCampbell J. A prospective descriptive study of cryptococcal meningitis in HIV uninfected \n\npatients in Vietnam. BMC Infect Dis. 2010;10:199\u2013207. \n\n21. Putignani L, Antonucci G, Paglia MG, Vincenzi L, Festa A, De Mori P, Loiacono L, \n\nVisca P. Cryptococcal lymphadenitis as a manifestation of immune reconstitution \n\ninflammatory syndrome in an HIV-positive patient: a case report and review of the literature. \n\nInt J Immunopathol Pharmacol. 2008;21:751\u20136. \n\n22. Xiao-guang XU, Xin-ling BI, Jian-hua WU, Hong XU, Wan-qing LIAO. Disseminated \n\ncryptococcal lymphadenitis with negative latex agglutination test. Chin Med J. \n\n2012;125:2393\u20136. \n\n23. Albuquerque PC, Rodrigues ML. Research trends on pathogenic Cryptococcus species in \n\nthe last 20 years: a global analysis with focus on Brazil. Future Microbiol. 2012;7:319\u201329. \n\n24. Nguyen MH, Husain S, Clancy JC, Peacock JE, Hung CC, Kontoyiannis DP, Morris AJ, \n\nHeath CH, Wagener M, Yu VL. Outcomes of central nervous system cryptococcosis vary \n\nwith host immune function: results from a multi-center, prospective study. J Infect. \n\n2010;61:419\u201326. \n\n25. Srinivasan R, Gupta N, Shifa R, Malhotra P, Rajwanshi A, Chakrabarti A. Cryptococcal \n\nlymphadenitis diagnosed by fine needle aspiration cytology: a review of 15 cases. Acta Cytol. \n\n2010;54:1\u20134. \n\n26. Kuttiatt V, Sreenivasa P, Garg I, Shet A. Cryptococcal lymphadenitis and immune \n\nreconstitution inflammatory syndrome: current considerations. Scand J Infect Dis. \n\n2011;43:664\u20138. \n\n27. Gonz\u00e1lez LA, V\u00e1squez G, Restrepo JP, Vel\u00e1squez M, Ram\u00edrez LA. Cryptococcosis in \n\nsystemic lupus erythematosus: a series of six cases. Lupus. 2010;19:639\u201345. \n\n28. Castro-Ferreira I, Carvalho C, Coentr\u00e3o L, Gai\u00e3o S, Bustorff M, Santos J, Sampaio S, \n\nPortugal R, Pestana M. Early-onset of disseminated cryptococcal infection in two renal \n\ntransplant recipients. Clin Nephrol. 2011;75:542\u20136. \n\n29. Qadir I, Ali F, Malik UZ, Umer M. Isolated cryptococcal osteomyelitis in an \n\nimmunocompetent patient. J Infect Dev Ctries. 2011;5:669\u201373. \n\n30. Qu Y, Liu G, Ghimire P, Liao M, Shi H, Yang G, Xu L, Wang G. Primary pulmonary \n\ncryptococcosis: evaluation of CT characteristics in 26 immunocompetent Chinese patients. \n\nActa Radiol. 2012;53:668\u201374.  \n\n31. Ye F, Xie JX, Zeng QS, Chen GQ, Zhong SQ, Zhong NS. Retrospective analysis of 76 \n\nimmunocompetent patients with primary pulmonary cryptococcosis. Lung. 2012;190:339\u201346.  \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Qadir%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21918309\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Ali%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21918309\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Malik%20UZ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21918309\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Umer%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21918309\nhttp://www.ncbi.nlm.nih.gov/pubmed/21918309\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Qu%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Liu%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Ghimire%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Liao%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Shi%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Xu%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Wang%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed/22798384\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Ye%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22246551\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Xie%20JX%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22246551\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Zeng%20QS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22246551\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20GQ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22246551\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Zhong%20SQ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22246551\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Zhong%20NS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22246551\n\n\n106 \n \n\n32. Iatta R, Hagen F, Fico C, Lopatriello N, Boekhout T, Montagna MT. Cryptococcus gattii \n\ninfection in an immunocompetent patient from Southern Italy. Mycopathol. 2012;174:87\u201392.  \n\n33. Huston SM, Mody, CH. Cryptococcosis: an emerging respiratory mycosis. Clin Chest \n\nMed. 2009;30:253\u201364. \n\n34. Gundes SG, Gulenc S, Bingol R. Comparative performance of Fungichrom I, Candifast \n\nand API 20C AUX systems in the identification of clinically significant yeasts. J Med \n\nMicrobiol. 2001;50:1105\u201310. \n\n35. Massonet C, Eldere JV, Vaneechoutte M, Baere T, Verhaegen J, Lagrou K. Comparison \n\nof VITEK 2 with ITS2-Fragment Length Polymorphism Analysis for Identification of Yeast \n\nSpecies. J Clin Microbiol. 2004;42:2209\u201311. \n\n36. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Lodderomyces elongisporus \n\nmasquerading as Candida parapsilosis as a cause of bloodstream infections. J Clin Microbiol. \n\n2008;46:374\u20136. \n\n37. Marklein G, Josten M, Klanke U, M\u00fcller E, Horr\u00e9 R, Maier T, Wenzel T, Kostrzewa M, \n\nBierbaum G, Hoerauf A, Sahl HG. Matrix-assisted laser desorption ionization-time of flight \n\nmass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin \n\nMicrobiol. 2009;47:2912\u20137. \n\n38. Putignani L, Del Chierico F, Onori M, Mancinelli L, Argentieri M, Bernaschi P, Coltella \n\nL, Lucignano B, Pansani L, Ranno S, Russo C, Urbani A, Federicibd G, Menichella D. \n\nMALDI-TOF mass spectrometry proteomic phenotyping of clinically relevant fungi. Mol \n\nBioSyst. 2011;7:620\u20139.  \n\n39. Davel G, Abrantes R, Brudny M, C\u00f3rdoba S, Rodero L, Canteros CE, Perrotta D. 1st \n\nenvironmental isolation of Cryptococcus neoformans var. gattii in Argentina. Rev Argent \n\nMicrobiol. 2003;35:110\u20132. \n\n40. Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfiel SL, Wengenack NL. Identification of \n\nCryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA \n\nsequencing. J Clin Microbiol. 2009;47:3669\u201372.  \n\n41. Faria RO, Nascente PS, Meinerz ARM, Cleff MB, Antunes TA, Silveira ES, Nobre MO, \n\nMeireles MCA, Mello JRB. Occurrence of Cryptococcus neoformans in pigeon excrement in \n\nthe city of Pelotas, State of Rio Grande do Sul. Rev Soc Bras Med Trop. 2010;43:198\u2013200. \n\n42. Levy PY, Habib G, Reynaud-Gaubert M, Raoult D, Rolain JM. Pericardial effusion due to \n\nCryptococcus neoformans in a patient with cystic fibrosis following lung transplantation. Int J \n\nInfect Dis. 2008;12:452. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Iatta%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22057831\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Hagen%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22057831\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Fico%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22057831\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Lopatriello%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22057831\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Boekhout%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22057831\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Montagna%20MT%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22057831\nhttp://www.ncbi.nlm.nih.gov/pubmed/22057831\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Davel%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Abrantes%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Brudny%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=C%C3%B3rdoba%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Rodero%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Canteros%20CE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Perrotta%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed/12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed/12920995\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Klein%20KR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19794048\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Hall%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19794048\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Deml%20SM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19794048\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Rysavy%20JM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19794048\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Wohlfiel%20SL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19794048\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Wengenack%20NL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19794048\nhttp://www.ncbi.nlm.nih.gov/pubmed/19794048\n\n\n107 \n \n\n43. Wu Y, Du PC, Li WG, Lu JX. Identification and molecular analysis of pathogenic yeasts \n\nin droppings of domestic pigeons in Beijing, China. Mycopathol. 2012;174:203\u201314.  \n\n44. Aminnejad M, Diaz M, Arabatzis M, Casta\u00f1eda E, Lazera M, Velegraki A, Marriott D, \n\nSorrell TC, Meyer W. Identification of novel hybrids between Cryptococcus neoformans var. \n\ngrubii VNI and Cryptococcus gattii VGII. Mycopathol. 2012;173:337\u201346.  \n\n45. Meyer W, Marszewska K, Amirmostofian M, Igreja RP, Hardtke C, Methling K, Viviani \n\nMA, Chindamporn A, Sukroongreung S, John MA, Ellis DH, Sorrell TC. Molecular typing of \n\nglobal isolates of Cryptococcus neoformans by a polymerase chain reaction fingerprinting and \n\nrandomly amplified polymorphic DNA: a pilot study to standardize techniques on which to \n\nbase a detailed epidemiological survey. Electrophor. 1999;20:1790\u20139. \n\n46. Casali AK, Goulart L, Rosa e Silva LK. Molecular typing of clinical and environmental \n\nCryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res. \n\n2003;3:405\u201315.  \n\n47. Trilles L, Laz\u00e9ra MS, Wanke BR, Oliveira V, Barbosa GG, Nishikawa MM, Morales BP, \n\nMeyer W. Regional pattern of the molecular types of Cryptococcus neoformans and \n\nCryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz. 2008;103:455\u2013462.  \n\n48. Escandon P, Sanchez A, Martinez M, Meyer W, Castaneda,E. Molecular epidemiology of \n\nclinical and environmental isolates of the Cryptococcus neoformans species complex reveals a \n\nhigh genetic diversity and the presence of the molecular type VGII mating type a in \n\nColombia. FEMS Yeast Res. 2006;6:625\u201335.  \n\n49. Day JN, Hoang TN,  Duong AV, Hong CTT,  Diep PT, Campbell JI, Sieu TPM, Hien TT, \n\nBui T, Boni MF, Lalloo DG, Carter D, Baker S, Farrar JJ. Most Cases of Cryptococcal \n\nmeningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment \n\nlength polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1. J Clin \n\nMicrobiol. 2011;49:658\u201364. \n\n50. Liaw SJ, Wu HC, Hsueh PR. Microbiological characteristics of clinical isolates of \n\nCryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence \n\nfactors, and antifungal susceptibility. Clin Microbiol Infect. 2009;16:696\u2013703. \n\n51. Silva CM, Parahym AMRC, Le\u00e3o MPC, Oliveira NT, Amorim RJM, Neves, RP. \n\nFungemia by Candida pelliculosa (Pichia anomala) in a neonatal intensive care unit: a \n\npossible clonal origin. Mycopathol. 2013;175\u20139. \n\n52. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant \n\nCryptococcus neoformans infection. J Clin Microbiol. 1999;37:3204\u20139. \n\n \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Wu%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22476559\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Du%20PC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22476559\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Li%20WG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22476559\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Lu%20JX%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22476559\nhttp://www.ncbi.nlm.nih.gov/pubmed/22476559\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Aminnejad%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Diaz%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Arabatzis%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Casta%C3%B1eda%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Lazera%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Velegraki%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Marriott%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Sorrell%20TC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Meyer%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed/22081254\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Hardtke%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Methling%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Viviani%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Viviani%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Chindamporn%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Sukroongreung%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=John%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Ellis%20DH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Sorrell%20TC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10435451\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Boni%20MF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21159929\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Lalloo%20DG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21159929\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Carter%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21159929\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Baker%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21159929\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Farrar%20JJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21159929\n\n\n108 \n \n\nTable 1. Phenotypic and Molecular determination of the Cryptococcus strains \n\nMicoteca URM Number    Substrate CGBa URA5-RFLPb M13c \n\n5809 LCR Cryptococcus neoformans C. neoformans    Cryptococcus spp \n\n5810 LCR C. neoformans C. neoformans    Cryptococcus spp \n\n5811 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5812 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5813 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5814 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5815 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5816 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5818 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5819 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5820 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5821 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5822 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5823 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5824 LCR C. neoformans C. neoformans Cryptococcus spp \n\n5825 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6895 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6896 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6897 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6898 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6899 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6900 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6901 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6902 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6903 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6904 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6905 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6906 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6907 LCR C. neoformans C. neoformans Cryptococcus spp \n\n6908 LCR C. neoformans C. neoformans Cryptococcus spp \n\n \n\n \n\nLCR= CerebroSpinal Fluid; aCGB= Canavanine-glycine-bromothymol blue agar medium \n\n(CGB); bURA5 restriction fragment length polymorphisms (URA5-RFLP), cMinisatellite-\n\nspecific sequence (M13). \n\n \n\n \n\n \n\n \n\n \n\n\n\n109 \n \n\n \n\n \n\n \n\nFig. 1 The URA5 RFLP profiles after double digestion of amplification products with the \n\nenzymes Sau96I (10 U/?L) and HhaI (20 U/ ?L) of thirty Cryptococcus isolates obtained \n\nfrom cerebrospinal fluid of patients \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n110 \n \n\n \n\nFig. 2 Bands patterns of microsatellite obtained after PCR amplification of thirty \n\nCryptococcus isolates, obtained from cerebrospinal fluid of patients admitted in public \n\nhospitals of Recife, Pernambuco, Brazil \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n111 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n6- CAP\u00cdTULO 3 \n\n(A ser submetido \u00e0 revista Antimicrobial agentes and Chemotherapy) \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n112 \n \n\nAntifungal activity of ciclopirox olamine-loaded stealth liposomes in mice \n\ninfected with the human fungal pathogen Cryptococcus neoformans \n\n \n\nPatr\u00edcia O. Kocerginskya,b, Rejane P. Nevesa*, Isabella M. F. Cavalcantib, Mariana P. \n\nCabrerab, Hannah F.S. Lyrab, Fab\u00edola M.M. Coutoa, Nicodemos T. Pontes-Filhoc, Jos\u00e9 V.M. \n\nLima-Filhod, Nereide S. Santos-Magalhaesb \n\na Laborat\u00f3rio de Micologia M\u00e9dica, Centro de Ci\u00eancias Biol\u00f3gicas (CCB), Universidade Federal de Pernambuco \n\n(UFPE), Cidade Universit\u00e1ria, Av. Morais Rego s/n, 50670-910, Recife, Brazil. \n\nbLaborat\u00f3rio de Imunopatologia Keizo-Asami, UFPE, Recife, Brazil. \n\n \n\naUniversidade Federal de Pernambuco (UFPE), Laborat\u00f3rio de Micologia M\u00e9dica, Centro de \n\nCi\u00eancias Biol\u00f3gicas (CCB), Recife, PE, Brazil. bUFPE,  Laborat\u00f3rio de Imunopatologia \n\nKeizo-Asami, Recife, PE, Brazil. cDepartamento de patologia, Universidade Federal de \n\nPernambuco, Recife - PE, Brazil. dDepartamento de Biologia, Universidade Federal Rural de \n\nPernambuco, Dois Irm\u00e3os, Recife, PE, Brazil.  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n*Corresponding author: rejadel@yahoo.com.br, Departamento de Micologia, Centro de \n\nCi\u00eancias Biol\u00f3gicas, Universidade Federal de Pernambuco (UFPE), Av. Prof. Nelson Chaves, \n\ns/n\u00ba- Cidade Universit\u00e1ria, 50670-420 Recife, PE, Brasil. \n\n \n\n \n\n \n\n \n\n\n\n113 \n \n\nABSTRACT \n\n \n\n \n\nThe in vivo antifungal activity of the Ciclopirox olamine-loaded stealth liposomes against \n\ndisseminated infection by Cryptococcus neoformans was investigated. Swiss mice were \n\nimmunosuppressed daily with dexamethasone (0.5 mg/mouse) intraperitoneally for 3 days. \n\nThis procedure was repeated 4 days later, and the animals were then infected intravenously \n\nwith C. neoformans (106 CFU/mL) 1 week later. Seven days after infection, the mice were \n\ndivided into groups and treated daily with CPO-loaded liposome (Lipo-CPO) (12.5 mg/kg, iv) \n\nfor 7 and 14 days. Amphotericin B (0.5 mg/kg) was used as comparator drug and an \n\nadditional group received empty liposome. The treatment with Lipo-CPO showed a \n\nsignificant decrease of C. neoformans population of 8% in spleen, 41% in liver, 63% in lungs \n\nand 90% in brain on day 14 (P&lt;0.05). The treatment with AmB led to a fungal burden \n\nreduction of 90.27% in spleen, 31% in liver, 48% in lungs and 58% in brain on day 14. \n\nHistological examination showed inflamatory infiltration in the liver of the Lipo-CPO and \n\namphotericin B groups, but less intense than observed in the liver slides of the control group. \n\nHistological damage in the brain demonstrated liquefactive and coagulative necrosis after 14 \n\ndays of infection. The remarkable studies of Lipo-CPO antifungal activity in vivo confirms \n\nthe further application this novel formulation in the systemic cryptococcosis therapy.  \n\n \n\n \n\n \n\nKeywords: Liposome-CPO, Cryptococcus neoformans, Cryptococcosis, Experimental \n\ninfection, Amphotericin B \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n114 \n \n\nINTRODUCTION \n\n \n\nCryptococcus neoformans is a life-threatening human fungal pathogen that is present \n\nin the environment. It is estimated that over 1 million cases of cryptococcosis occurs each \n\nyear, accounting for more than 600,000 deaths predominantly meningoencephalitis in HIV-\n\ninfected patients (1-3). C. neoformans exists in two varieties, C. neoformans var. grubii \n\n(serotype A), which causes the majority of infections worldwide, and C. neoformans var. \n\nneoformans (serotype D), which is commonly found in Europe (4).  \n\nThe first choice in the primary therapy of central nervous system (CNS) infections \n\nremains fungicidal drugs, with amphotericin B (AMB) alone or in combination with \n\nflucytosine (5, 6). Fungistatic drugs like itraconazole and fluconazole, with less toxicity, are \n\nalso used in the maintenance of the pulmonary cryptococcosis therapy, but their use in CNS \n\ninfections has been less than satisfactory. In addition, the extended duration of the therapy \n\nwith these azoles increases the risk of developing drug resistance (5, 7, 8). Despite antifungal \n\ntherapies, cryptococcosis still has mortality rates near 20%, which emphasizes the importance \n\nto improve and search for alternatives to the current therapy (6).  \n\nCurrently, liposomes have been developed which are successfully applied against \n\nantimicrobial infections (9). Among them, liposomal drug delivery has been used to improve \n\nthe distribution of antimicrobial agents with low solubility and reduce its toxicity for the \n\ntreatment of bacterial and fungal infections, as well as cancer (9, 10).  \n\nOn the basis of the promising in vitro results obtained with the antifungal agent \n\nciclopirox olamine (CPO) against clinical isolates of C. neoformans in vitro (Oliveira et al., \n\n2010), we have evaluated in this study the efficacy of CPO-loaded stealth liposomes in a \n\nmurine model of disseminated infection by C. neoformans for further management of \n\ndisseminated cryptococcosis.  \n\nMATERIAL AND METHODS \n\n\n\n115 \n \n\nC. neoformans URM5811. The isolate used in our study was Cryptococcus neoformans \n\nURM5811 obtained from AIDS patient and stored in the Culture Collection of the URM \n\nMicoteca from the Federal University of Pernambuco (11). The strain was chosen among \n\nthirty isolates of C. neoformans due to its high virulence and sensitivity results in \n\nsusceptibility tests by standard methodology in prior in vitro characterization with ciclopirox \n\nolamine (CPO) free and encapsulated into stealth liposomes (Data not shown). The minimum \n\ninhibitory concentration (MIC) and minimum fungicidal concentration (MFC) for ciclopirox \n\nolamine in its free form was 0.30 \u00b5g/mL and 1.22 \u00b5g/mL, respectively. Ciclopirox olamine-\n\nloaded stealth liposomes showed MIC and MFC of 1.22 \u00b5g/mL.  \n\nAnimals and immunosuppression protocol. The experiments were carried out on male \n\nSwiss mice, 4-6 weeks old, and each treatment group comprised of six mice. The animals \n\nwere obtained from the Keizo-Azami Immunopathology Laboratory (LIKA/UFPE) and were \n\nkept in animal house with controlled light and dark cycles (12 h), temperature (25\u00b0C\u00b13), and \n\nhumidity (60\u201370%) and had free access to water and commercial sterile diet (Purina, Paul\u00ednia, \n\nSP, Brazil). Experimental procedures and animal handling were performed in accordance with \n\nthe guidelines approved by The Institutional Animal Care and Use Committee of Federal \n\nUniversity of Pernambuco (#23076.014650/2012-04). \n\nThe immunosuppression protocol was conducted as described by Medeiros et al. 2010. \n\nEach mouse received 0.5 mg of dexamethasone (Teuto\u00ae, Brazil) intraperitoneally for 3 days \n\nand then 4 days thereafter in all experiments. Total leukocyte enumeration in the blood of the \n\nimmunosuppressed (IS) mice was used to confirm immunosuppression. \n\nSub-chronic toxicity assays on dexamethasone-treated immunosuppressed mice. Male \n\nSwiss mice with approximately 40g in weight were used for sub-chronic toxicity tests, \n\nfollowing institutional rules stated by the Animal Ethics Committee of the UFPE. Ciclopirox \n\nolamine-loaded stealth liposomes (Lipo-CPO) concentration was 12.5 mg/Kg based on DL50 \n\n\n\n116 \n \n\ndata obtained previously by Eberhard et al. (12). Then, 0.2 mL of Lipo-CPO was administered \n\ndaily by the tail vein to IS Swiss mice (N = 5) for 1 week. The control animals (N = 5) \n\nreceived only empty liposomes. The animals were observed during seven days for changes in \n\nbehavior and physiology patterns. At the end of experiments, the survival animals were \n\nsacrificed by anesthesia with Halothane (Halocarbon Laboratories, NJ, USA) and their liver \n\nand kidneys were submitted to histological examination.  \n\nC. neoformans infection model and treatment with Ciclopirox olamine-Loaded liposome \n\n(Lipo-CPO). The experimental model of cryptococcosis was performed accordingly to \n\nMedeiros et al. (11) in two steps: \n\n1) In order to analyze the protective effect of the Lipo-CPO, seven days after the beginning of \n\nimmunosuppression, the animals (N = 6) were treated with 0.2 mL Lipo-CPO (0.5 mg/Kg) \n\nand Amphotericin B (AmB) (0.5 mg/Kg) by the tail vein.  Then, the animals were infected \n\nwith 0.2 mL C. neoformans URM5811 (106cells/mL). Control group mice (N= 6) were treated \n\nwith empty liposomes under the same experimental conditions. \n\n2) To observe the ability of Lipo-CPO to reduce fungal burden, seven days after infection, 0.2 \n\nmL CPO-loaded liposome (0.5 mg/kg) was administered daily by the tail vein to IS mice for 7 \n\n(N = 6) and 14 (N = 10) days of treatment. The dose of AmB used for the control experiment \n\ncorresponded to 0.5 mg/kg, and the untreated control group received only empty liposomes. \n\nThe animals were observed for clinical signs and for mortality every day until the end of the \n\nexperiments. \n\nC. neoformans enumeration and histological examination. An aliquot of blood for white \n\nblood cell count was collected by cardiac puncture after euthanasia with halothane. The \n\norgans such as spleen, liver, lungs and brain were removed, weighed and macerated in \n\nPhosphate Buffer Saline (PBS) (1:10 or 1:100, w/v). All samples were submitted to serial \n\ndilutions and 100 \u00b5L aliquots were stained with China ink to direct examination and the same \n\n\n\n117 \n \n\namount was added to plates containing Sabouraud Dextrose Agar (Difco) plus \n\nchloramphenicol (50 mg/mL), incubated at 37\u00b0C for 48-72 h. Concomitantly, tissues were \n\nfixed in 10% formaldehyde, processed for paraffin embedding and stained with hematoxylin-\n\neosin for visualization of cytotoxics effects. \n\nStatistical analysis. Data regarding white cell counts and CFU counts were analyzed \n\nstatistically by the ANOVA and Tukey test, with the level of significance set at P &lt;0.05. \n\nRESULTS \n\nImmunosuppression protocol and C. neoformans infection model. As expected, the total \n\nand differentiated cell counts showed a decrease after 14 days of infection except for \n\nmonocyte counts, which remained the same as during the first week (P &lt;0.05) (Fig. 1). In \n\naddition, C. neoformans URM5811 produced a disseminated infection in IS mice that ranged \n\nfrom 104 to 106 CFU/g organ 14 days post-infection (P &lt;0.05). \n\nIn vivo sub-chronic cytotoxicity of Lipo-CPO. Lipo-CPO at 12.5 mg/kg was not highly \n\ntoxic to IS mice after daily inoculation for 1 week, since all animals were healthy and \n\nsurvived during the experiment. The formulation used had a particle size of 102 nm and \n\nEncapsulation efficiency of 97.36 \u00b1 0.10%. Indeed, histological examination of the liver and \n\nkidneys showed no morphological alterations.  \n\nTreatment of disseminated cryptococcosis with Lipo-CPO. Lipo-CPO treatment reduced \n\nthe C. neoformans population in the spleen, liver, lungs and brain 7 and 14 days after \n\ninfection when compared to the empty Liposome group (Fig. 2A and 2B). The treatment with \n\nLipo-CPO showed a significant decrease of C. neoformans population of 8% in spleen, 41% \n\nin liver, 63% in lungs and 89% in brain on day 14 (P<0.05). The treatment with AmB led to a \n\nfungal burden reduction of 90 % in spleen, 31% in liver, 48 % in lungs and 58% in brain on \n\nday 14. \n\n\n\n118 \n \n\nHistological examination showed inflammatory infiltration in the liver of the Lipo-\n\nCPO and amphotericin B groups, but less intense than observed in the liver slides of the \n\ncontrol group. Indeed, liquefative and coagulative necrosis were visualized in the brain after 7 \n\ndays of infection. (Figure 3).  \n\nDISCUSSION \n\n \n\nIn the present study, a reliable infection model for experimental cryptococcosis was \n\ndeveloped to investigate the ability of the Ciclopirox olamine-loaded liposomes to control the \n\ndisease. Pharmacokinetics studies of ciclopirox olamine in rabbits revealed the relationship \n\nbetween free and total (free + glucuronide derivatives) ciclopirox is about 50% in the first \n\nhour and between 15-20% four hours after intravenous administration. These results suggest \n\nthat ciclopirox olamine is mainly transformed into glucuronide derivates, not remarkably \n\ntoxic to mammalian cells (13). In addition, the authors demonstrated a short half-life for the \n\ndrug (2.1h), a medium total clearance (0.73 1.h-1) and a good distribution volume (2.2 l). Our \n\ndata showed Lipo-CPO at 0.5 mg/ kg as nontoxic after 2 weeks of daily exposure, supporting \n\nits use in a C. neoformans infection model. Moreover, treatment with Lipo-CPO reduced C. \n\nneoformans population in the lungs (63%) and brain (89%), suggesting that long-term \n\ntreatment could enhance sterilization in all organs. Regarding the presence of remaining \n\nyeasts in all organs analyzed, it may be due to the immunosuppression setting, since the \n\neffectiveness antifungal therapy also depends on the immune host mechanisms. (14, 15). \n\nThis protective effect was confirmed by histological examination (Figure 3), which \n\nrevealed a minor organ injury when compared to the empty liposome (EL) group. Conversely, \n\nthe murine death rate in the Lipo-CPO group may be attributed to some progressively toxic \n\nside effect of this drug, since these animals were not especially susceptible to the disease, \n\nhaving leukocyte cell counts similar to those of the EL and amphotericin B groups.  \n\n\n\n119 \n \n\nGupta (2001) reported that CPO mechanisms of action differ from other antimycotic \n\ndrugs. CPO exerts its activity not directly on the fungal plasma membrane but by the \n\nintracellular depletion of some essential substrates and/or ions caused by the inhibition of \n\ntheir uptake. According to Escarrone et al. (16), the complexity of the mechanism of action of \n\nciclopirox olamine should make the development of resistance less likely than with other \n\nantifungal drugs.  \n\nAlthough the CPO mechanism of action against cryptococcosis remains unclear, it \n\nappears not to be related to activation of the immune system, which could enhance organ \n\nclearance. This idea was corroborated by the immune status of Swiss mice during the present \n\nexperiments, since dexamethasone is known to abrogate B and T cell activation, thereby \n\nsubstantially decreasing humoral and cellular immunity (17). Medeiros et al. (11) also \n\ndemonstrated an infection model of C. neoformans in immunocompromised mice with \n\ndexamethasone, in which the leukocytes counts significantly decreased after 14 days of \n\ninfection, except for the monocytes counts. It was also observed no statistically significant \n\ndifference in cell count, showing that immunosuppression occurred similarly among the \n\ndifferent groups tested.  \n\nAs expected, all animals treated with empty liposomes had no reduction in CFU of all \n\norgans analysed, which confirms the absence of antifungal activity in empty liposomes. Khan \n\net al. (14) observed that empty liposome failed to reduce the fungal burden in lungs and brains \n\nof leucopenic mice infected with C. neoformans.  \n\nFurthermore, the stealth liposomes containing CPO showed efficacy when related to \n\namphotericin B with reduction of C. neoformans population of CFU/g organ of 41% in the \n\nliver, 63% in the lung and 89% in the brain. Amphotericin B reduced the fungal burden in \n\n31% in liver, 48% in lung and 58% in brain. \n\n\n\n120 \n \n\nOn the order hand, AmB reduced the spleen fungal burden in 90%, whereas the lipo-\n\nCPO decreased only 8%. This significant discrepancy may be explained since the stealth \n\nliposomes formulation present the PEG on its surface which conferers a hydrophilic character, \n\ntherefore the reticuloendothelial system (RES) will not recognize and capture the drug in the \n\nspleen. For this reason, the Lipo-CPO will take a longer period of time to act in the spleen \n\n(which is the organ central of the RES) and, consequently, is available in the blood circulation \n\nto operate in other organs, such as the liver and the brain (18).  \n\nAll in vivo experiments were performed with pegylated liposomes since the   \n\nconventional liposomes will be quickly cleared from the blood, especially because of the \n\nadsorption of plasma proteins (opsonins) onto the phospholipid membrane, triggering \n\nrecognition and uptake of liposomes by the mononuclear phagocytic system (MPS). \n\nAttachment of hydrophilic polymers, usually derivatives of poly ethylene glycol (PEG), could \n\nprovide steric-stabilization of the vesicles, enabling them to have a prolonged circulating time \n\nwithout being opsonized, recognized and cleared by the MPS, and consequently improve \n\ntherapeutic efficacy (19, 20). The optimal level of PEGylation on liposomes for long \n\ncirculation half-life has been extensively studied (19, 21-23). \n\nThe particle size is another important parameter when designing liposomes for in vivo \n\napplications in order to prevent opsonization and RES recognition. We developed and tested a \n\nCPO lipossomal formulation with final mean size of 102 nm aiming to evaluate its \n\ncriptococcal activity particularly in lungs and brain, the two target-organs of C. neoformans. \n\nThis particle diameter is corroborated with studies of Lockman et al. (24), when these authors \n\ndescribed that nanocarriers for drug delivery cross the Blood-Brain Barrier (BBB) must have \n\na particle diameter about 100 nanometers. This result also justified the high reduction of \n\nCryptococcus neoformans population in brain (89%) observed in our study. The use of \n\nliposomes in clinical use for therapeutic diagnostics application represents a substantial \n\n\n\n121 \n \n\nadvantage for drug delivery systems across the BBB for effective treatments of many central \n\nnervous system disorders.  \n\nThe present study demonstrated that it is possible to incorporated ciclopirox olamine \n\ninto stealth liposomes with an encapsulation efficiency above 95%. The developed \n\nformulation presented an effectiveness antifungal activity compared to amB which is \n\ncurrently the drug of choice of cryptococcosis. Since AmB is a drug with several side effects \n\nsuch as high nephrotoxicity (3), the search for new therapy strategies for treatment of \n\nsystemic infections is imperative and Lipo-CPO represents a promising alternative for further \n\nclinical application especially in immunocompromised patients.  \n\n \n\n \n\n \n\n \n\n \n\nREFERENCES \n\n1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. \n\nEstimation of the current global burden of cryptococcal meningitis among persons living with \n\nHIV/AIDS. AIDS 23:525\u2013530, 2009. \n\n2. Calvo E,  Pastor FJ,1 Rodr\u00edguez M.M, Pujol I, Guarro J. 2010. Antifungal Therapy in a \n\nMurine Model of Disseminated Infection by Cryptococcus gattii . Antimicrob. Agents \n\nChemother. 54: 4074\u20134077.  \n\n3. Albuquerque, P.C.; Rodrigues, M.L. 2012.  Research trends on pathogenic Cryptococcus \n\nspecies in the last 20 years: a global analysis with focus on Brazil. Future Microbiol. 7:319\u2013\n\n329. \n\n4. Desnos-Ollivier M,  Patel S,  Spaulding AR,  Charlier C, Garcia-Hermoso D,   Nielsen \n\nK, Dromera F. 2010. Mixed Infections and In Vivo Evolution in the Human Fungal Pathogen \n\nCryptococcus neoformans. MBio. 1: e00091-10. \n\n\n\n122 \n \n\n5. Saag, M. S., J. R. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. Powderly, \n\nJ. D. Sobel, and W. E. Dismukes. 2000. Practice guidelines for the management of \n\ncryptococcal disease. Clin. Infect. Dis. 30:710\u2013718. \n\n6. Perfect, J. R., W. E. Dismukes, F. Dromer, D. L. Goldman, J. R. Graybill, R. J. \n\nHamill, T. S. Harrison, R. A. Larsen, O. Lorthoraly, M. H. Nguyen, P. G. Pappas, W. G. \n\nPowderly, N. Singh, J. D. Sobel, and T. C. Sorrell. 2010. Practice guidelines for the \n\nmanagement of cryptococcal disease: 2010 update by the infectious diseases society of \n\nAmerica. Clin. Infect. Dis. 50:291\u2013322. \n\n7. Friese, G., T. Discher, R. Fu\u00a8ssle, A. Schmalreck, and J. Lohmeyer. 2001. Development \n\nof azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal \n\ndisease. AIDS 15:2344\u20132345. \n\n8. Soares, B. M., D. A. Santos, L. M. Kohler, G. da Costa Ce\u00b4sar, I. R. de Carvalho, M. \n\ndos Anjos Martins, and P. S. Cisalpino. 2008. Cerebral infection caused by Cryptococcus \n\ngattii: a case report and antifungal susceptibility testing. Rev. Iberoam. Micol. 31:242\u2013245. \n\n9. Olson JA, Schwartz  J, Hahka D, George A, Proffitt RT, Adler- Moore JP. 2012. \n\nDifferences in Efficacy and Cytokine Profiles following Echinocandin or Liposomal \n\nAmphotericin B Monotherapy or Combination Therapy for Murine Pulmonary or Systemic \n\nAspergillus flavus Infections. Antimicrob. Agents Chemother. 56:218\u2013230. \n\n10. Cavalcanti IMF, Mendon\u00e7a EAM, Lira MCB, Honrato SB, Camara CA, Amorim \n\nRVS, Filho, J M, Rabello MM, Hernandes MZ, Ayala AP, Santos-Magalh\u00e3es NS. 2011. \n\nThe encapsulation of b-lapachone in 2-hydroxypropyl-b-cyclodextrin inclusion complex into \n\nliposomes: A physicochemical evaluation and molecular modeling approach. Eur. J. Pharm. \n\nSci. doi:10.1016/j.ejps.2011.08.011. \n\n11. Medeiros CSQ, Lima-filho JV, Oliveira PC, Andrade SL, Leal AFG, Camara CA, \n\nNeves RP. 2010. Antifungal activity of beta-lapachone against disseminated infection by \n\nCryptococcus neoformans var. neoformans strain 5811 on immunosuppressed Swiss mice. \n\nBraz. J. Med. Biol. Res. 43:345-349. \n\n12. Eberhard Y, McDermott SP, Wang x, Gronda M, Venugopal A, Wood TE, Datti A, \n\nBatey RA, Wrana J, Antholine WE, Dick JE, Schimmer, AD. 2009. Chelation of \n\nintracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia \n\nand myeloma cells. Blood 114: 3064-3073.  \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/?term=Olson%20JA%5Bauth%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed/?term=Schwartz%20J%5Bauth%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed/?term=Hahka%20D%5Bauth%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed/?term=George%20A%5Bauth%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed/?term=Proffitt%20RT%5Bauth%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed/?term=Adler-Moore%20JP%5Bauth%5D\n\n\n123 \n \n\n13. G. Coppi, S. Silingardi. 1992. HPLC method for pharmacokinetic studies on ciclopirox \n\nolamine in rabbits after intravenous and intravaginal administrations. Farmaco 47:779-786. \n\n14. Khan MA, Nasti TH, Owais M. 2005. Incorporation of amphotericin B in tuftsin-bearing \n\nliposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J. \n\nAntimicrob. Chemother. 56:726\u2013731. \n\n15. Schop J. 2007. Protective immunity against Cryptococcus neoformans infection. Mcgill J. \n\nMed. 10: 35-43.  \n\n16. Escarrone ALV, Bittencourt CF, Laporta LV, Santos MR, Primel EG, Caldas SS. \n\n2008. LC-UV method with Pre-Column derivatization for the determination of Ciclopirox \n\nolamine in raw material and topical solution. Chromatographia 67:967-971. \n\n17. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht DM, \n\nChrousos GP, O'Shea JJ. 2000. Inhibition of Th1 immune response by glucocorticoids: \n\ndexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J. \n\nImmunol. 164: 1768-1774.  \n\n19. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. \n\n1994. Trends Pharmacol. Sci. 15:215\u201320. \n\n20 Marjan JM, Allen TM. 1996. Long circulating liposomes: past, present and future. \n\nBiotechnol. Adv. 14:151\u201375. \n\n21. D. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, \n\nLee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. 1991. Sterically stabilized \n\nliposomes \u2014 improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. \n\nNatl. Acad. Sci. U S A 88:11460\u201311464. \n\n22. Chow T, Lin Y, Hwang J, Wang H, Tseng Y, Pang VF, Liu R, Lin W, Yang C, Ting \n\nG. 2009. Therapeutic efficacy evaluation of 111In-labeled pegylated liposomal vinorelbine in \n\nmurine colon carcinoma with multimodalities of molecular imaging. J. Nucl. Med. 50:2073\u2013\n\n2081. \n\n23.  Lee CM, Choi YD, Huh EJ, Lee KY, Song HC, Sun MJ, Jeong HJ, Cho CS, Bom \n\nHS. 2005. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving \n\nblood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother. \n\nRadiopharm. 20: 620\u2013628. \n\n24. Lockman PR, Mumper RJ, Khan MA, Allen DD. 2002. Nanoparticle Technology for \n\nDrug Delivery Across the Blood-Brain Barrier. Drug Dev. Ind. Pharm. 28:1-13. \n\n \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Frucht%20DM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10657623\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Chrousos%20GP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10657623\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=O%27Shea%20JJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10657623\n\n\n124 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\nWL AmB Lipo-CPO\n0\n\n1000\n\n2000\n\n3000\n\nLC-7 days\n\nLC-14 days\n\nSegmented-7 days\n\nSegmented-14 days\n\nMonocytes-7 days\n\nMonocytes-14 days\n\nLymphocytes-7 days\n\nLymphocytes-14 days\n\nAnimal groups\n\nT\no\n\nta\nl \n\nle\nu\n\nk\no\n\nc\ny\nte\n\nc\no\n\nu\nn\n\nts\n/m\n\nL\n b\n\nlo\no\n\nd\n\n \n\nFIG 1. Leukocyte cell counts in dexamethasone-immunosuppressed mice infected with \n\nCryptococcus neoformans URM5811 and treated with Ciclopirox olamine-Loaded Liposome. \n\nEL= Empty Liposome; AmB= Amphotericin B; Lipo-CPO= Ciclopirox olamine-loaded \n\nliposome. *P &lt;0.05, 7 days compared to 14 days of treatment per cell group (ANOVA and \n\nTukey test). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nEL \n\n\n\n125 \n \n\n \n\n \n\nSpleen Liver Lung Brain\n0\n\n2\n\n4\n\n6\n\n8\nWhite Liposome\n\nAmphotericin B\n\nLipo- CPO\n\nA\n\nL\no\n\ng\n C\n\nF\nU\n\n/g\n o\n\nr\ng\n\na\nn\n\ns\n\n \n\n \n\nSpleen Liver Lung Brain\n0\n\n2\n\n4\n\n6\n\n8\nWhite Liposome\n\nAmphotericin B\n\nLipo- CPO\n\nB\n\nL\no\n\ng\n C\n\nF\nU\n\n/g\n o\n\nrg\na\nn\n\ns\n\n \n\nFIG 2  Seven days after infection, mice were treated daily with Lipo-CPO (0.5 mg/kg Lipo-\n\nCPO) or amphotericin B (0.5 mg/kg) for 7 (A) or 14 days (B). *P &lt;0.05 compared to the \n\nempty liposome group (Tukey test and ANOVA). \n\n \n\n \n\n \n\n \n\n \n\n \n\nEmpty Liposome \n\nEmpty Liposome \n\n* \n\n* \n* \n\n* * * \n* \n\n* \n* \n\n* \n* * * * \n\n* \n\n\n\n126 \n \n\n \n\nFIG 3 Histopatological examination of cryptococcosis infection model: 2A and 2B show \n\nnormal glomerulus and tubular cells (kidney) and hepatocytes and vessels (liver) without \n\nalterations, respectively, indicating ausence of CPO citotoxity at 12.5 mg/Kg; 2C-2E \n\ndemonstrate fungal infiltrate in the liver of empty liposome, Lipo-CPO and AmB groups after \n\n7 days of infection. The histological damage in brain after 7 days is shown in 2F-2H. \n\nLiquefative and coagulative necrosis are indicated by white and black stars respectively. \n\nYellow arrow indicates inflammatory infiltrates near the lesion (400x) \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n127 \n \n\nCONSIDERA\u00c7\u00d5ES GERAIS \n\nCom base nos resultados obtidos podese concluir que: \n\n? O l\u00edquido cefalorraquidiano \u00e9 a amostra ideal para isolamento esp\u00e9cies de \n\nCryptococcus. \n\n? Criptococose \u00e9 a micose mais frequente em pacientes imunocomprometidos. \n\n? Ciclopirox olamina pode ser encapsulada em lipossomas furtivos em concentra\u00e7\u00f5es \n\nsatisfat\u00f3rias. \n\n? Ciclopirox olamina pode ser encapsulado na fase org\u00e2nica de lipossomas nas \n\nconcentra\u00e7\u00f5es de 1, 2 e 2,5 mg/mL. \n\n? Planejamento fatorial a 2(4-1) otimiza o tamanho de part\u00edcula, PDI,  e quantidade de \n\nf\u00e1rmaco encapsulado. \n\n? Lipossomas furtivos contendo ciclopirox olamina apresentam in vitro uma velocidade \n\nde libera\u00e7\u00e3o mais controlada do f\u00e1rmaco quando comparado \u00e0 formula\u00e7\u00e3o \n\nconvencional. \n\n? Amostras de Cryptococcus neoformans rec\u00e9m isoladas s\u00e3o sens\u00edveis a ciclopirox \n\nolamina livre nas concentra\u00e7\u00f5es de 0,3 to 0.61 ?g/mL e em lipossomas furtivos e \n\nconvencionais nas concentra\u00e7\u00f5es variando de 1.22 a 2.44 ?g/mL. \n\n? O primer M13 n\u00e3o revela variabilidade gen\u00e9tica entre os isolados, enquanto que o \n\nURA5 \u00e9 capaz de diferenciar C. neoformans de C. gattii. \n\n? Lipo-CPO com tamanho de part\u00edcula de 102 nm apresenta efic\u00e1cia antif\u00fangica in vivo \n\ne reduz a popula\u00e7\u00e3o de Cryptococcus neoformans no ba\u00e7o, f\u00edgado, pulm\u00e3o e c\u00e9rebro. \n\n? A utiliza\u00e7\u00e3o de um m\u00e9todo padronizado e reprodut\u00edvel facilita a compara\u00e7\u00e3o entre \n\ndiferentes antif\u00fangicos e entre as diferentes concentra\u00e7\u00f5es inibit\u00f3rias m\u00ednimas. \n\n? Encapsula\u00e7\u00e3o de Ciclopirox olamina em lipossomas representa uma nova alternativa \n\nterap\u00eautica para criptococose sist\u00eamica. \n\n? Esta \u00e9 a primeira vez em que ciclopirox olamina \u00e9 encapsulado em lipossomas para \n\nviabilizar sua aplica\u00e7\u00e3o sist\u00eamica no tratamento de micoses. \n\n \n\n \n\n \n\n \n\n \n\n\n\n128 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nANEXOS \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n129 \n \n\nANEXO A: Instru\u00e7\u00e3o aos autores para Submiss\u00e3o na Revista Antimicrobial Agents and \n\nChemotherapy \n\n \n\nSubmiss\u00e3o \n\nAll submissions to AAC must be made electronically via the eJournalPress (eJP) online submission and peer review system \n\nat the following URL: http://aac.msubmit.net/cgi-bin/main.plex. (E-mailed submissions will not be accepted.) First-time \n\nusers must create an Author account, which may be used for submitting to all ASM journals. Instructions for creating an \n\nAuthor account are available at the above URL via the \u201chelp for authors\u201d link, and step-by-step instructions for submitting a \n\nmanuscript via eJP are also available through the same link on the log-in screen or on the account holder's home page. \n\nInformation on file types acceptable for electronic submission can be found under the Files heading in the help for authors \n\nscreen. \n\nORGANIZATION AND FORMAT  \n\nEditorial Style  \n\nThe editorial style of ASM journals conforms to the ASM Style Manual for Journals (American Society for Microbiology, \n\n2016, in-house document) and How To Write and Publish a Scientific Paper, 7th ed. (Greenwood, Santa Barbara, CA, 2011), \n\nas interpreted and modified by the editors and the ASM Journals Department. \n\nThe editors and the Journals Department reserve the privilege of editing manuscripts to conform with the stylistic \n\nconventions set forth in the aforesaid publications and in these Instructions. Please note that ASM uses the serial comma. \n\nOn receipt at ASM, an accepted manuscript undergoes an automated preediting, cleanup, and tagging process specific to the \n\nparticular article type. To optimize this process, manuscripts must be supplied in the correct format and with the appropriate \n\nsections and headings. \n\nType every portion of the manuscript double-spaced (a minimum of 6 mm between lines), including figure legends, table \n\nfootnotes, and references, and number all pages in sequence, including the abstract, figure legends, and tables. Place the last \n\ntwo items after the References section. Manuscript pages must have continuous line numbers; manuscripts without line \n\nnumbers may be editorially rejected by the editor, with a suggestion of resubmission after line numbers are added. The font \n\nsize should be no smaller than 12 points. It is recommended that the following sets of characters be easily distinguishable in \n\nthe manuscript: the numeral zero (0) and the letter \u201coh\u201d (O); the numeral one (1), the letter \u201cel\u201d (l), and the letter \u201ceye\u201d (I); \n\nand a multiplication sign (\u00d7) and the letter \u201cex.\u201d (x). Do not create symbols as graphics or use special fonts that are external \n\nto your word processing program; use the \"insert symbol\" function. Set the page size to 8.5 by 11 inches (ca. 21.6 by 28 cm). \n\nItalicize any words that should appear in italics, and indicate paragraph lead-ins in boldface type. \n\nManuscripts may be editorially rejected, without review, on the basis of poor English or lack of conformity to the standards \n\nset forth in these Instructions. \n\nAuthors who are unsure of proper English usage should have their manuscripts checked by someone proficient in the English \n\nlanguage or engage a professional language editing service for help. \n\n \n\nhttp://aac.msubmit.net/cgi-bin/main.plex\n\n\n130 \n \n\nManuscript Submission Checklist  \n\nDouble-space all text, including references and figure legends. \n\nNumber pages. \n\nNumber lines continuously. \n\nPresent statistical treatment of data where appropriate. \n\nFormat references in ASM style. \n\nProvide accession numbers for all newly published sequences in a dedicated paragraph, and if a sequence or sequence \n\nalignment important for evaluation of the manuscript is not yet available, provide the information as supplemental material \n\nnot for publication or make the material available on a website for access by the editor and reviewers. \n\nConfirm that genetic and chemical nomenclature conforms to instructions. \n\nInclude as supplemental material not for publication in-press and submitted manuscripts that are important for judgment of \n\nthe present manuscript. \n\nFull-Length Papers  \n\nFull-length papers should include the elements described in this section. \n\nTitle, running title, byline, affiliation line, and corresponding author. Each manuscript should present the results of an \n\nindependent, cohesive study; thus, numbered series titles are not permitted. Exercise care in composing a title. Avoid the \n\nmain title/subtitle arrangement, complete sentences, and unnecessary articles. On the title page, include the title, the running \n\ntitle (not to exceed 54 characters and spaces), the name of each author, all authors' affiliations at the time the work was \n\nperformed, the name(s) and e-mail address(es) of the corresponding author(s), and a footnote indicating the present address \n\nof any author no longer at the institution where the work was performed. Place a number sign (#) in the byline after the name \n\nof the author to whom inquiries regarding the paper should be directed (see \"Correspondent footnote\" below). Please review \n\nthis sample title page for guidance. \n\nStudy group in byline. A study group, surveillance team, working group, consortium, or the like (e.g., the Active Bacterial \n\nCore Surveillance Team) may be listed as a coauthor in the byline if its contributing members satisfy the requirements for \n\nauthorship and accountability as described in these Instructions. The names (and institutional affiliations if desired) of the \n\ncontributing members may be given as a separate paragraph in Acknowledgments. \n\nIf the contributing members of the group associated with the work do not fulfill the criteria of substantial contribution to and \n\nresponsibility for the paper, the group may not be listed in the author byline. Instead, it and the names of its contributing \n\nmembers may be listed in the Acknowledgments section. \n\n \n\n\n\n131 \n \n\nCorrespondent footnote. The e-mail address for the corresponding author should be included on the title page of the \n\nmanuscript. This information will be published in the article as a footnote to facilitate communication and will be used to \n\nnotify the corresponding author of the availability of proofs and, later, of the PDF file of the published article. No more than \n\ntwo authors may be designated corresponding authors. \n\nAbstract. Limit the abstract to 250 words or fewer and concisely summarize the basic content of the paper without presenting \n\nextensive experimental details. Avoid abbreviations and references, and do not include diagrams. When it is essential to \n\ninclude a reference, use the format shown under \u201cReferences\u201d below (see the \u201cCitations in abstracts\u201d section). Conclude the \n\nabstract with a summary statement. Because the abstract will be published separately by abstracting services, it must be \n\ncomplete and understandable without reference to the text. \n\nIntroduction. The introduction should supply sufficient background information to allow the reader to understand and \n\nevaluate the results of the present study without referring to previous publications on the topic. The introduction should also \n\nprovide the hypothesis that was addressed or the rationale for the study. References should be chosen carefully to provide the \n\nmost salient background rather than an exhaustive review of the topic. \n\nMaterials and Methods. The Materials and Methods section should include sufficient technical information to allow the \n\nexperiments to be repeated. When centrifugation conditions are critical, give enough information to enable another \n\ninvestigator to repeat the procedure: make of centrifuge, model of rotor, temperature, time at maximum speed, and \n\ncentrifugal force (\u00d7 g rather than revolutions per minute). For commonly used materials and methods (e.g., media and protein \n\nconcentration determinations), a simple reference is sufficient. If several alternative methods are commonly used, it is helpful \n\nto identify the method briefly as well as to cite the reference. For example, it is preferable to state \u201ccell were broken by \n\nultrasonic treatment as previously described (9)\u201d rather than \u201ccells were broken as previously described (9).\u201d This allows the \n\nreader to assess the method without constant reference to previous publications. Describe new methods completely, and give \n\nsources of unusual chemicals, equipment, or microbial strains. When large numbers of microbial strains or mutants are used \n\nin a study, include tables identifying the immediate sources (i.e., sources from whom the strains were obtained) and \n\nproperties of the strains, mutants, bacteriophages, and plasmids, etc. \n\nA method or strain, etc., used in only one of several experiments reported in the paper may be described in the Results \n\nsection or very briefly (one or two sentences) in a table footnote or figure legend. It is expected that the sources from whom \n\nthe strains were obtained will be identified. \n\nAs noted above, a paragraph dedicated to new accession numbers for nucleotide and amino acid sequences, microarray data, \n\nprotein structures, high-throughput sequencing data, and MycoBank data should appear at the end of Materials and Methods \n\nwith a paragraph lead-in specific to the type of data. \n\nResults. In the Results section, include the rationale or design of the experiments as well as the results; reserve extensive \n\ninterpretation of the results for the Discussion section. Present the results as concisely as possible in one of the following: \n\ntext, table(s), or figure(s). Avoid extensive use of graphs to present data that might be more concisely or more quantitatively \n\npresented in the text or tables. Limit photographs (particularly photomicrographs and electron micrographs) to those that are \n\nabsolutely necessary to show the experimental findings. Number figures and tables in the order in which they are cited in the \n\ntext, and be sure that all figures and tables are cited. \n\nDiscussion. The Discussion should provide an interpretation of the results in relation to previously published work and to the \n\nexperimental system at hand and should not contain extensive repetition of the Results section or reiteration of the \n\nintroduction. In short papers, the Results and Discussion sections may be combined. \n\n\n\n132 \n \n\nAcknowledgments. Please do not include information about direct funding in the Acknowledgments. (See \u201cFunding \n\ninformation\u201d below.) Statements regarding indirect financial support (e.g., commercial affiliations, consultancies, stock or \n\nequity interests, and patent-licensing arrangements) may, however, be included. It is the responsibility of authors to provide a \n\ngeneral statement disclosing financial or other relationships that are relevant to the study. (See the \u201cConflict of interest\u201d \n\nsection above.) Recognition of personal assistance should be given in the Acknowledgments section, as should any \n\nstatements disclaiming endorsement or approval of the views reflected in the paper or of a product mentioned therein. \n\nFunding information. In the fields associated with the Funding Sources question in the online submission form, authors \n\nshould list any sources of funding, providing relevant grant numbers where possible, and the authors associated with the \n\nspecific funding sources. In the event that your submission is accepted, the funding source information provided in the \n\nsubmission form may be published, so please ensure that all information is entered accurately and completely. (It will be \n\nassumed that the absence of any information in the Funding Sources fields is a statement by the authors that no support was \n\nreceived.) \n\nAuthors may also provide a funding statement. In general, an appropriate funding statement will indicate what role, if any, \n\nthe funding agency had in your study (for example, \u201cThe funders had no role in study design, data collection and \n\ninterpretation, or the decision to submit the work for publication.\u201d) Funding agencies may have specific wording \n\nrequirements, and compliance with such requirements is the responsibility of the author. \n\nIn cases in which research is not funded by any specific project grant, funders need not be listed, and the following statement \n\nmay be used: \u201cThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit \n\nsectors.\u201d \n\nAppendixes. Appendixes that contain additional material to aid the reader are permitted. Titles, authors, and reference \n\nsections that are distinct from those of the primary article are not allowed. If it is not feasible to list the author(s) of the \n\nappendix in the byline or the Acknowledgments section of the primary article, rewrite the appendix so that it can be \n\nconsidered for publication as an independent article, either full-length or Short-Form style. Equations, tables, and figures \n\nshould be labeled with the letter \"A\" preceding the numeral to distinguish them from those cited in the main body of the text. \n\nReferences  \n\nIn the reference list, references are numbered in the order in which they are cited in the article (citation-sequence reference \n\nsystem). In the text, references are cited parenthetically by number in sequential order. Data that are not published or not peer \n\nreviewed are simply cited parenthetically in the text (see section ii below). \n\n(i) References listed in the References section. The following types of references must be listed in the References section: \n\nJournal articles (both print and online) \n\nBooks (both print and online) \n\nBook chapters (publication title is required) \n\nPatents \n\nTheses and dissertations \n\n\n\n133 \n \n\nPublished conference proceedings \n\nMeeting abstracts (from published abstract books or journal supplements) \n\nLetters (to the editor) \n\nCompany publications \n\nIn-press journal articles, books, and book chapters \n\nProvide the names of all the authors and/or editors for each reference; long bylines should not be abbreviated with \u201cet al.\u201d All \n\nlisted references must be cited in the text. Abbreviate journal names according to the PubMed Journals Database (National \n\nLibrary of Medicine, National Institutes of Health), the primary source for ASM style (do not use periods with abbreviated \n\nwords). The EndNote output style for ASM Journals\u2019 current reference style can be found here; click \u201cOpen\u201d and then \n\n\u201cDownload and Install\u201d to save it to your EndNote Styles folder (it should replace any earlier output styles for ASM journals \n\n[all ASM journals use the same reference style]). \n\nFollow the styles shown in the examples below for print references. \n\nCaserta E, Haemig HAH, Manias DA, Tomsic J, Grundy FJ, Henkin TM, Dunny GM. 2012. In vivo and in vitro analyses of \n\nregulation of the pheromone-responsive prgQ promoter by the PrgX pheromone receptor protein. J Bacteriol 194:3386-3394. \n\nFalagas ME, Kasiakou SK. 2006. Use of international units when dosing colistin will help decrease confusion related to \n\nvarious formulations of the drug around the world. Antimicrob Agents Chemother 50:2274-2275. (Letter.) {\"Letter\" or \n\n\"Letter to the editor\" is allowed but not required at the end of such an entry.}  \n\nCox CS, Brown BR, Smith JC. J Gen Genet, in press.* {Article title is optional; journal title is mandatory.}  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n134 \n \n\nANEXO B: Instru\u00e7\u00e3o aos autores para Submiss\u00e3o na Revista Mycopathologia \n\n \n\nManuscript Submission \n\nSubmission of a manuscript implies: that the work described has not been published before; that it is not under consideration \n\nfor publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible \n\nauthorities \u2013 tacitly or explicitly \u2013 at the institute where the work has been carried out. The publisher will not be held legally \n\nresponsible should there be any claims for compensation. \n\nPermissions \n\nAuthors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain \n\npermission from the copyright owner(s) for both the print and online format and to include evidence that such permission has \n\nbeen granted when submitting their papers. Any material received without such evidence will be assumed to originate from \n\nthe authors. \n\nOnline Submission \n\nPlease follow the hyperlink \u201cSubmit online\u201d on the right and upload all of your manuscript files following the instructions \n\ngiven on the screen. \n\nTitle Page \n\nThe title page should include: \n\nThe name(s) of the author(s) \n\nA concise and informative title \n\nThe affiliation(s) and address(es) of the author(s) \n\nThe e-mail address, telephone and fax numbers of the corresponding author \n\nAbstract \n\nPlease provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified \n\nreferences. \n\nKeywords \n\nPlease provide 4 to 6 keywords which can be used for indexing purposes. \n\nManuscripts should be submitted in Word. \n\nUse a normal, plain font (e.g., 10-point Times Roman) for text. \n\nUse italics for emphasis. \n\nUse the automatic page numbering function to number the pages. \n\n\n\n135 \n \n\nDo not use field functions. \n\nUse tab stops or other commands for indents, not the space bar. \n\nUse the table function, not spreadsheets, to make tables. \n\nUse the equation editor or MathType for equations. \n\nSave your file in docx format (Word 2007 or higher) or doc format (older Word versions). \n\nManuscripts with mathematical content can also be submitted in LaTeX. \n\nLaTeX macro package (zip, 182 kB) \n\nHeadings \n\nPlease use no more than three levels of displayed headings. \n\nAbbreviations \n\nAbbreviations should be defined at first mention and used consistently thereafter. \n\nFootnotes \n\nFootnotes can be used to give additional information, which may include the citation of a reference included in the reference \n\nlist. They should not consist solely of a reference citation, and they should never include the bibliographic details of a \n\nreference. They should also not contain any figures or tables. \n\nFootnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or \n\nasterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given \n\nreference symbols. \n\nAlways use footnotes instead of endnotes. \n\nAcknowledgments \n\nAcknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding \n\norganizations should be written in full. \n\nReferences \n\nCitation \n\nReference citations in the text should be identified by numbers in square brackets. Some examples: \n\n1. Negotiation research spans many disciplines [3]. \n\n\n\n136 \n \n\n2. This result was later contradicted by Becker and Seligman [5]. \n\n3. This effect has been widely studied [1-3, 7]. \n\nReference list \n\nThe list of references should only include works that are cited in the text and that have been published or accepted for \n\npublication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or \n\nendnotes as a substitute for a reference list. \n\nThe entries in the list should be numbered consecutively. \n\nJournal article \n\nSmith JJ. The world of science. Am J Sci. 1999;36:234\u20135. \n\nArticle by DOI \n\nSlifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med. 2000; \n\ndoi:10.1007/s001090000086 \n\nBook \n\nBlenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: \n\nBlackwell Science; 1998. \n\nBook chapter \n\nWyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. \n\nInternational review of cytology. London: Academic; 1980. pp. 251\u2013306. \n\nOnline document \n\nDoe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. \n\nhttp://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999. \n\nAlways use the standard abbreviation of a journal\u2019s name according to the ISSN List of Title Word Abbreviations, see \n\nISSN.org LTWA \n\nIf you are unsure, please use the full journal title. \n\nFor authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference \n\nlist. \n\nEndNote style (zip, 3 kB) \n\n\n\n137 \n \n\nTables \n\nAll tables are to be numbered using Arabic numerals. \n\nTables should always be cited in text in consecutive numerical order. \n\nFor each table, please supply a table caption (title) explaining the components of the table. \n\nIdentify any previously published material by giving the original source in the form of a reference at the end of the \n\ntable caption. \n\nFootnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and \n\nother statistical data) and included beneath the table body. \n\n1) Statement of human rights \n\nWhen reporting studies that involve human participants, authors should include a statement that the studies have been \n\napproved by the appropriate institutional and/or national research ethics committee and have been performed in accordance \n\nwith the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical \n\nstandards. \n\nIf doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable \n\nstandards, the authors must explain the reasons for their approach, and demonstrate that the independent ethics committee or \n\ninstitutional review board explicitly approved the doubtful aspects of the study. \n\nThe following statements should be included in the text before the References section: \n\nEthical approval: \u201cAll procedures performed in studies involving human participants were in accordance with the ethical \n\nstandards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later \n\namendments or comparable ethical standards.\u201d \n\nFor retrospective studies, please add the following sentence: \n\n\u201cFor this type of study formal consent is not required.\u201d \n\n2) Statement on the welfare of animals \n\nThe welfare of animals used for research must be respected. When reporting experiments on animals, authors should indicate \n\nwhether the international, national, and/or institutional guidelines for the care and use of animals have been followed, and \n\nthat the studies have been approved by a research ethics committee at the institution or practice at which the studies were \n\nconducted (where such a committee exists). \n\nFor studies with animals, the following statement should be included in the text before the References section: \n\nEthical approval: \u201cAll applicable international, national, and/or institutional guidelines for the care and use of animals were \n\nfollowed.\u201d \n\nIf applicable (where such a committee exists): \u201cAll procedures performed in studies involving animals were in accordance \n\nwith the ethical standards of the institution or practice at which the studies were conducted.\u201d \n\n\n\n138 \n \n\nIf articles do not contain studies with human participants or animals by any of the authors, please select one of the following \n\nstatements: \n\n\u201cThis article does not contain any studies with human participants performed by any of the authors.\u201d \n\n\u201cThis article does not contain any studies with animals performed by any of the authors.\u201d \n\n\u201cThis article does not contain any studies with human participants or animals performed by any of the authors.\u201d \n\nUpon acceptance of your article you will receive a link to the special Author Query Application at Springer\u2019s web page \n\nwhere you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, \n\nor printing of figures in color. \n\nOnce the Author Query Application has been completed, your article will be processed and you will receive the proofs. \n\nOpen Choice \n\nIn addition to the normal publication process (whereby an article is submitted to the journal and access to that article is \n\ngranted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open \n\nChoice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is \n\nmade available publicly through Creative Commons Attribution-NonCommercial 4.0 International License. \n\n? Springer Open Choice \n\nCopyright transfer \n\nAuthors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and \n\ndissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws. \n\nOpen Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, \n\nthe author(s) agree to publish the article under the Creative Commons Attribution License. \n\n? Creative Commons Attribution-NonCommercial 4.0 International License \n\nOffprints \n\nOffprints can be ordered by the corresponding author. \n\nColor illustrations \n\nOnline publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a \n\ncontribution towards the extra costs. \n\nProof reading \n\nThe purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables \n\nand figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without \n\nthe approval of the Editor. \n\nAfter online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the \n\narticle. \n\nhttp://springer.com/openchoice\nhttp://creativecommons.org/licenses/by-nc/4.0/\n\n\n139 \n \n\nOnline First \n\nThe article will be published online after receipt of the corrected proofs. This is the official first publication citable with the \n\nDOI. After release of the printed version, the paper can also be cited by issue and page numbers. \n\nOPEN CHOICE \n\nIn addition to the normal publication process (whereby an article is submitted to the journal and access to that article is \n\ngranted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open \n\nChoice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is \n\nmade available publicly through Springer\u2019s online platform SpringerLink. \n\nCopyright and license term \u2013 CC BY \n\nOpen Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, \n\nthe author(s) agree to publish the article under the Creative Commons Attribution License. \n\nThis journal is committed to upholding the integrity of the scientific record. As a member of the Committee on \n\nPublication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of \n\nmisconduct. \n\nAuthors should refrain from misrepresenting research results which could damage the trust in the journal, the \n\nprofessionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the \n\nresearch and its presentation can be achieved by following the rules of good scientific practice, which include: \n\nThe manuscript has not been submitted to more than one journal for simultaneous consideration. \n\nThe manuscript has not been published previously (partly or in full), unless the new work concerns an expansion of \n\nprevious work (please provide transparency on the re-use of material to avoid the hint of text-recycling (\u201cself-\n\nplagiarism\u201d)). \n\nA single study is not split up into several parts to increase the quantity of submissions and submitted to various \n\njournals or to one journal over time (e.g. \u201csalami-publishing\u201d). \n\nNo data have been fabricated or manipulated (including images) to support your conclusions \n\nNo data, text, or theories by others are presented as if they were the author\u2019s own (\u201cplagiarism\u201d). Proper \n\nacknowledgements to other works must be given (this includes material that is closely copied (near verbatim), \n\nsummarized and/or paraphrased), quotation marks are used for verbatim copying of material, and permissions are \n\nsecured for material that is copyrighted. \n\nImportant note: the journal may use software to screen for plagiarism. \n\nConsent to submit has been received explicitly from all co-authors, as well as from the responsible authorities - \n\ntacitly or explicitly - at the institute/organization where the work has been carried out, before the work is submitted. \n\nAuthors whose names appear on the submission have contributed sufficiently to the scientific work and therefore \n\nshare collective responsibility and accountability for the results."}]}}}